



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : <b>C12N 15/19, C07K 15/00 C12N 1/19, A61K 37/02</b>		A1	(11) International Publication Number: <b>WO 93/13206</b> (43) International Publication Date: <b>8 July 1993 (08.07.93)</b>
(21) International Application Number: <b>PCT/GB92/02390</b>		(74) Agents: SHEARD, Andrew, Gregory et al.; Kilburn & Strode, 30 John Street, London WC1N 2DD (GB).	
(22) International Filing Date: <b>23 December 1992 (23.12.92)</b>		(81) Designated States: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG).	
(30) Priority data: 9127319.3 23 December 1991 (23.12.91) GB 9221587.0 14 October 1992 (14.10.92) GB		(71) Applicant (for all designated States except US): BRITISH BIO-TECHNOLOGY LIMITED [GB/GB]; Watlington Road, Cowley, Oxford OX4 5LY (GB).	
(72) Inventors; and		(75) Inventors/Applicants (for US only) : CRAIG, Stewart [GB/GB]; HUNTER, Michael, George [GB/GB]; EDWARDS, Richard, Mark [GB/GB]; CZAPLEWSKI, Lloyd, George [GB/GB]; GILBERT, Richard, James [GB/GB]; British Bio-technology Limited, Watlington Road, Cowley, Oxford OX4 5LY (GB).	

**(54) Title: STEM CELL INHIBITING PROTEINS****(57) Abstract**

Proteinaceous molecules with stem cell inhibition activity are analogues of LD78 or MIP-1 $\alpha$  which have mutations to prevent or reduce multimer formation beyond certain stages (for example a dodecamer). Aggregate formation is therefore inhibited, and the resulting low molecular weight monomers (or oligomers) have improved solution properties leading to enhanced productivity and greater therapeutic utility as stem cell protective agents, which are useful in tumour therapy.

**BEST AVAILABLE COPY**

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

## STEM CELL INHIBITING PROTEINS

This invention relates to proteinaceous compounds having the properties of inhibitors of stem cell proliferation. In particular, the invention relates to 5 engineered variants of protein molecules with stem cell inhibition activity, their preparation and pharmaceutical compositions containing them and their use as adjuncts to chemotherapy or radiotherapy, for example in the treatment of cancer.

10 The diverse cells of the haemopoietic system are derived from multipotential stem cells by a process of sequential division and differentiation. The proliferation of the stem cell population is controlled in part by an inhibitory molecule produced by bone marrow macrophages (Lord *et al.*, *Brit. J. Haematol.* 34 441, (1976)). The murine haemopoietic stem cell inhibitor has been shown to be an 8kDa 15 protein, macrophage inflammatory protein-1 alpha (MIP-1 $\alpha$  (Graham *et al.*, *Nature* 344 442, (1990)). The properties of the stem cell inhibitor include protecting stem cells from the toxic effects of cell cycle specific cytotoxic agents (Lord and Wright, *Blood Cells*, 6 581 (1980)). Stem cell inhibitors therefore have enormous 20 clinical potential as agents to protect the stem cells from the chemotherapy or radiotherapy regimes used in tumour therapy. Additionally, stem cell inhibitors may be used in the treatment of hyperproliferative diseases such as psoriasis, either alone or in conjunction with cytotoxic agents. Amino acid sequence homologies suggested that either the human LD78 or ACT2 gene products were the human 25 homologues of the murine stem cell inhibitor (Figure 1a) (Schall, *Cytokine* 3 165-183 (1991)). It has been demonstrated that the human LD78 gene product is the functional homologue of murine MIP-1 $\alpha$ , (Pragnell CRC Beatson Laboratory Scientific Report pp 21-25, (1990), Dunlop *et al.*, *Blood* 79:2221-2225 (1992)).

As a component of the present invention, the secondary and tertiary structure of LD78 and MIP-1 $\alpha$  have been shown to be almost identical. Only a difference in

the nature of a side-chain or charge interaction in the vicinity of Trp-57 is observed for the two proteins. Despite having a similar secondary structure to LD78 and MIP-1 $\alpha$ , near u.v. c.d. studies show ACT2 has a different tertiary conformation as highlighted by the shape and intensity of the spectrum. This 5 provides strong evidence that LD78 and not ACT2 is the human homologue of MIP-1 $\alpha$ .

A major problem shared by murine MIP-1 $\alpha$  and human LD78, which limits their potential clinical utility, is that at concentrations as low as 25 $\mu$ g/ml in 10 physiological ionic strength buffer they form large soluble multimeric complexes which have a tendency to aggregate. The native MIP-1 $\alpha$  and LD78 protein molecules have a molecular weight of 7,866Da and 7,712Da respectively. For both proteins, the soluble multimeric complexes show a broad heterogeneous mixture of molecular weights ranging from 100,000Da to > 200,000Da. The 15 principal consequence of the multimerisation and aggregation phenomena is that clinical administration of the protein is compromised. Aggregation and multimerisation can lead to varying efficacy, impaired tissue penetration and enhanced immunogenicity. Another important shortcoming is that, during production and formulation, aggregation will result in heterogeneous 20 pharmaceutical preparations.

Cloudy aggregates are often observed upon reconstitution of pure, lyophilised LD78 or MIP-1 $\alpha$  protein in physiological ionic strength buffer at pH 7.4. Aggregates are removed by centrifugation prior to further analysis. Size exclusion 25 chromatography (Comparative Example 3) of the soluble reconstituted MIP-1 $\alpha$  and LD78 following clarification show that the majority of the protein chromatographs as broad peaks of molecular weights of 100,000-800,000Da. The broad trailing edge of the peaks demonstrates the existence of a range of high molecular weight complexes for each protein. The size exclusion profile of MIP-1 $\alpha$  also reveals a 30 population of tetrameric molecules in equilibrium with the large multimers.

Although the problem of aggregation of stem cell inhibitors (and LD78 in particular) has been recognised in the art, those working in the field have hitherto attempted to address it by formulating unusual buffering systems (Mantel *et al.*, *Expt. Haematol.* 20: No. 368 800 (1992), Dunlop *et al.*, *Blood* 79:2221-2225 (1992) and Graham & Pagnell *Dev. Biol.* 151 377-81 (1992)) to keep the otherwise multimeric molecule in a low molecular weight form. This approach has its disadvantages, not least that, whatever the ingredients of the buffer, the molecule may well reaggregate on administration *in vivo*.

10 The present invention approaches the problem in a radically different way. It has been discovered not only how stem cell inhibitors such as LD78 and MIP-1 $\alpha$  aggregate but also that it is possible to inhibit the aggregation or multimerisation at certain stages in the aggregation process, while still retaining biological activity.

15 MIP-1 $\alpha$ , LD78 and ACT-2 show sequence homology to the chemotactic cytokine superfamily of proteins which contains Interleukin-8 (IL-8), platelet factor 4 (PF-4) and monocyte chemo-attractant and activating protein (MCAF). Of these related proteins, it is known that IL-8 exists as a dimer (Clore *et al.*, *Biochemistry* 29 1689-1696 (1990)) and PF-4 is a tetramer at physiological ionic strength (Moore *et al.*, *Biochim. Biophys. Acta.* 379, 379-384, 1975). The model of MCAF built using IL-8 as a template (Gronenborn & Clore, *Protein Engineering* 4 263-269 (1991)) is consistent with a basic dimeric structure. However, trimerisation of tetramers to dodecamers has not previously been reported.

20

25 It has now been found that the high-order multimers of MIP-1 $\alpha$  and LD78 are formed *via* intermediate dimers, tetramers and dodecamers (three associated tetramer units). So to prevent the undesirable higher order multimerisation and aggregation, it is necessary to prevent multimerisation either at the level of or lower than the dodecamer. At its broadest, therefore, in a first aspect the invention

provides a proteinaceous molecule with stem cell inhibition (SCI) activity, the molecule being substantially incapable at physiological ionic strength of forming a stable multimer higher than a dodecamer. The molecular weight of molecules in accordance with the invention will generally be about or less than 100,000 Da at physiological ionic strength. Such variants would require no further formulation, at least in respect of the multimerisation properties, and would therefore represent a clinical advantage in terms of ease of use and a manufacturing advantage as its homogeneity would better lend itself to GMP. Additionally, the increased molecular surface area may lead to advantages in tissue penetrability and increased efficacy.

Preferred embodiments of the invention are substantially incapable at physiological ionic strength of forming a stable multimer higher than a tetramer; the molecular weight in such cases will generally be about or less than 32,000 Da. Some embodiments are substantially incapable at physiological ionic strength of forming a stable multimer higher than a dimer; in these cases, the molecular weight will generally be about or less than 16,000 Da. Certain embodiments of the invention are substantially incapable of forming multimers at all; their molecular weight will generally be about or less than 8,000 Da, which is the monomeric molecular weight of LD78 and MIP-1 $\alpha$ , based on amino acid sequences.

Molecules which form substantially homogenous populations of multimers (or monomers) are preferred.

The molecular weight and/or degree of multimerisation of molecules of the invention can be assessed by any suitable means. Electrophoresis (for example native PAGE), size-exclusion chromatography and, particularly, ultracentrifuge sedimentation coefficient analysis are methods of choice.

When it is stated in this specification that a molecule is "substantially incapable" of forming a multimer higher than a given order, it should be understood that a minor proportion of higher order multimers can be tolerated and may in fact be inevitable from a consideration of thermodynamic equilibria. While it is not possible to put precise quantitative limits on this proportion, in general no more than 15, 10 or even 5% of the species present will be above the threshold stated.

The term "stem cell inhibition activity" (or "SCI activity") is known to those skilled in the art. It may be taken to refer to a biological activity exhibited by MIP-1 $\alpha$  and/or LD78 and in particular to the inhibition of proliferation of stem cells or, more precisely, to the prevention of movement of stem cells through a proliferative cell cycle. Proteinaceous molecules in accordance with the invention may therefore be regarded as analogues of MIP-1 $\alpha$  and/or LD78. "Stem cells", as generally indicated above, are dividing cells which maintain cells of various lineages, particularly cells of the haemapoietic system or the epithelial system; more particularly, haemapoietic stem cells are cells which are capable of self renewal and are capable of giving long term repopulation of cells of the haemapoietic system when transplanted into a lethally irradiated animal.

Stem cell inhibition activity can be determined experimentally in a variety of ways. For example, an *in vitro* assay of activity can be made. Such an assay is preferably a receptor binding assay: molecules in accordance with the invention are assessed for their ability to displace LD78 (or MIP-1 $\alpha$ ), which may be appropriately detectably labelled, from a suitable source of receptors, such as the murine stem cell line FDCP cell mix (A4 cells). Details of such an assay are given in Example 164 below; stem cell inhibition activity may be said to be exhibited by a molecule if a statistically significant proportion of wild type activity (for example at least 1%, 5%, 10%, or 20%, in increasing order of preference, of the activity of the corresponding wild type molecule) is observed for a

preparation of given concentration. Receptor binding activity which is as good as, or even better than, wild type is not essential but may well be preferred.

5 An alternative but functional, although still *in vitro* assay for experimental determination is an assay which measures the inhibition of proliferation of murine day 12 CFU-S cells. Molecules are assayed for their ability to inhibit colony formation of day 12 CFU-S cells sorted from murine bone marrow. Details can be found in:

10 Lord and Spooner *Lymphokine Research B* 59 (1986) and Lord and Marsh in "Haemopoiesis, A Practical Approach" IRL Press, Oxford, 1992, Testa and Molineux, Eds., page 21 (for murine bone marrow cell sorting);

15 Heyworth and Spooncer in "Haemopoiesis, A Practical Approach" IRL Press, Oxford, 1992, Testa and Molineux, Eds., page 37 (for general cell culture techniques); and

Pragnell *et al. Blood* 72 196 (1988) (for assay and conditioned medium).

20 More precise details of such an assay are given in Example 165 below. Molecules possess stem cell inhibition activity if they inhibit colony formation in this assay. Inhibition which is as good as or even better than wild type is not essential but may be preferred.

25 A further alternative functional, but still *in vitro*, assay is to be found in WO-A-9104274, Pragnell *et al.*, *Blood* 72 196-201 (1988) and Lorimer *et al. Leukemia Research* 14 481-489 (1990).

Alternatively or additionally, activity *in vivo* can be assessed. First, a CFU-S *in vivo* assay, in which the ability of the candidate stem cell inhibitor is used to protect the stem cell population (measured as CFU-S) against the cytotoxic effects of chemotherapeutic agents such as hydroxyurea or cytosine arabinoside (ara-C).

5 A suitable assay is described in Lord *et al.*, *Blood* 79:2605-2609 (1992) and also by Lord in "Haemopoiesis - A Practical Approach", pages 1-20, IRL Press, Oxford, 1992, (Testa and Molineux, Eds.), pages 1-20 and by Lord and Schofield in "Cell Clones: Manual of Mammalian Cell Techniques", Churchill Livingstone, 1985 (Potten and Henry, Eds.), pages 13-26.

10

Further in the alternative, or in addition, an assay which indirectly reflects the CFU-S population measures the recovery of neutrophil numbers following chemotherapy with ara-C; such an assay is described in Dunlop *et al.*, *Blood* 79:2221-2225.

15

A molecule can be regarded as having stem cell inhibiting activity if it gives a significant improvement over negative control (whether or not an improvement over the wild type molecule) in any or all of the above assays. Certain preferred molecules show such an improvement over negative control in more than one, or even all, of the assays.

20

The term "physiological ionic strength" is well known to those skilled in the art. It is generally equivalent to about 137mM NaCl, 3mM KCl and about 10mM phosphate. Physiological pH is about 7.4.

25

The invention enables the preparation of analogues of LD78 and MIP-1 $\alpha$  in dodecameric, tetrameric, homo-dimeric and monomeric forms, wherein each form is substantially incapable of forming a stable higher order complex under conditions of physiological ionic strength and pH. The analogues may form a

substantially homogeneous population of multimers; analogues which form a substantially homogeneous preparation of tetramers are preferred.

5        The term "analogue" is used, broadly, in a functional sense. As a practical matter, though, most analogues will have a high degree of homology with the prototype molecule if biological activity is to be substantially preserved. It will be realised that the nature of changes from the prototype molecule is more important than the number of them. As guidance, though, at the amino acid level, it may be that (in increasing order of preference) at least 40, 50, 60, 65, 67 or 68 of the residues 10      will be the same as the prototype molecule; at the nucleic acid level, nucleic acid coding for an analogue may for example hybridise under stringent conditions (such as at approximately 35°C to 65°C in a salt solution of approximately 0.9 molar) to nucleic acid coding for the prototype molecule, or would do so but for the degeneracy of the genetic code.

15      Many analogue MIP-1 $\alpha$  and LD78 molecules of this invention reproducibly form a stable quaternary structure no greater than either a tetramer or three associated tetramer units (a dodecamer). It may well be that the stability of dimers, tetramers, dodecamers or other multimers will vary depending on the environment of the molecules; if so, it will be preferably at physiological ionic strength and more 20      preferably when the analogue is presented in a clinically administrable (usually aqueous) formulation, and at a clinically acceptable dose, that multimerisation beyond a dodecamer cannot (or at least does not) substantially occur. Often the clinically administrable formulation will be reconstituted from a lyophilised protein preparation. Preferably, multimers beyond dodecamers will not substantially occur 25      in conditions likely to be encountered during production, formulation and administration. The absence of multimers of molecular weight greater than a tetramer or dodecamer reduces the aggregation of recombinant or other analogues of MIP-1 $\alpha$  and LD78. Such stable preparations of MIP-1 $\alpha$  and LD78 analogues

with a defined, reproducible quaternary structure represent a distinct advantage in production, formulation and administration of the therapeutic entity.


4 A stable monomeric, dimeric, tetrameric or dodecameric variant may have  
5 improved pharmaceutical and pharmacokinetic properties, such as: the advantage  
of improved tissue penetration; a lesser likelihood of being immunogenic; and  
much more reproducible efficacy, by virtue of a stable quaternary structure. An  
added advantage of this approach lies in the fact that some of these surface  
residues may be involved in receptor activation and modify the pharmacology.  
10 Identification of biologically important residues can therefore be used to improve  
the pharmacokinetics of stem cell proliferation inhibition and lead to the design of  
low molecular weight mimics. Stable monomers, dimers, tetramers and  
dodecamers should provide powerful research tools, being particularly useful in the  
identification and characterisation of receptors for SCIs, of which little is known  
15 (Oh *et al.*, *J. Immunol.* 147 2978-2983 (1991)). Disruption of the dimer interface  
interactions to produce a monomer would provide a useful research tool. A further  
advantage of this approach is the possibility of eliminating any cross reaction of  
LD78 or MIP-1 $\alpha$  with the murine inflammatory protein-1 $\beta$  receptor or its human  
equivalent. Activation of the MIP-1 $\beta$  receptor elicits a major part of the  
20 inflammatory response of the body to these molecules and represents a potential  
unwanted side-effect during therapy. Elimination of this response would therefore  
provide a further clinical advantage.

25 An unexpected additional advantage conferred by the lack of multimerisation is the  
greatly enhanced productivity of such variants in eukaryotic cells, for example  
yeast species such as *Saccharomyces cerevisiae* and *Pichia pastoris*. The invention  
therefore relates additionally to a method of increasing protein expression levels  
in a system in which the desired protein normally forms multimeric complexes  
(which may be soluble) at physiological ionic strength (the "multimeric protein"),

which method comprises using in the expression system cells which are transformed or transfected with a vector comprising DNA coding, not for the multimeric protein, but instead for a mutant thereof which has a reduced tendency to form (eg soluble) multimeric complexes relative to the multimeric protein. Such 5 a method may be of general applicability, but has particular utility when applied to the production of proteins having stem cell inhibitor activity.

From studies involved in the making of this invention, it appears that LD78 and MIP-1 $\alpha$  associate along the following pathway:

10



wherein M represents a monomer, D represents a homo-dimer and T represents 15 a tetramer. Figures 1c and 1d illustrate how this putatively comes about. Circumstantial evidence in support of this proposal comes from Mayo and Chen (*Biochemistry* 28 9469-9478 (1989)), who demonstrated that tetramers of PF-4 form via a similar pathway.

20 The pathway proposed above consists of a series of reversible equilibria up to the point of the irreversible aggregation of multimers. There are in principle four stages in the association mechanism at which it is possible to prevent the formation of large multimers (and therefore aggregates) of SCIs. Inhibition of each of these stages could be influenced by a mutation in a different region of the SCI molecule.

25

First, further association of tetramers can be inhibited. Secondly, if the SCI dimers are prevented from associating to tetramers, then further multimerisation will be inhibited. Thirdly, SCI monomers may be prevented from dimerising. Fourthly, further association of dodecamers to higher order multimers can be

inhibited. Any of these options can be implemented by specific mutation of residues involved in promoting and/or stabilising the association events. A further option would be to use a combination of mutations simultaneously to block two or all of the association events.

5

The following amino acid residues are preferred for modification:

(i) amino acid residues which could be involved in stabilising the interaction between two dimers; and

10

(ii) amino acid residues at surface regions, on the external faces of the tetramer, which could act as sites for higher order association.

15 Radical mutation of individual or combinations of key residues stabilising the association of dimers into tetramers will yield a dimeric recombinant SCI variant or analogue molecule. Similarly, mutation of residues at the sites of association of tetramers to multimers will yield a tetrameric SCI variant or analogue molecule. The amino acid modification preferably involves a substitution, although deletions and additions are contemplated within the scope of the invention.

20

The types of mutation preferred for producing the desired effects are:

(i) charge repulsions (successfully used to produce monomeric insulin;  
5 Dodson, *Prospects in Protein Engineering Meeting Abstracts*, 49-53,

(1989));

(ii) hydrophobic to hydrophilic changes;

(iii) neutral/hydrophobic to charged.

10

It is generally better not to substitute very hydrophobic residues into the protein in order to avoid contributing to the hydrophobic effect in association. Equally, it is preferred to avoid mutations which significantly disrupt secondary structural elements of the protein: so, for example, known  $\beta$ -breakers are preferably not 15 introduced into  $\beta$ -sheet regions.

Certain types of mutation are most effective in producing desirable changes within the SCI molecule. These are :

20

charge reversal;

charged residue to neutral;

hydrophobic to hydrophilic.

25

For optimum results substitutions should be made at particular sites within the molecule. The residues which should be altered are dependent on the level of multimerisation which is to be prevented.

The following discussion of preferred sites for mutation deals primarily with LD78, the proposed structure of which is shown in Figure 1b. In Figure 1b, the

ribbon traces the predicted path of backbone atoms for the LD78 monomer. The labelled residues define the putative secondary structure elements.  $\beta$ -sheet strand 1 runs from Phe23 to Thr30;  $\beta$ -sheet strand 2 runs from Lys35 to Thr43;  $\beta$ -sheet strand 3 runs from Ser46 to Pro53; and the C-terminal helix runs from Trp57 to Ala69. Analogous secondary structural elements may be inferred for other SCIs, including MIP-1 $\alpha$ , for example using the amino acid alignment shown in Figure 1a.

It is apparent that some faces of the monomer are involved in more than one part of the multimerisation pathway. The extent of disruption/inhibition of self-association in those faces is related to the nature of the amino acid substitution.

Inhibition of monomer to dimer formation can be achieved by one or more mutations, for example at residue 19 (Ile) or 39 (Val). Either residue may be changed to Ala.

Dimer to tetramer formation is affected by mutations in residues projecting away from the surface of the dimer in strand 1 of the  $\beta$  sheet, and/or in the turn between strands 2 and 3 of the sheet. Examples of the first region are amino acids 24-29 of LD78 and of the second region are amino acids 43-47 of LD78. In particular, Ile24>Asn, Tyr27>Asn, Phe28>Glu, Glu29>Arg, Lys44>Glu (especially with Arg45>Gln) and Arg 45>Glu are preferred.

Tetramer to dodecamer formation can be inhibited or disrupted by mutations of the nature described above in either the residues which form a chain N-terminal to the turn into strand 1 of the sheet (where two changes are preferred), particularly residues 16-21, especially 17-19 or at position 4, 12, 26, 44, 48 or 66 of LD78. In particular, Ala4>Glu, Phe12>Asp, Arg17>Ser, Asp26>Ala (especially with Gln18>Glu), Arg17>Glu (again especially with Gln18>Glu), Asp26>Ala,

Lys44>Ser, Gln48>Glu (especially with Phe28>Glu) and Glu66>Ser are preferred.

Dodecamer to higher order multimer formation is prevented or disrupted by 5 mutations at positions 12 to 21, especially positions 12, 18 and 21, of LD78, or at position 65. In particular, Phe12>Gln, Gln18>Glu, Gln21>Ser and Leu65>Ala are preferred.

Generally preferred LD78 analogues of the invention include molecules which 10 comprise a sequence substantially corresponding to LD78, but with a mutation at one or more (but preferably no more than two) of the following amino acid residues: Ser1, Leu2, Ala3, Ala4, Asp5, Thr6, Ala9, Phe12, Ser13, Tyr14, Ser16, Arg17, Gln18, Ile19, Pro20, Gln21, Phe23, Ile24, Asp26, Tyr27, Phe28, Glu29, Ser31, Ser32, Gln33, Ser35, Lys36, Pro37, Gly38, Val39, Ile40, Leu42, Thr43, 15 Lys44, Arg45, Ser46, Arg47, Gln48, Asp52, Glu55, Glu56, Gln59, Lys60, Tyr61, Val62, Asp64, Leu65, Leu67, Glu66, Ser68, and Ala69.

Preferred LD78 analogues in accordance with the invention include Lys44>Glu 20 (with Arg45>Gln), Arg47>Glu, Phe28>Glu, Phe28>Glu (with Gln48>Glu), Phe28>Glu (with Arg47>Glu), Arg17>Ser (with Gln18>Glu), Phe12>Ala, Val39>Ala, Ile40>Ala, Asp26>Ala (with Glu29>Arg and Arg47>Glu). More preferred LD78 analogues in accordance with the invention include Arg17>Ser, Glu29>Arg, Gln18>Glu, Asp26>Ser, Gln48>Ser, Thr15>Ala, Gln21>Ser, Phe23>Ala, Ser32>Ala, Ala51>Ser, Ala4>Glu, Phe12>Asp, Asp26>Gln, 25 Lys36>Glu, Lys44>Glu, Arg45>Glu, Glu66>Gln. The most preferred LD78 analogues in accordance with the invention are Phe12>Gln, Lys44>Ser, Arg17>Glu (with Gln18>Glu) and, especially, Asp26>Ala and Glu66>Ser.

Generally preferred MIP-1 $\alpha$  analogues of the invention include molecules which comprise a sequence substantially corresponding to MIP-1 $\alpha$ , but with a mutation at one or more (but preferably not more than two) of the following amino acid residues: Ala1, Pro2, Tyr3, Gly4, Ala5, Asp6, Thr7, Ala10, Phe13, Ser14, 5 Tyr15, Ser16, Arg17, Lys18, Ile19, Pro20, Arg21, Phe23, Ile24, Asp26, Phe28, Glu29, Ser31, Ser32, Glu33, Ser35, Gln36, Pro37, Gly38, Val39, Ile40, Leu42, Thr43, Lys44, Arg45, Asn46, Arg47, Gln48, Asp52, Glu55, Thr56, Gln59, Glu60, Tyr61, Ile62, Asp64, Leu65, Glu66, Leu67, Asn68 and Ala69.

10 Preferred MIP-1 $\alpha$  analogues of the invention correspond to the preferred LD78 analogues described above.

15 Molecules in accordance with the invention will for preference be free of N-terminal extensions preceding Ser-1 (in the case of LD78) or Ala-1 (in the case of MIP-1 $\alpha$ ). This is because such N-terminally extended forms of the molecule are compromised with respect to their ability to bind to the LD78 receptor present on stem cells. Such molecules can still give rise to active species in functional *in vitro* assays, such as CFU-A or mitogenesis assays, possibly due to processing by aminopeptidases. It is preferable, however, not to depend on such processing 20 events for the clinical application of a stem cell inhibitor, as it leads to greater uncertainty over the pharmacokinetics of the active species, and increased variation in the response.

25 In contrast to the N-terminally extended variants, molecules carrying N-terminal deletions of between 1 and 7 residues are active in receptor binding, though the full length form with serine at position 1 is preferred.

SCI analogues in accordance with the invention can in principle be made by any convenient method including chemical modification of existing (for example

natural) proteins and/or chemical coupling of two or more oligo- or polypeptide chains. Far greater flexibility, though, can be obtained by using recombinant DNA methodology, which enables successive amino acid residues to be coupled together *in vivo*.

5

According to a second aspect of the invention, therefore, there is provided nucleic acid coding for a protein as described above. Both DNA and RNA are within the scope of the invention. DNA may be chemically synthesised and/or recombinant.

10 Mutations may be introduced by *de novo* polynucleotide synthesis, by site-directed mutagenesis using appropriately designed oligonucleotide primers or by any other convenient method.

15 Recombinant DNA in accordance with the invention may be in the form of a vector. The vector may for example be a plasmid, cosmid or phage. Vectors will frequently include one or more selectable markers to enable the selection of cells transformed (or transfected: the terms are used interchangeably in this specification) with them and, preferably, to enable selection of cells harbouring vectors incorporating heterologous DNA. Appropriate translational initiating and 20 termination signals will generally be present. Additionally, if the vector is intended for expression, sufficient transcriptional regulatory sequences to drive expression will be included. Vectors not including regulatory sequences are useful as cloning vectors.

25 Cloning vectors can be introduced into *E. coli* or any other suitable hosts which facilitate their manipulation. Expression vectors may be adapted for prokaryotic expression but for preference are adapted for expression in a microbial eukaryotic cell, such as a yeast (including but not limited to *Saccharomyces cerevisiae* and *Pichia pastoris*) or a higher eukaryotic cell such as insect or mammalian cells.

Performance of the invention is neither dependent on nor limited to any particular strain of microorganism or cell type: those suitable for use with the invention will be apparent to those skilled in the art, following the teaching of this specification. According to a third aspect of the invention there is provided a host cell transfected or transformed with DNA described above. Host cells may be of any suitable source; eukaryotic host cells are preferred; yeast cells may be those of choice.

5 Production of stem cell inhibitors, whether wild type or altered as described above has been found to be particularly advantageous when carried out in the yeast host *Pichia pastoris*. According to a fourth aspect of the invention, therefore, there is provided a process for the production of a molecule having stem cell inhibitor activity, the process comprising culturing a yeast of the genus *Pichia*, and preferably of the species *pastoris*, the yeast having expressible heterologous nucleic acid coding for the molecule.

10 15 DNA in accordance with the invention can be prepared by any convenient method involving coupling together successive nucleotides, and/or ligating oligo- and /or poly-nucleotides, including *in vitro* processes, but recombinant DNA technology forms the method of choice.

20 25 However the proteinaceous compounds of the invention are made, they may be useful either as research tools or in medicine. Other uses are not ruled out. In a fifth aspect, the invention provides proteinaceous compounds as described above for use in medicine, particularly in the protection of stem cells, for example in tumour therapy (whether radiotherapy or chemotherapy).

The invention therefore provides in a sixth aspect the use of a proteinaceous compound as described above in the preparation of an agent for use as a stem cell protective agent, particularly in tumour therapy. The invention can be used in a

method for the protection of stem cells, particularly in conjunction with tumour therapy, the method comprising administering to a patient an effective amount of a proteinaceous compound as described above. This method is preferably performed *in vivo*. Alternatively, the method may be performed *ex vivo* where the 5 resulting marrow is purged of leukaemia cells by the chemotherapeutic agent and then reinjected into the patient.

Formulations of the proteinaceous compounds described above themselves form an aspect of the invention and comprise active compound and a pharmaceutically acceptable carrier. While oral formulations which lead to bioactive and bioavailable active compound may in principle be preferred, in practice the compounds of the invention may have to be administered parenterally. Parenterally administrable formulations will generally be sterile and may comprise one or more proteinaceous compounds dissolved in a suitable liquid excipient such as water for injections, 10 PBS or physiological saline. Dosages will be determinable by the clinician or physician and will generally be such as to ensure an active dose is delivered. 15

Compounds of the invention may also be used to treat psoriasis or other disorders related to hyper-proliferative stem cells either alone or in conjunction with 20 cytotoxic agents. Topical or transdermal formulations of compounds of the invention, as well as parenteral formulations, may advantageously be used in this aspect of the invention.

It is to be understood that preferred features for each aspect of the invention are 25 as for each other aspect of the invention, *mutatis mutandis*.

Certain preferred embodiments of the invention will now be described with reference to the accompanying drawings, in which:

FIGURE 1a illustrates the alignment of the LD78 amino acid sequence with those of MIP-1 $\alpha$  and ACT-2;

5

FIGURE 1b shows the structural model of the LD78 monomer. The ribbon traces the predicted path of the backbone atoms for the LD78 monomer. The labelled residues define the predicted secondary structure elements. Strand 1 of the  $\beta$ -sheet is from Phe23 to Thr30, strand 2 is from Lys35 to Thr43, strand 3 is from Ser46 to Pro53 and the C-terminal helix is from Trp57 to Ala69.

10

FIGURE 1c shows schematically the putative multimer interfaces on the LD78 monomer.

15

FIGURE 1d shows how the LD78 monomer shown in Figure 1c are proposed to form dimers, tetramers, dodecamers and aggregates.

FIGURE 2 illustrates the plasmid of yeast expression vector pSW6.

20

FIGURE 3 demonstrates that the tertiary conformation of LD78 and MIP-1 $\alpha$  are identical as determined by near ultra-violet circular dichroism.

FIGURE 4 demonstrates that the tertiary conformation of ACT2 differs from that of MIP-1 $\alpha$  as determined by near ultra-violet circular dichroism.

25

FIGURE 5 illustrates a western blot of MIP-1 $\alpha$ , LD78 and ACT2 with anti-MIP-1 $\alpha$  antibody. The result demonstrates cross-reaction of LD78 but not ACT2 with anti-MIP-1 $\alpha$ .

5

FIGURE 6 shows a representative size exclusion chromatographic profile of MIP-1 $\alpha$ , LD78 and ACT2, reconstituted as described in Comparative Example 4. Also shown is the elution profile of proteins used as standard of molecular weights demonstrating the correct separation of standard proteins and a table of molecular weight species determined for reconstituted LD78, MIP-1 $\alpha$  and ACT-2.

10

FIGURE 7 shows a Coomassie-stained native PAGE analysis of LD78, MIP-1 $\alpha$  and ACT-2 with mixed molecular weight markers and EGF standard. The gel demonstrates that the three proteins all run as high molecular weight multimers under native conditions.

15

FIGURE 8 shows the distribution of protein solute mass in the analytical ultracentrifuge cell at equilibrium for LD78 wild type in various buffer conditions.

20

FIGURE 9 shows the near u.v. circular dichroism spectra of tetrameric LD78 is independent of the buffer conditions used to achieve the defined structure.

25

FIGURE 10 shows that the near u.v. c.d. spectrum of tetrameric LD78 is different to that of the high molecular weight multimer form.

FIGURE 11 shows that quenching of Trp-57 fluorescence emission energy occurs is present in the multimeric complexes but not in the tetramer. This quenching of emission energy arises due to the presence of an electrostatic interaction unique to the multimers which is proximal to Trp-57.

5 FIGURE 12 shows a coomassie stained native PAGE gel with wild type LD78, mutant 10, 11, 52 and mixed molecular weight markers. The gel demonstrates the different electrophoretic mobilitie observed for LD78 variants. [Mutant 10 is the subject of Example 7, mutant 11 is the subject of Example 8 and mutant 52 is the subject of Example 64.]

10 FIGURE 13 shows a Coomassie blue stained native PAGE gel with native LD78, 7 mutant constructs and mixed molecular weight markers. The gel demonstrates that mutants 1, 2, 10, 15, 26, 29 and 30 (of Examples 1, 2, 7, 11, 16, 19 and 20, respectively) have different multimerisation properties from wild type exhibiting (to different extents) faster electrophoretic mobility.

15 FIGURE 14 shows the size exclusion chromatography (SEC) profiles in 150mM PBS pH7.4 of selected mutant constructs with wild type LD78 for comparison.

20 FIGURE 15a shows the *Pichia pastoris* expression vector pHLD4.

FIGURE 15b shows the *Pichia pastoris* expression vector pLHD4 which includes an EGF gene fused to the a factor preprosequence.

25 FIGURE 16 shows the *Pichia pastoris* expression vector pHLD1.

FIGURE 17 shows the *Pichia pastoris* expression vector pLH23, which is based on pLHD4 modified to direct expression and secretion of LD78.

FIGURE 18 shows the construction of the optimised *Pichia pastoris* LD78 secretion vector pLH23.

FIGURE 19 shows the correlation between multimerisation state and receptor binding.

5

FIGURE 20 shows a computer-generated model of the proposed LD78 tetramer with receptor binding residues highlighted in black.

10

FIGURE 21 shows the annealed oligonucleotides for the construction of LD78 synthetic gene (SEQ ID NOS 4-13) with overlapping cohesive ends.

15

FIGURE 22 shows the annealed oligonucleotides used in the construction of the MIP-1 $\alpha$  gene (SEQ ID NOS 20-31) with overlapping cohesive ends.

FIGURE 23 shows the annealed oligo nucleotides used in the construction of the ACT-2 gene (SEQ ID NOS 37-46) with overlapping cohesive ends.

20

FIGURE 24 shows the effect of mutant 10 on *in vitro* colony formation using purified murine stem cells.

FIGURE 25 shows the effect of mutant 82 on *in vitro* colony formation using purified murine stem cells.

25

Preparations 1-14 describe the construction of synthetic genes for LD78, MIP-1 $\alpha$  and ACT-2, the development of yeast expression vectors and the production and preliminary characterisation of their protein products.

Comparative Examples 1-7 describe the biophysical properties of LD78, MIP-1 $\alpha$  and ACT-2, a comparison of their molecular weight under a range of solution conditions and a spectroscopic assay for the extent of LD78 multimerisation.

Examples 1-124 describe the design and construction of LD78 variants and their incorporation into expression vectors. Example 125 discloses a convenient gel screen for the detection of variants with altered multi-merisation properties. Examples 126-153 describe the effect on multimerisation of mutations at particular residues. Example 154 shows that previously described variants of LD78 are wild-type with respect to their multimerisation characteristics. Example 155 discloses the molecular faces involved in LD78 multimerisation.

5 Examples 156-157 disclose the unexpected observation that LD78 variants exhibiting reduced multimerisation give higher expression levels in *S. cerevisiae* than wild-type LD78. Examples 158-163 describe the construction of an improved *Pichia pastoris* expression vector, the construction of LD78 producing strains and the unexpectedly high yields of wild-type LD78 that are obtained, and demonstrate that further increases in yield are observed with variants exhibiting reduced multimerisation.

10 15

Example 164 demonstrates that variants exhibiting reduced multimerisation are active in an *in vitro* model of receptor binding. Example 165 shows that demultimerised mutants can inhibit the proliferation of haematopoietic progenitor cells (day 12 CFU-S).

20

## METHODOLOGY

The techniques of genetic engineering and genetic manipulation used in the manufacture of the genes described and in their further manipulation for construction of expression vectors are well known to those skilled in the art. Descriptions of modern techniques can be found in the laboratory manuals "Current Protocols in Molecular Biology", Volumes 7 and 2, edited by F. M. Ausubel *et al*, published by Wiley-Interscience, New York and in "Molecular

25

Cloning, A Laboratory Manual" (second edition) edited by Sambrook, Fritsch and Maniatis published by Cold Spring Harbor Laboratories, New York. M13mp18, M13mp19 and pUC18 and pUC19 DNAs were purchased from Pharmacia Ltd., Midsummer Boulevard, Central Milton Keynes, Bucks, MK9 3HP, United Kingdom. Restriction endonucleases were purchased either from Northumbria Biologicals Limited, South Nelson Industrial Estate, Cramlington, Northumberland, NE23 9HL, United Kingdom or from New England Biolabs, 32 Tozer Road, Beverly, MA 01915-5510 USA.

10 **Preparation 1 - Construction of a Synthetic Gene for Human LD78**

**Gene Design**

15 The published amino acid sequence for LD78 was reverse-translated to give a gene sequence. The codon usage was then optimised to maximise expression in *S. cerevisiae*. The 5' end of the synthetic gene was designed to include codons for the last five amino acid residues (Ser Leu Asp Lys Arg) of the yeast mating type factor alpha. The sequence was then modified to include a *Hind*III restriction site at the 5' end and a *Bam*HI restriction site at the 3' end (SEQ ID:1).

20 The gene sequence was divided into 12 oligonucleotides (SEQ ID:4 to SEQ ID:13). Each internal oligonucleotide was designed so that a unique 7 base cohesive end is left after annealing each pair of complementary oligonucleotides. This allows for perfect oligo matching during gene construction. Figure 21 shows the annealed oligonucleotides with overlapping cohesive ends.

25

**Oligonucleotide Synthesis**

30 The oligonucleotides were synthesised on an Applied Biosystems 380B Gene Synthesiser, using cyanoethyl phosphoramidite chemistry. The methodology is now widely used and has been described (Beaucage, S. L. and Caruthers, M. H. *Tetrahedron Letters* 24, 245 (1981)).

Gene Construction

In order to create a full length gene, 100 pmole of each oligonucleotide was dried down in a vacuum dessicator. The 5' ends of internal oligonucleotides were kinased to provide a 5' phosphate to allow subsequent ligation. 100pmoles of 5 dried oligomer was resuspended in 20 $\mu$ l of kinase buffer (70mM Tris, pH7.6, 10mM MgCl<sub>2</sub>, 1mM ATP, 0.2 mM spermidine, 0.5 mM dithiothreitol). T4 polynucleotide kinase (2  $\mu$ l. 10,000 U/ml) was added and the mixture was incubated at 37°C for 30 minutes. The kinase was then inactivated by heating at 70°C for 10 minutes. Note that end oligonucleotides BB5615 and BB5624 were 10 not kinased to prevent concatemerisation during the construction (SEQ ID:2).

Complementary pairs of oligonucleotides were annealed in single pairs (90°C, 5 minutes, followed by slow cooling to room temperature). The 6 annealed pairs were then mixed together, heated at 50°C for 5 minutes, and ligated overnight at 15 14°C using T4 DNA ligase. The ligated full length product was then separated from non-ligated material by electrophoresis on a 2% low melting temperature agarose gel. The DNA fragment corresponding to the LD78 gene was excised and extracted from the gel. The purified fragment was then ligated to *Hind*III and *Bam*HI treated pUC18 plasmid DNA. The ligated products were transformed into 20 a suitable *E. coli* host strain using standard methodology. The strain used was HW87 which has the following genotype:

*araD139* $\Delta$ (*ara-leu*) 7697 $\Delta$ (*lacIPOZY*)74 *galU galK hsdR rpsL srl recA56*

25 The use of this particular strain is not critical: any suitable recipient could be used (eg MC1061, available from the American Type Culture Collection (ATCC)). Transformants were selected on L-agar carbenicillin plates. Twelve carbenicillin-resistant colonies were picked and used to prepare plasmid DNA for sequence analysis. Double stranded dideoxy sequence analysis using a universal

sequencing primer (United States Biochemical Corporation, (5'-GTTTTCCCAGTCACGAC-3' (SEQ ID NO 14)), was used to identify a correct clone pUC18-LD78. The pUC18-LD78 vector was used as a source of the LD78 gene to construct the expression vector.

5

#### Preparation 2 - Construction of a Yeast Expression Vector for Human LD78

An expression vector was designed to enable secretion of LD78 to the extracellular medium after expression in *S. cerevisiae*. Secretion aids purification and rapid 10 analysis of LD78. The secretion signals from the yeast mating type factor alpha were used to direct export of the LD78 protein.

The yeast expression vector pSW6 (SEQ ID NO 15, Figure 2) is based on the 2 micron circle from *S. cerevisiae*. (pSW6 was deposited in *S. cerevisiae* strain 15 BJ2168 at the National Collection of Industrial and Marine Bacteria Limited, 23 St. Machar Drive, Aberdeen AB2 1RY, Scotland United Kingdom on 23rd October 1990 under Accession No. NCIMB 40326.) pSW6 is a shuttle vector capable of replication in both *E. coli* and *S. cerevisiae* and contains an origin of DNA replication for both organisms, the *leu 2* gene (a selectable marker for plasmid 20 maintenance in the yeast host) and the ampicillin resistance locus for selection of plasmid maintenance in *E. coli*. (The DNA sequence for the vector has been determined; the *E. coli* sequences are derived from the *E. coli* ColE1-based replicon pAT153.) The full sequence is given in SEQ ID NO 15. The ability to passage this vector through *E. coli* greatly facilitates its genetic manipulation and ease of purification. pSW6 contains an alpha-factor pre-pro-peptide gene fused 25 in-frame to a gene encoding human epidermal growth factor (EGF). The expression of this fusion is under the control of an efficient galactose regulated promoter which contains hybrid DNA sequences from the *S. cerevisiae* GAL 1-10 promoter and the *S. cerevisiae* phosphoglycerate kinase (PGK) promoter.

Transcription of the EGF gene is terminated in this vector by the natural yeast PGK terminator. The EGF gene in pSW6 can be removed by digestion with restriction endonucleases *Hind*III and *Bam*HI. This removes DNA encoding both EGF and 5 amino acids from the C-terminus of the alpha-factor pro-peptide. Genes to be inserted into the pSW6 expression vector must therefore have the general composition: *Hind*III site-alpha factor adaptor-gene-*Bam*HI site.

After digestion with *Hind*III and *Bam*HI endonucleases, the pSW6 vector contains the alpha factor gene minus the codons for the last five amino acid residues. To construct the alpha factor-LD78 fusion gene in the pSW6 vector, the pUC18-LD78 vector of Preparation 1 was treated with *Hind*III and *Bam*HI endonucleases. The products of this digestion reaction were separated by electrophoresis on a 1% low gelling temperature agarose gel. The DNA fragment (ca. 235 bp) corresponding to the LD78 gene was excised and purified from the gel matrix. This DNA fragment was then ligated into *Hind*III and *Bam*HI treated pSW6 DNA (the vector DNA fragment lacking the EGF insert was purified for use in this ligation). The recombinant ligation products were transformed into competent HW87 *E. coli* cells. Transformants were selected on L-agar ampicillin plates. 12 Ampicillin resistant transformants were screened by preparation of plasmid DNA and restriction endonuclease analysis with *Hind*III and *Bam*HI followed by agarose gel electrophoresis. A clone (pSW6-LD78) with the correct electrophoretic pattern was selected. A plasmid preparation of this vector was prepared and the integrity of the construct was confirmed by dideoxy sequence analysis on the plasmid DNA using sequencing primer BB1330 (5'-AGGATGGGGAAAGAGAA-3') (SEQ ID NO: 16). This plasmid is the expression vector used for wild-type LD78 expression.

**Preparation 3 - Expression of Human LD78 Synthetic gene in *S. cerevisiae***

pSW6-LD78 plasmid DNA of Preparation 2 was prepared and electroporated into yeast (*S. cerevisiae*) strain MC2 which has the following genotype: *prc1-407*  
5 *prb1-1122, pep4-3, leu23-112, trp1 ura3-52* mating type  $\alpha$ . The use of strain MC2 is not critical for use either in this preparation or in the invention in general. Any suitable strain can be used, such as for example strain BJ2168, which is genetically almost identical to MC2 and is deposited (see Preparation 2 above).

10 Using the method described in the Bio-Rad manual (GENE PULSER™ transfection apparatus, Operating Instructions and Applications Guide, Version 10-90, Bio-Rad Laboratories, 3300 Regatta Boulevard, Richmond, CA 94804 USA) the plasmid DNA was electroporated. Briefly, yeast strain MC2 was grown overnight in YPD medium at 30°C overnight. Cells were harvested by centrifugation at 3000 r.p.m  
15 for 5 mins in a Beckman GS-6KR centrifuge, washed in sterile water and resuspended in 1M sorbitol, and then added in 40 $\mu$ l aliquots to various amounts (0.1  $\mu$ g - 1 $\mu$ g) of plasmid DNA. The resulting mixtures were subjected to a pulse of 1500 volts for 5 msec, and added to 300 $\mu$ l of 1M sorbitol. The electroporated cells were then plated out onto agar-sorbitol plates and allowed to grow for 4-5  
20 days at 30°C.

All yeast media were as described by Sherman *et al.*, "Methods in Yeast Genetics", Cold Spring Harbor Laboratory, (1986)).

25 **Yeast Expression and Purification**

After 4-5 days, electroporants were picked and plated onto fresh agar plates. Single colonies were obtained after a further 1-2 days growth at 30°C. Single colonies were then used to inoculate 5ml of YPD medium and the cultures were grown overnight at 30°C. This 5ml overnight culture was then used to inoculate

0.5 litre shake flasks containing 50ml of 0.67% synthetic complete medium, yeast nitrogen base, with amino acids minus leucine and 1% glucose as a carbon source and grown overnight at 30°C. After 24hrs growth, cells were harvested by centrifugation at 3000 rpm for 5 minutes in a SORVALL™ RC3-B centrifuge and used to inoculate 100ml of the same synthetic complete medium (except that 1% galactose and 0.2% glucose were used as the carbon source). This induces gene expression from the hybrid PGK promoter. Induction was carried out by growth in the galactose containing medium at 30°C for 48-72 hours.

5

10 After either 48 or 72 hrs the culture supernatant was collected by centrifugation in a SORVALL™ RC3-B centrifuge at 3000 rpm for 5 minutes to remove cells. This supernatant was used for further analysis and purification of LD78 according to the methods described in Preparation 4.

15 **Preparation 4 - Purification of human LD78 expressed from a synthetic gene in yeast**

20 Supernatant from the shake flasks described in preparation 3 was spun at 6500 rpm (SORVALL™ RC5-B centrifuge) for 15 minutes to clarify. Typically 3 litres of yeast supernatant were adjusted to pH8 and 30ml of Q-SEPAHROSE™ ion exchange resin (Pharmacia) pre-equilibrated in 50mM Tris pH8.0 was added. Protein was batch adsorbed overnight at 4°C with gentle agitation. The resin was then allowed to settle and the supernatant removed. The resin was then poured into a column 1.6cm in diameter and washed with 10 volumes of 50mM Tris pH8.0, the protein

25 was then eluted in 0.5M NaCl, 50mM Tris pH8.0 (typically 50ml total volume of eluent). The eluent was transferred into prewetted SPECTRAPOR™ dialysis membrane (3000Da cutoff) and dialysed against 10 x volume 50mM Tris pH8.0 at 4°C with one change of buffer. The sample was adjusted to 20% acetonitrile (final concentration) and the pH brought to 3.0 with hydrochloric acid. The protein

sample was then pumped directly (bypassing the Rheodyne injection loop) onto a 20ml VYDAC™ C-18 (10 $\mu$  pore-size) semi-preparative reverse phase HPLC column pre-equilibrated at 3ml/min in 20% acetonitrile, 0.1% trifluoracetic acid (TFA) and eluted with a linear gradient from 20% to 50% acetonitrile, 0.1% TFA over 5 40 minutes. Eluting fractions were detected by u.v. absorbance at 280nm and analysed by SDS-PAGE PHASTGEL™ (as described in Preparation 11). The pure LD78 protein was found to elute around 43% acetonitrile, 0.1% TFA. Purified LD78 was freeze-dried and stored at -20°C. The sequence of the protein is given as SEQ ID NO 2.

10

**Preparation 5 - Construction of a Synthetic Gene for Murine MIP-1 $\alpha$**

**Gene Design**

15 The published amino acid sequence for MIP-1 $\alpha$  was reverse-translated to give a gene sequence. The codon usage was then optimised to maximise expression in *S. cerevisiae*. SEQ ID NO 17 shows the sequence of the synthetic gene, the protein sequence is given as SEQ ID NO 18 and the antisense strand of the gene is SEQ ID NO 19. The method of Preparation 1 was followed for the construction of the MIP-1 $\alpha$  gene except that the oligonucleotides differ from those in preparation 1. 20 Figure 22 shows the annealed oligonucleotides used in the construction of the MIP-1 $\alpha$  gene (SEQ ID NOS 20-31). The synthetic gene was cloned into plasmid pUC18 to create pUC18MIP-1 $\alpha$ .

25

**Preparation 6 - Construction of a Yeast Expression Vector for Murine MIP-1 $\alpha$**

With the exception of the changes detailed below, the method of Preparation 2 was followed for the construction of a yeast expression vector designed to enable secretion of MIP-1 $\alpha$  from *S. cerevisiae*.

The MIP-1 $\alpha$  synthetic gene in pUC18MIP-1 $\alpha$  vector of Preparation 5 must be engineered prior to its inclusion into the pSW6 expression vector. This is because the synthetic MIP-1 $\alpha$  gene lacks sequences at the 5' end suitable for the construction of an in frame fusion to the alpha factor gene in the pSW6 vector.

5 To rebuild the DNA encoding the amino acids at the C-terminal end of the alpha-factor pro-peptide and to fuse this to the synthetic MIP-1 $\alpha$  gene, an oligo nucleotide adapter BB985 (5'-AGCTTGGATAAAAGA-3' (SEQ ID 32, top strand), BB986 5'-TCTTTATCCA-3' (SEQ ID 33, bottom strand)) containing a *Hind*III site and codons encoding the Ser, Leu, Asp, Lys and Arg from the C-terminal end of the alpha-factor pro-peptide was constructed. The alpha factor adaptor was ligated to the synthetic MIP-1 $\alpha$  gene such that the recombinant gene encoded an in-frame alpha-factor pro-peptide fusion to MIP-1 $\alpha$ . The pUC18MIP-1 $\alpha$  plasmid of Preparation 5 was first cleaved with *Bsp*MI and the overhanging ends were filled using DNA polymerase I to create a blunt ended linear DNA fragment. The linearised DNA fragment was separated from uncut plasmid DNA on a 1 % low gelling temperature agarose gel matrix, then further treated with *Hind*III. The fragment was then ligated to the alpha-factor adaptor described above. Note that the two strands of the adaptor were annealed prior to ligation. The recombinant ligation products were transformed into competent cells of *E. coli* HW87. Ampicillin-resistant transformants were analysed by preparation of plasmid DNA, digestion with *Hind*III and *Bam*HI and agarose gel electrophoresis. A correct recombinant plasmid was identified. The integrity of this vector was confirmed by dideoxy sequencing analysis using sequencing primers BB3376 and BB3379. (BB3376 and BB3379 are shown together in SEQ.

10 15 20 25 ID: 5.)

This plasmid was used as a source of DNA for construction of the yeast expression vector. The method of Preparation 2 was followed. Briefly the modified pUC18 MIP-1 $\alpha$  vector now containing the alpha factor adaptor was digested with *Hind*III

and *Bam*HI and the MIP-1 $\alpha$  DNA fragment was purified. This fragment was ligated to *Hind*III and *Bam*HI treated pSW6 DNA according to the method in Preparation 2. The MIP-1 $\alpha$  expression vector, the subject of Preparation 7, was called pSW6MIP-1 $\alpha$ . This vector was used for subsequent expression.

5

**Preparation 7 - Expression of Synthetic Murine MIP-1 $\alpha$  in Yeast**

10 The method of Preparation 3 was used for the expression of the murine MIP-1 $\alpha$  gene with the exception that the expression vector used was pSW6MIP-1 $\alpha$  and transformation was used in place of electroporation. The method of Sherman F. *et al.*, ("Methods in Yeast Genetics", Cold Spring Harbor Laboratory, (1986)) was used for transformation.

15 **Preparation 8 - Purification of murine MIP-1 $\alpha$  expressed from a synthetic gene in yeast**

20 Supernatant from the shake flasks described in Preparation 7 was centrifuged at 5000 rpm in a SORVALL™ RC-5B centrifuge to clarify. Typically 5 litres of clarified supernatant were adjusted to 20% acetonitrile, 0.1% TFA (final concentration) and 30g of C-18 silica resin was added as a dry powder. Protein was batch adsorbed onto the resin overnight at 4°C with gentle agitation. The silica resin was then allowed to settle and the supernatant removed. Resin was then poured into a 2.5cm (diameter) column, washed with 10 column volumes of 25% acetonitrile, 0.1% TFA and eluted with 50% acetonitrile, 0.1% TFA; 30ml fractions were collected manually. Aliquots of these fractions were dried and analysed by SDS-PAGE PHASTGEL™ (Pharmacia) as described in Preparation 13. The protein concentration was estimated from the absorbance at 280nm in a 1cm pathlength cell and a calculated absorbance of 1.37 for a 1mg/ml protein solution under the same conditions. The eluted fractions were then freeze-dried. For further

purification, the dried fractions were reconstituted in 0.1% TFA (final concentration) and 4mg aliquots loaded onto a 20ml DYNAMAX™ semi-preparative C-18 reverse phase column (10 $\mu$  pore-size) at 3ml/min equilibrated in 25% acetonitrile, 0.1% TFA. MIP-1 $\alpha$  was eluted using a linear 25-45% acetonitrile, 0.1% TFA gradient over 50 minutes. Eluting fractions were detected by u.v. absorbance at 280nm and collected manually. Purified MIP-1 $\alpha$  was freeze dried and stored at -20°C.

## Preparation 9 - Construction of a Synthetic Gene for Human ACT-2

10

## Gene Design

The published amino acid sequence for human ACT-2 was reverse-translated to give a gene sequence. The codon usage was then optimised to maximise expression in *S.cerevisiae*. SEQ ID NOS 34 and 36 show the sequence of the two strands of the synthetic gene and the protein sequence is given as SEQ ID NO 35. The method of Preparation 1 was followed for the construction of the ACT-2 gene except that the oligonucleotides differ from those in preparation 1. Figure 23 shows the annealed oligo nucleotides used in the construction of the ACT-2 gene. The synthetic gene was cloned into plasmid pUC18 to create pUC18ACT-2.

20

## Preparation 10 - Construction of a Yeast Expression Vector for Human ACT2

The method of Preparation 2 was followed except that the ACT-2 gene from pUC18 ACT-2 was used in place of the pUC18-LD78. The resultant ACT-2 expression vector was called pSW6 ACT-2.

## Preparation 11 - Expression of Human ACT-2 Synthetic Gene in Yeast

The method of Preparation 3 was followed except that pSW6 ACT-2 DNA was a used as the expression vector.

**Preparation 12 - Purification of human ACT2 expressed from a synthetic gene in yeast**

Supernatant from the shake flasks described in Preparation 11 was spun at 6500 rpm for 15 minutes to clarify. Typically 3 litres of yeast supernatant were adjusted to pH8 and 30ml of Q-SEPHAROSE™ pre-equilibrated in 50mM Tris pH8.0 added. Protein was batch-adsorbed onto the resin overnight at 4°C with gentle agitation. The resin was allowed to settle and the supernatant removed. Resin was poured into a column 1.6 cm in diameter, washed with 10 x volumes 50mM Tris pH8.0, then eluted in 0.5M NaCl, 50mM Tris pH8.0 (typically 50ml total eluent). The eluent was transferred into a prewetted SPECTRAPOR™ dialysis membrane (3000 dalton cutoff) and dialysed against 10 x volumes of 50mM Tris pH8.0 at 4°C with one change of buffer. The sample was then loaded onto an 8ml Heparin-SEPHAROSE™ column (1.6cm diameter) equilibrated in 50mM Tris pH8.0 and the column washed with the same buffer. ACT-2 was eluted in 50mM Tris, 1M NaCl pH8.0. The eluent was then transferred to a prewetted SPECTRAPOR™ dialysis membrane (3000 dalton cutoff) and dialysed against 10 x volume 0.1% TFA at 4°C with one change of buffer. After dialysis the sample was adjusted to 25% acetonitrile (final concentration). The protein sample was then loaded onto a 20ml VYDAC™ C-18 (10 $\mu$  pore-size) semi-preparative reverse phase HPLC column pre-equilibrated at 3ml/min in 20% acetonitrile, 0.1% Trifluoracetic acid (TFA) and eluted with a linear gradient from 20% to 50% acetonitrile, 0.1% TFA over 40 minutes. Eluting fractions were detected by u.v. absorbance at 280nm and collected manually. The ACT-2 protein was found to elute around 43% acetonitrile, 0.1% TFA. Purified ACT-2 was freeze-dried and stored at -20°C.

**Preparation 13 - Confirmation of the Identity and Purity of Human LD78, Human ACT-2 and Murine MIP-1 $\alpha$  expressed from Synthetic Genes in Yeast**

5 A purity of greater than 97% was confirmed using a range of analytical procedures. Small aliquots (5 $\mu$ g in 5 $\mu$ l of sample buffer as described in Comparative Example 2) of the dried material were analysed with sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) using an 8-25% acrylamide gradient PHASTGEL™ (Pharmacia) using the manufacturers' recommended sample buffer and running programme. Gels were stained and  
10 destained according to the manufacturers' recommended procedures.

15 Analytical reverse phase-HPLC was carried out using a 2ml VYDAC™ C-18 analytical reverse-phase column (5 $\mu$  pore-size) equilibrated in 20% acetonitrile, 0.1% TFA at 1ml/min. Approximately 10-50  $\mu$ g of protein was loaded and eluted with a linear gradient of 20-50% acetonitrile, 0.1% TFA at a flow rate of 1ml/min  
20 over 20minutes.

20 Near ultra-violet absorbance spectroscopy in the 240-320nm range, with a 1cm pathlength and 1nm bandwidth was used to ensure that no turbidity (light scattering) arising from aggregated rSCI was present in the purified preparation.

25 The identity of the purified proteins were confirmed from the N-terminal sequence and the mass of the product. Electrospray mass spectroscopy was carried out on a VG BIO-Q™ spectrometer with 50 $\mu$ g of sample dissolved in 1:1 (v/v methanol/water containing 1% acetic acid. In some cases, substantial populations of LD78 protein + metal adduct mass peaks were observed. Typically potassium and copper were noted. Major copper contamination was found to originate from a metal line within the spectrometer, however, the LD78 proteins were shown to tightly hold this metal ion even in the large electric field applied on injection. The

strength of association suggests that LD78 has an ability to bind this divalent metal ion with reasonable affinity if exposed to significant quantities.

5 N-terminal sequencing was carried out using an Applied Biosystems 471A sequenator, Applied Biosystems Ltd, Kelvin Close, Birchwood Science Park North, Warrington WA3 7PB. Typically 250 picomoles of protein dissolved in 0.1%TFA was loaded onto a BIOBRENE™ precycled glass fibre disc and subjected to 14 cycles of automated Edman degradation. All procedures and sequencing cycles were as recommended by the manufacturer.

10

## COMPARATIVE EXAMPLES

### Comparative Example 1 - Conformational Analysis of Recombinant Human LD78, Human ACT-2 and Murine MIP-1 $\alpha$

15

Near and far ultra-violet circular dichroism (u.v. c.d.) measurements of MIP-1 $\alpha$ , LD78 and ACT-2 were carried out using a Jobin-Yvon Dichrographe VI. Samples were reconstituted in 10mM acetic acid pH3.2 and a u.v. absorbance scan from 240-320nm used to confirm the absence of protein aggregates. The protein concentration was determined using calculated values for the absorbance of a 1mg/ml solution at 280nm with a 1cm pathlength of 1.37 for MIP-1 $\alpha$ , 1.25 for LD78 and 1.57 for ACT-2. Mean residue weights were calculated to be 114, 113.7 and 113.3 for MIP-1 $\alpha$ , LD78 and ACT-2 respectively. Near u.v. c.d. spectra (250-320nm) were collected using a scan speed of 5nm/min, 1 second response, 2nm bandwidth and a 1cm pathlength. Far u.v. c.d. spectra (190-250nm) were collected using a 10nm/min scan speed, 1 second response, 2nm bandwidth and either a 0.01cm or 0.05cm pathlength. All spectra are calculated and displayed as a mean residue molar ellipticity [ $\theta$ ] with baseline subtracted.

20  
25

Analysis of the far ultra-violet circular dichroism of these sequence related proteins using the CONTIN™ programme (Provencher, *Comput. Phys. Commun.*, **27**, 229-242, (1982); Provencher & Gloeckner, *Biochemistry*, **20**, 33-37, (1981)) has confirmed that MIP-1 $\alpha$ , LD78 and ACT-2 contain 14-18% helix and a high proportion of  $\beta$ -sheet structure which is consistent with the known secondary structure contents of IL-8 (Clore *et al.*, *J. Biol. Chem.*, **264**, 18907-18911, (1989)) and PF-4 (St. Charles *et al.*, *J. Biol. Chem.*, **264**, 2092-2099, (1989)).

In the 250-320 nm wavelength range, circular dichroism spectra arise from disulphide bonds and aromatic groups such as tyrosine, tryptophan and to a lesser extent phenylalanine (Strickland, *C.R.C. Crit. Rev. Biochem.*, **2**, 113-175, (1974)). Circular dichroism bands in the near u.v. often (but not always) coincide with their chromophore absorption bands. The magnitude, sign (positive/negative) and wavelength position of the c.d. bands are highly sensitive to the conformational environment of the contributing side-chain. Whilst no definitive set of rules exist for interpretation of the contributions to near u.v. c.d. spectra, the intensity and position of shoulders, shape and maxima or minima can nevertheless be used to identify side-chain types. For example, characteristic tyrosine bands are often observed with minima centred at 276nm and 268nm, in single tryptophan proteins the  $0_0^1L_b$  band is observed characteristically at 288-293nm. Phenylalanine produces fine structure, often seen as shoulders in c.d. spectra, in the 250-270nm range. Disulphide bonds have very broad featureless contributions which are variable in intensity and can extend from 250nm up to 360nm.

Excepting Tyr3 of MIP-1 $\alpha$ , the tyrosines and the single tryptophan residues are conserved in the sequence of LD78 and MIP-1 $\alpha$ . The near u.v. circular dichroism spectra of LD78 and MIP-1 $\alpha$  are almost superimposable (Figure 3). The intense negative ellipticity below 290nm with the minima centred at 268nm and 276nm is characteristic of tyrosine with some phenylalanine fine structure superimposed. The

intensity of the spectra between 250-290nm may reflect coupling of transitions between a tyrosine residue and another aromatic group. The broad trough of negative ellipticity observed above 290nm appears to exhibit a minima at 296nm with a broad trail to higher wavelength. This shape is somewhat unusual for a tryptophanyl band and it might, therefore, reflect a disulphide contribution. The data demonstrate that Tyr3 of MIP-1 $\alpha$  is not contributing to the spectrum. Given that the N-terminal regions of IL-8 and PF-4 are known to be disordered then the absence of Tyr3 c.d. in MIP-1 $\alpha$  is not unexpected.

5

10 The near ultra-violet circular dichroism spectra demonstrate that the environment of aromatic amino acids in LD78 and MIP-1 $\alpha$  is almost identical. These data demonstrate that the two homologues have the same tertiary structure and conformation.

15 Comparison of the near u.v. c.d. of ACT-2 with MIP-1 $\alpha$  highlights distinct differences in the shape and intensity of the spectra (Figure 4). The ACT-2 spectrum shows a less intense negative tyrosine contribution combined with a distinct  $\text{O}_\text{O}^1\text{L}_\text{b}$  tryptophan contribution from the (conserved) single tryptophan residue-58. The only sequence difference between the proteins likely to contribute to the near u.v. c.d. is Tyr29 in ACT-2 (Phe28 in MIP-1 $\alpha$ ). The nature of the shape and intensity changes observed for the ACT-2 c.d. are not consistent with addition or cancellation simply of a tyrosine band. The data demonstrate, therefore, that there are distinct differences in the conformation of ACT-2 compared to that of MIP-1 $\alpha$  and LD78. These proteins all have similar multimerisation properties as detailed in Comparative Example 3. The variation in conformation for ACT-2 is not therefore a result of different quaternary structure.

20

25

**Comparative Example 2 - LD78 is Immunologically Cross-Reactive with Anti-MIP-1 $\alpha$**

5        5 $\mu$ g each of MIP-1 $\alpha$ , LD78, ACT-2 and human epidermal growth factor (as a standard marker) were dissolved in 5 $\mu$ l of sample buffer (25mM Tris pH6.8, 2.3% sodium dodecyl sulphate, 5%  $\beta$ -mercaptoethanol, 10% glycerol, 0.01% bromophenol blue) and heated at 90°C for 5 minutes to reduce and denature the protein. Approximately 1 $\mu$ g of protein per track was loaded onto 2 identical 8-25% (acrylamide) SDS-PAGE PHASTGELS™; pre-stained low molecular weight markers (Bethesda Research Laboratories) were also run on each gel. The gels were 10        electrophoresed using the manufacturers' recommended conditions. Following electrophoresis, one of the gels was stained with 0.02% PHASTGEL BLUE R™, 30% methanol, 10% acetic acid followed by destaining in 30% methanol, 10% acetic acid. The second gel was sandwiched between nitrocellulose membrane and 15        electroblotted for 40 minutes at 100 volts using 25mM Tris, 192mM glycine, 20% methanol transfer buffer. After transfer of protein onto the nitrocellulose membrane, the membrane was incubated in 0.5% casein, 154mM NaCl, 20mM Tris pH7.4, 0.05% Triton blocking buffer for 1 hour at room temperature. The membrane was then incubated for an hour with a 1:5000 (v/v) dilution of the 20        primary antibody (polyclonal rabbit anti-MIP-1 $\alpha$ , generated by standard immunological techniques following immunisation with the protein of Preparation 8) in blocking buffer at room temperature. After washing 3x5min with blocking buffer, the second antibody (anti-rabbit peroxidase conjugated (Sigma)) was incubated with the membrane at 1:10000 (v/v) in blocking buffer for a further 1 25        hour at room temperature (Sigma Chemical Company Ltd, Fancy Road, Poole, Dorset BH17 7BR). After 3x5min washes in 150mM phosphate buffered saline pH7.4 (PBS) the blot was developed in 25ml of developing solution (0.04% 3,3'-diaminobenzidine tetrahydrochloride, PBS, 0.015% cobalt chloride, 0.015% ammonium nickel sulphate, 0.2% hydrogen peroxide). Development was stopped

by washing the membrane with distilled water. The membrane was then dried and photographed.

5 The immunoblot (Figure 5; 8-25% SDS-PAGE (Reducing)) demonstrates that there is no cross-reaction of anti-MIP-1 $\alpha$  with ACT-2, however, there is a strong cross-reaction with LD78. MIP-1 $\alpha$  and LD78 have the same epitope and immunological profile whereas ACT-2 is immunologically distinct. Together with the conformational data of Comparative Example 1, this evidence strongly supports the suggestion that LD78 is the human homologue of murine MIP-1 $\alpha$ .

10

**Comparative Example 3 - Characterization of the molecular weight of LD78 and MIP-1 $\alpha$  (expressed from synthetic genes in yeast) under physiological conditions**

15 LD78 and MIP-1 $\alpha$  are non-glycosylated, with theoretical molecular weights of 7712Da and 7866Da, respectively. ACT-2 has a theoretical molecular weight of 7704Da, though the authentic molecule is thought to be glycosylated. Size exclusion chromatography (SEC) was carried out using a SUPEROSE 12<sup>TM</sup> column attached to an Fast Protein Liquid Chromatography system (Pharmacia). The column was calibrated at 1ml/min in 150mM phosphate buffered saline, pH 7.4  
20 (Sigma) using blue dextran, aldolase, bovine serum albumin, carbonic anhydrase and lysozyme as standards. Samples (50-100 $\mu$ g) of MIP-1 $\alpha$ , LD78 and ACT-2 were dissolved in 0.2ml of 150mM phosphate buffered saline, pH 7.4 (Sigma) and loaded onto the column running at the calibrated speed of 1ml/min. Eluting fractions were detected by u.v. absorbance at 280nm.

25

Reconstitution of each of lyophilized recombinant LD78, MIP-1 $\alpha$  and ACT-2 as described above yields a product which is predominantly a soluble multimeric complex when analysed by size exclusion chromatography (Figure 6). The soluble multimers range in size from 100,000Da to >> 200,000Da with the predominant

weights apparently in the region of 350,000Da. The column excludes particles of greater than 180,000Da; therefore, accurate determinations of masses above this limit are impossible. Over a period of hours the multimeric complexes can form insoluble aggregates which visibly precipitate. A population of low molecular weight species is observed in the SEC profile of all three proteins. In view of the elution at >20,000Da, and given that the SDS-PAGE results (described in Comparative Example 2) show stable tetramers, it is suggested that these proteins associate to stable tetramers similar to their sequence homologue PF-4. The results described in detail in Comparative Examples 4 and 5 confirm that a basic quaternary structural unit of these molecules is a tetramer.

Samples of LD78, MIP-1 $\alpha$  and ACT-2 were also analysed using native polyacrylamide gel electrophoresis. 5 $\mu$ g of each protein were reconstituted in 25mM Tris pH6.8, 10% glycerol, 0.01% bromophenol blue. Samples were loaded with high molecular weight markers (Flowgen) and human EGF standard and electrophoresed on a 5-50% GRADIPORE HYLINK™ native gel (Flowgen) at 100 volts for 15 minutes in 0.0825M Tris, 0.0808M boric acid, 0.003M EDTA, pH8.3. The gel was subsequently Coomassie blue-stained and destained (as described in Comparative Example 2).

The stained gel (Figure 7) shows that human EGF (6,200 daltons) standard runs at the correct weight under native conditions. MIP-1 $\alpha$ , LD78 and ACT-2 however, all run at the top of the gel with broad smearing bands demonstrating a range of molecular weight species. No low molecular weight species are observed.

The two techniques described above provide some quantitative estimates of the molecular size of LD78 and MIP-1 $\alpha$  in solution. In both cases, however, a solid support resin is present (acrylamide or SEPHADEX™) which can affect equilibrium populations of molecules. The recognized method of absolute molecular mass

determination in solution is by Sedimentation Equilibrium in the analytical ultracentrifuge (see for example Yphantis (1964) or Harding *et al* (1992)).

Using a BECKMAN OPTIMA™ XL-A analytical ultracentrifuge, protein solute distributions can be recorded by u.v. absorbance during sedimentation equilibrium experiments (for example see Morgan *et al*, (1992)). In a population of protein molecules distributed at equilibrium through the rotor cell, approximate values for the smallest (protein) mass in solution are obtained from the cell meniscus ( $M_w(\zeta=0)$ ), and the largest (protein) mass in solution determined from the cell base ( $M_w(\zeta=1)$ ). This technique provides the whole-cell weight average molecular weight ( $M_w^*$ ) (i.e. the average molecular weight of solute distributed through the rotor cell). In this manner the self-association properties (if present) of a protein molecule can accurately be determined from the measured polydispersity in the observed mass ranges. Characteristically, such polydisperse solutions show an upward curvature when logarithm of absorbance is plotted as a function of the normalised radial displacement parameter ( $\zeta$ ) in analyses of the type detailed by Creeth & Harding (*J.Biochem. Biophys.Methods*, 7 25-34 (1982)) and Creeth & Pain, (*Prog. Biophys & Mol. Biol.* 17 217-287 (1967)). Proteins which exist in solution at a single defined mass (i.e. a monodisperse population) exhibit linear plots of  $\ln A$  vs  $\zeta$ . Non-ideal solution conditions typically yield a downward curvature of  $\ln A$  vs  $\zeta$ . It is possible for the effects of polydispersity and non-ideality to cancel each other and give a linear plot of  $\ln A$  vs  $\zeta$  (Creeth & Pain, *loc. cit.* (1967)). This must be considered during data interpretation.

The sedimentation equilibrium behaviour of pure wild type LD78 was measured at 20°C with a protein concentration of 0.5mg/ml using the OPTIMA™ XL-A ultracentrifuge with a rotor speed of 9000, 10000 or 12000r.p.m. and absorbance detection at 278nm. For masses in the range of monomers, a rotor speed of 28000r.p.m. is necessary at 20°C. The methodology and analysis were as

described by Morgan *et al.* (1992). The results (Figure 8) showed that wild type LD78 exists in solution as a polydisperse population of protein species ranging in mass from approx. 10,000Da ( $M_w(\zeta=0)$ ) to 250,000Da ( $M_w(\zeta=1)$ ). The whole cell weight average molecular weight ( $M^{\circ}_w$ ) was found to be 160,000Da.

5

Pure MIP-1 $\alpha$  was analysed in the same manner except that the rotor speed was 15,000 r.p.m.. In this case, the protein was shown to exist as a polydisperse solution of protein species ranging in mass from 230,000Da ( $M_w(\zeta=0)$ ) to 350,000Da ( $M_w(\zeta=1)$ ) with ( $M^{\circ}_w$ ) = 310,000Da.

10

The results from the independent techniques described above confirm that MIP-1 $\alpha$ , LD78 and ACT-2 form large, soluble, heterogenous, multimeric complexes on reconstitution in low ionic strength aqueous buffers.

15

It is known that 0.5M NaCl prevents formation of the high molecular weight forms of MIP-1 $\alpha$  and that in culture medium, around 5% of the total protein is a low molecular weight form (Oh *et al.* (1991)). Our studies demonstrate that in the absence of salt (i.e. in native PAGE sample buffer) no low molecular weight forms are present. In physiological ionic strength (150mM phosphate buffered saline, pH7.4), a distinct population of low molecular weight protein species is present as seen in the size exclusion profiles. An equilibrium is, therefore, present between the high and low molecular weight species. This equilibrium is influenced by the ionic strength of the buffer - see Comparative Example 4.

20

25

**Comparative Example 4 - Characterization of the molecular weight of LD78 and MIP-1 $\alpha$  (expressed from synthetic genes in yeast) in 10mM MES, 500mM NaCl pH6.5**

Salt concentrations of 0.5M have been claimed to prevent formation of high

molecular weight forms of MIP-1 $\alpha$  (Wolpe and Cerami (1989). In order to characterize fully the effect of salt and to elucidate the association pathway of SCI multimers, the molecular weight of LD78 and MIP-1 $\alpha$  were examined in conditions of high ionic strength.

5

Size exclusion chromatography was carried out using a SUPEROSE 12<sup>TM</sup> column attached to an FPLC system (Pharmacia). The column was calibrated at 1ml/min in 10mM MES (Sigma), 500 mM NaCl pH6.5 using the standards described in Comparative Example 3. Samples (100 $\mu$ g) of MIP-1 $\alpha$  and LD78 were dissolved in 0.2ml of 10mM MES (Sigma), 500mM NaCl pH6.5 and loaded onto the column running at the calibrated speed of 1ml/min. Eluted fractions were detected by u.v. absorbance at 280nm.

10 Reconstitution of the lyophilized recombinant LD78 under these conditions gives an SEC elution profile containing a single symmetrical peak of mass around 20-25KDa. The peak symmetry indicates that a single homogenous population of protein molecules exists. It is unclear from the determined mass whether trimeric or tetrameric LD78 represents the observed species.

15 20 Reconstitution of lyophilized recombinant MIP-1 $\alpha$  under these conditions gives an SEC elution profile containing an asymmetric peak of approximate mass 25kDa trailing down to around 5kDa. The shape of the peak suggests the protein exists in a number of mass species under these conditions. The elution profile most probably reflects the presence of tetramer, dimer and monomer populations in solution.

25 Analytical ultracentrifugation of LD78 was carried out in these buffer conditions as described in Comparative Example 3. The whole cell weight average molecular weight was calculated to be a single population with molecular mass of 29  $\pm$  2

kDa. Under these conditions of 10mM MES, 500mM NaCl pH6.4, LD78 exists in solution as a defined tetramer in the absence of higher and lower molecular weight forms (Figure 8).

5 These data demonstrate that ionic interactions play a key role in the association of LD78 tetramers to form the large heterogeneous multimers.

**Comparative Example 5 - Characterization of the molecular weight of LD78 (expressed from a synthetic gene in yeast) in 50mM Tris, 1M Glycine pH 8.3**

10

In order to correlate the molecular mass profiles obtained on native PAGE immunoblots described in Comparative Example 3 with data generated from other methods of mass determination, SEC was carried out in native PAGE buffer. SUPERDEX 75™ FPLC resin has a comparable mass resolution range (3 - 70kDa) 15 as the Biorad (MINIPROTEAN™ 12% acrylamide) pre-cast gels. This size exclusion column was, therefore, used to recreate the gel conditions as closely as possible. 100 $\mu$ g of LD78 was reconstituted in 0.2ml of 50mM Tris, 1M Glycine pH8.3 buffer and injected at a flow rate of 1ml/min onto the SUPERDEX 75™ column equilibrated in the same buffer. Eluting fractions were detected by u.v. absorbance 20 at 280nm.

25 The SEC elution profile of LD78 shows a major asymmetric peak of high molecular weight (> 70kDa) protein partially excluded from the column, a small dimer peak at approx. 15KDa and a major symmetrical peak corresponding to the monomer mass around 8,000Da. The presence of a large population of monomeric LD78 in equilibrium with high molecular weight multimers suggests that the quaternary structure of LD78 is extremely sensitive either to:

(i) a 0.9 unit shift in pH between this buffer system and that in Comparative Example 3

or

5

(ii) the presence of significant concentrations of the free amino acid glycine.

10 Sedimentation equilibrium studies of LD78 (method as described in Comparative Example 3) at a protein concentration of 0.5mg/ml under these buffer conditions reveal the presence of a polydisperse population of mass species ranging from 8,000Da ( $M_w(\zeta=0)$ ) to  $> 300,000$ Da ( $M_w(\zeta=1)$ ).

15 As described in Preparation 13, electrospray mass spectroscopy reveals the presence of mono-valent and di-valent metal ions bound to purified LD78. Many chemical methods involve the use of metal ions to chelate to free amino and carboxyl groups of amino acids to enable the modification of side-chain groups in reaction mixtures (Chemistry of the Amino Acids, Volume 1 - Chapter 6, Krieger Publishing Florida, ed. Greenstein & Winitz (1961)). The glycine present in this 20 buffer could therefore act as a chelator for metal ions. Only a small population of dimeric LD78 is evident in the SEC profile and no tetrameric species are observed. It is suggested, therefore, that metal ions can play a role in the stabilization of both the LD78 tetramer and dimer units.

25 Comparative Example 6 - Characterization of the molecular weight of LD78 (expressed from a synthetic gene in yeast) in 10mM acetic acid pH3.2

The stem cell inhibitor protein LD78 is very soluble in mild acidic conditions. Size exclusion chromatography is not ideal under acidic conditions, therefore, analytical

ultracentrifugation of LD78 was carried out. At a protein concentration of 0.5mg/ml in 10mM acetic acid pH3.2, a monodisperse mass species of  $33 \pm 3$ kDa was observed (Figure 8). This mass equates to a monodisperse population of tetramers.

5

The relatively low ionic strength acidic conditions may titrate Glu and/or Asp groups involved in the electrostatic interactions involved in the association of tetramers to multimers described in Comparative Example 4.

10 **Comparative Example 7 - Spectroscopic assay for the state of multimerisation of LD78 protein expressed from a synthetic gene in yeast**

LD78 exists in solution as a tetramer in 10mM acetic acid pH3.2 and 10mM MES, 500mM NaCl pH 6.4 (Comparative Example 4 & 6). In solutions such as 150mM PBS pH7.4 the protein is present as a heterogeneous population of soluble multimeric complexes stabilized by electrostatic interactions between charged side-chains (Comparative Example 3).

20 The near u.v. c.d. spectra of LD78 (measured as described in Comparative Example 1) in 10mM acetic acid pH3.2 and 10mM MES, 500mM NaCl pH6.4 are identical (Figure 9). This data demonstrates that the buffer conditions used to produce tetrameric LD78 do not affect the tertiary conformation of the protein.

25 Comparison of the near u.v. c.d. spectrum of tetrameric LD78 with that of the high molecular weight multimers in 150mM PBS pH7.4 (Figure 10) shows that the asymmetric environment of Trp57 is different in the two states (See Comparative Example 1 for discussion of c.d. spectra interpretation).

Examination of the steady state fluorescence emission spectra (method as described in Comparative Example 1) of LD78 in 10mM acetic acid, 10mM MES, 500mM NaCl pH6.4 and 150mM PBS pH7.4 (Figure 11) shows that in the high molecular weight multimers, quenching of emission intensity occurs. The fact that  $\lambda_{max}$  has not shifted, indicates that no conformational changes have occurred giving rise to quenching. It is known that electrostatic interactions proximal to tryptophan residues will quench the emission of fluorescence energy (Lackowicz (1983)). Stabilizing interactions between acidic and basic amino acids are known to be key for the association of tetramers to form multimeric complexes (Comparative Example 4). The change in environment observed for Trp-57 is entirely consistent with the formation of an ionic interaction spatially close to the side-chain.

Near u.v. c.d. and/or fluorescence emission spectroscopy can provide a sensitive probe for the multimer state of LD78.

15

## EXAMPLES

20 **Example 1 - Design and Construction of LD78 Variant Gln48>Glu (Mutant 1) and Construction of an LD78 Gln48>Glu Expression Vector**

25 The strategy for construction of an LD78 variant (eg. Gln48>Glu) by oligonucleotide directed mutagenesis and molecular cloning is described below. Mutagenesis was carried out according to the method of Kunkel *et al.*, *Methods in Enzymology* 154 367-382 (1987). Host strains and methods are described below.

### *E. coli* strains

RZ1032 is a derivative of *E. coli* that lacks two enzymes of DNA metabolism: (a) dUTPase (*dur*), the lack of which results in a high concentration of intracellular

5 dUTP, and (b) uracil N-glycosylase (*ung*) which is responsible for removing mis-incorporated uracils from DNA (Kunkel *et al.*, *loc. cit.*). A suitable alternative strain is CJ236, available from Bio-Rad Laboratories, Watford WD1 8RP, United Kingdom. The principal benefit is that these mutations lead to a higher frequency of mutants in site directed mutagenesis. RZ1032 has the following genotype:

HfrKL16PO/45[*lysA*961-62), *dut1*, *ung1*, *thi1*, *recA*, *Zbd-279*::*Tn10*, *supE44*

10 JM103 is a standard recipient strain for manipulations involving M13 based vectors. The genotype of JM103 is  $\Delta$  (*lac-pro*), *thi*, *supE*, *strA*, *endA*, *sbcB15*, *hspR4*, F' *traD36*, *proAB*, *lacIq*, *lacZ* $\Delta$ M15. A suitable commercially available alternative *E. coli* strain is *E. coli* JM109, available from Northumbria Biologicals Ltd.

15

Mutagenesis

Prior to mutagenesis it was necessary to transfer the LD78 gene into a suitable vector. This was accomplished as described below.

20 pSW6 LD78 plasmid DNA of Preparation 2 was prepared and an aliquot was treated with restriction enzymes *Hind*III and *Bam*HI. A ca. 235 bp DNA fragment from this digestion was gel purified and ligated to *Hind*III and *Bam*HI treated *E. coli* bacteriophage M13 mp19 DNA. The products of the ligation reaction were transfected into competent cells of *E. coli* strain JM103. Single stranded DNAs from 6 putative recombinant plaques were then prepared and sequenced, by the dideoxy method, with a universal primer BB22 (5'-GTTTCCCAGTCACGAC-3' (SEQ ID NO 47)).

Single stranded DNA of M13mp19-LD78 was prepared from *E. coli* RZ1032 and used as a template for oligonucleotide directed mutagenesis as described by Kunkel *et al.*, using 22-mer oligonucleotide BB6298 (5'-GCACAGACTTCTCGAGCGCT-3' (SEQ ID NO 48)). The required mutant (pGHC600) was identified by dideoxy sequence analysis of single stranded DNAs prepared from putative mutant plaques. Primer BB22 (see above) was used as the sequencing primer in all cases. Double stranded replicative form (RF) DNA was prepared from the bacteriophage carrying the required mutation. The RF DNA was then digested with *Hind*III and *Bam*HI. The DNA fragment carrying the LD78 Gln48 > Glu gene was then purified after electrophoretic separation on a low gelling temperature agarose gel by standard methods. This fragment was then ligated to *Hind*III and *Bam*HI treated pSW6 DNA to create an expression vector for the LD78 Gln48 > Glu gene. The sequence of a correct clone (pSJE50) was verified by plasmid DNA sequencing. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

Example 2 - Design and Construction of LD78 Variant Lys44 > Glu Arg45 > Gln (Mutant 2) and Construction of an LD78 Lys44 > Glu Arg45 > Gln Expression Vector

LD78 Lys44 > Glu Arg45 > Gln was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 30-mer oligonucleotide BB6299 (5'-GACTTGTCTCGATTGCTCAGTCAAGAAGAT-3' (SEQ ID NO 49)) was used to mutate the LD78 gene and a correct clone identified (pGHC601). The mutant gene was cloned into the expression vector to create pSJE51. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

Example 3 - Design and Construction of LD78 Variant Ala9>Ser (Mutant 3) and Construction of an LD78 Ala9>Ser Expression Vector

LD78 Ala9>Ser was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 22-mer oligonucleotide BB6300 (5'AAACACAAGAGGTTGGAGTGT-3' (SEQ ID NO 50)) was used to mutate the LD78 gene and a correct clone identified (pGHC602). The mutant gene was cloned into the expression vector to create pSJE52. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

10

Example 4 - Design and Construction of LD78 Variant Phe28>Ser (Mutant 4) and Construction of an LD78 Phe28>Ser Expression Vector

LD78 Phe28>Ser was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 25-mer oligonucleotide BB6381 (5'-GAAGAAGTTCA(G/C/T)AGTAGTCAGCAA-3' SEQ ID NO 51) was used to mutate the LD78 gene and a correct clone identified (pGHC603). The mutant gene was cloned into the expression vector to create pSJE53. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

20

Example 5 - Design and Construction of LD78 Variant Arg17>Ser (Mutant 5) and Construction of an LD78 Arg17>Ser Expression Vector

LD78 Arg17>Ser was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 25-mer oligonucleotide BB6302 (5'-GTGGAATTGAGAAGAGGTGTAAGA-3' SEQ ID NO 52) was used to mutate the LD78 gene and a correct clone identified (pGHC604). The mutant gene was cloned into the expression vector to create pSJE54. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

Example 6 - Design and Construction of LD78 Variant Phe23>Asn Ile24>Thr (Mutant 6) and Construction of an LD78 Phe23>Asn Ile24>Thr Expression Vector

5 LD78 Phe23>Asn Ile24>Thr was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 27-mer oligonucleotide BB6303 (5'-GTAGTCAGCAGTGTATTGTGGAAT-3' SEQ ID NO 53) was used to mutate the LD78 gene and a correct clone identified (pGHC605). The mutant gene was cloned into the expression vector to create pSJE55. Expression of the mutant  
10 LD78 protein was achieved according to methods described in Preparation 3.

Example 7 - Design and Construction of LD78 Variant Asp26>Ala (Mutant 10) and Construction of an LD78 Asp26>Ala Expression Vector

15 LD78 Asp26>Ala was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 25-mer oligonucleotide BB6625 (5'-TTTCAAAGTAG(G/A)CAGCAATGAAATT-3' SEQ ID NO 54) was used to mutate the LD78 gene and a correct clone identified (pGHC609). The mutant gene was cloned into the expression vector to create pSJE59. Expression of the mutant  
20 LD78 protein was achieved according to methods described in Preparation 3.

Example 8 - Design and Construction of LD78 Variant Phe12>Gln (Mutant 11) and Construction of an LD78 Phe12>Gln Expression Vector

25 LD78 Phe12>Gln was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 24-mer oligonucleotide BB6301 (5'-AGGTGTAAGATTGACAACAAGCGG-3' SEQ ID NO 55) was used to mutate the LD78 gene and a correct clone identified (pGHC610). The mutant gene was cloned into the expression vector to create pSJE60. Expression of the mutant  
30 LD78 protein was achieved according to methods described in Preparation 3.

**Example 9 - Design and Construction of LD78 Variant Ile24 > Thr (Mutant 13)**  
**and Construction of an LD78 Ile24 > Thr Expression Vector**

LD78 Ile24 > Thr was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 25-mer oligonucleotide BB6382 (5'-AGTAGTCAGCA(G/C/T)TGAAATTTGTGG-3' SEQ ID NO 56) was used to mutate the LD78 gene and a correct clone identified (pGHC612). The mutant gene was cloned into the expression vector to create pSJE62. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

10

**Example 10 - Design and Construction of LD78 Variant Ile40 > Arg (Mutant 14)**  
**and Construction of an LD78 Ile40 > Arg Expression Vector**

LD78 Ile40 > Arg was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 24-mer oligonucleotide BB6383 (5'-TAGTCAAGAACATCTGACACCTGGCT-3' SEQ ID NO 57) was used to mutate the LD78 gene and a correct clone identified (pGHC613). The mutant gene was cloned into the expression vector to create pSJE63. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

15

**Example 11 - Design and Construction of LD78 Variant Arg47 > Glu (Mutant 15)**  
**and Construction of an LD78 Arg47 > Glu Expression Vector**

LD78 Arg47 > Glu was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 26-mer oligonucleotide BB6384 (5'-GCACAGACTTCCGAGCGCTTAGT-3' SEQ ID NO 58) was used to mutate the LD78 gene and a correct clone identified (pGHC614). The mutant gene was cloned into the expression vector to create pSJE64. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

Example 12 - Design and Construction of LD78 Variant Lys60>Gln Asp64>Asn (Mutant 16) and Construction of an LD78 Lys60>Gln Asp64>Asn Expression Vector

5 LD78 Lys60>Gln Asp64>Asn was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 35-mer oligonucleotide BB6385 (5'-AATTCCAAGTTAGAACATATTGTTGAACCCATT-3' SEQ ID NO 59) was used to mutate the LD78 gene and a correct clone identified (pGHC615). The mutant gene was cloned into the expression vector to create pSJE65. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

10

Example 13 - Design and Construction of LD78 Variant Phe28>Glu (Mutant 17) and Construction of an LD78 Phe28>Glu Expression Vector

15 LD78 Phe28>Glu was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 25-mer oligonucleotide BB6345 (5'-GAAGAAGTTCTTCGTAGTCAGCAA-3' SEQ ID NO 60) was used to mutate the LD78 gene and a correct clone identified (pGHC616). The mutant gene was cloned into the expression vector to create pSJE66. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

20

Example 14 - Design and Construction of LD78 Variant Ile24>Asn (Mutant 24) and Construction of an LD78 Ile24>Asn Expression Vector

25 LD78 Ile24>Asn was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 25-mer oligonucleotide BB6382 (5'-AGTAGTCAGCA(G/C/T)TGAAATTGTGG-3' SEQ ID NO 56) was used to mutate the LD78 gene and a correct clone identified (pGHC623). The mutant gene

was cloned into the expression vector to create pSJE73. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

5 Example 15 - Design and Construction of LD78 Variant Phe28>Glu Gln48>Glu (Mutant 25) and Construction of an LD78 Phe28>Glu Gln48>Glu Expression Vector

LD78 Phe28>Glu Gln48>Glu was constructed and cloned into the pSW6 yeast expression vector essentially as described in Example 1. A 27-mer oligonucleotide 10 BB7015 (5'-TGAGAAGAAGTTCTTCGTAGTCAGCA-3' SEQ ID NO 61) was used to mutate the LD78 Gln48>Glu gene (pGHC600 of Example 1) and a correct clone identified (pGHC624). The mutant gene was cloned into the expression vector to create pSJE74. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

15 Example 16 - Design and Construction of LD78 Variant Phe28>Glu Arg47>Glu (Mutant 26) and Construction of an LD78 Phe28>Glu Arg47>Glu Expression Vector

20 LD78 Phe28>Glu Arg47>Glu was constructed and cloned into the pSW6 yeast expression vector essentially as described in Example 1. A 27-mer oligonucleotide BB7015 (5'-TGAGAAGAAGTTCTTCGTAGTCAGCA-3' SEQ ID NO 61) was used to mutate the LD78 Arg47>Glu gene (pGHC614 of Example 11) and a correct clone identified (pGHC625). The mutant gene was cloned into the 25 expression vector to create pSJE75. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

Example 17 - Design and Construction of LD78 Variant Glu55 > Arg Glu56 > Arg (Mutant 27) and Construction of an LD78 Glu55 > Arg Glu56 > Arg Expression Vector

5 LD78 Glu55 > Arg Glu56 > Arg was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 27-mer oligonucleotide BB9112 (5'-TTGAACCCAGCGCGAGATGGGTAGC-3' SEQ ID NO 62) was used to mutate the LD78 gene and a correct clone identified (pGHC626). The mutant gene was cloned into the expression vector to create pSJE76. Expression of the mutant  
10 LD78 protein was achieved according to methods described in Preparation 3.

Example 18 - Design and Construction of LD78 Variant Glu29 > Arg (Mutant 28) and Construction of an LD78 Glu29 > Arg Expression Vector

15 LD78 Glu29 > Arg was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 24-mer oligonucleotide BB9109 (5'-TTGAGAAGAAGTTCTAAAGTAGTC-3' SEQ ID NO 63) was used to mutate the LD78 gene and a correct clone identified (pGHC627). The mutant gene was cloned into the expression vector to create pSJE77. Expression of the mutant  
20 LD78 protein was achieved according to methods described in Preparation 3.

Example 19 - Design and Construction of LD78 Variant Gln18 > Glu (Mutant 29) and Construction of an LD78 Gln18 > Glu Expression Vector

25 LD78 Gln18 > Glu was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 24-mer oligonucleotide BB9110 (5'-ATTTGTGGAATTCTAGAGGT-3' SEQ ID NO 64) was used to mutate the LD78 gene and a correct clone identified (pGHC628). The mutant gene was cloned into the expression vector to create pSJE78. Expression of the mutant  
30 LD78 protein was achieved according to methods described in Preparation 3.

Example 20 - Design and Construction of LD78 Variant Arg17>Ser Gln18>Glu (Mutant 30) and Construction of an LD78 Arg17>Ser Gln18>Glu Expression Vector

5 LD78 Arg17>Ser Gln18>Glu was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 30-mer oligonucleotide BB9111 (5'-ATTTTGTGGAATTCAGAAGAGGTGTAAGA-3' SEQ ID NO 65) was used to mutate the LD78 gene and a correct clone identified (pGHC629). The mutant gene was cloned into the expression vector to create pSJE79. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

10

Example 21 - Design and Construction of LD78 Variant Ser-Ala-LD78 (Mutant 31) and Construction of a Ser-Ala-LD78 Expression Vector

15 Ser-Ala-LD78 was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 30-mer oligonucleotide BB9104 (5'-AGCAGCCAAGGAAGCAGATCTTTATCCAA-3' SEQ ID NO 66) was used to mutate the LD78 gene and a correct clone identified (pGHC630). The mutant gene was cloned into the expression vector to create pSJE80. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

20

Example 22 - Design and Construction of LD78 Variant Leu-Ser-Ala-Ser1>Pro LD78 (Mutant 32) and Construction of a Leu-Ser-Ala-Ser1>Pro LD78 Expression Vector

25 Leu-Ser-Ala-Ser1>Pro LD78 (in which the residues Leu, Ser and Ala have been added to the N-terminus of LD78 and in which Pro has been substituted for Ser1) was constructed and cloned into the pSW6 yeast expression vector as described in

Example 1. A 36-mer oligonucleotide BB9105 (5'-GTCAGCAGCCAATGGAGCAGACAATCTTTATCCAA-3' SEQ ID NO 67) was used to mutate the LD78 gene and a correct clone identified (pGHC631). The mutant gene was cloned into the expression vector to create pSJE81. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

10 Example 23 - Design and Construction of an LD78 Variant With the First Three N-terminal Amino Acids Deleted (N1-3 LD78) (Mutant 33) and Construction of an N1-3 LD78 Expression Vector

15 N1-3 LD78 was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 24-mer oligonucleotide BB9106 (5'-TGGAGTGTAGCTCTTTATCCAA-3' SEQ ID NO 68) was used to mutate the LD78 gene and a correct clone identified (pGHC632). The mutant gene was cloned into the expression vector to create pSJE82. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

20 Example 24 - Design and Construction of LD78 Variant Ala-Ser1 > Pro LD78 (Mutant 34) and Construction of an Ala-Ser1 > Pro LD78 Expression Vector

25 Ala-Ser1 > Pro LD78 (in which the residue Ala has been added to the N-terminus of LD78 and in which Pro has been substituted for Ser1) was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 30-mer oligonucleotide BB9103 (5'-GTCAGCAGCCAATGGAGCTCTTTATCCAA-3' SEQ ID NO 69) was used to mutate the LD78 gene and a correct clone identified (pGHC633). The mutant gene was cloned into the expression vector to create pSJE83. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

Example 25 - Design and Construction of LD78 Variant Leu-Ser-Ala-Ser1 > Pro Gly38 > Ser Ser46 > Gly (Mutant 35) and Construction of a Leu-Ser-Ala-Ser1 > Pro Gly38 > Ser Ser46 > Gly Expression Vector

5 LD78 Leu-Ser-Ala-Ser1 > Pro Gly38 > Ser Ser46 > Gly (in which the residues Leu, Ser and Ala have been added to the N-terminus of LD78 and in which Pro has been substituted for Ser1, Ser has been substituted for Gly 38 and Gly has been substituted for Ser 46) was constructed and cloned into the pSW6 yeast expression vector essentially as described in Example 1. A 48-mer oligonucleotide BB9108  
10 (5'-ACAGACTTGTCTACCGCGCTTAGTCAAGAAGATGACAGATGGC-TTGGGA-3' SEQ ID NO 70) was used to mutate the Leu-Ser-Ala-Ser1 > Pro LD78 gene (pGHC631 of Example 22) and a correct clone identified (pGHC634). The mutant gene was cloned into the expression vector to create pSJE84. Expression of the mutant LD78 protein was achieved according to methods described in  
15 Preparation 3.

Example 26 - Design and Construction of an LD78 Variant With the First Three N-terminal Amino Acids Deleted (N1-3) and Thr15 > Phe (Mutant 36) and Construction of an (N1-3) Thr15 > Phe LD78 Expression Vector

20 N1-3 Thr15 > Phe LD78 was constructed and cloned into the pSW6 yeast expression vector essentially as described in Example 1. A 24-mer oligonucleotide BB9107 (5'-AATTTGTCTAGAGAAGTAAGAGAA-3' SEQ ID NO 71) was used to mutate the N1-3 LD78 gene (pGHC632 of Example 23) and a correct clone identified (pGHC635). The mutant gene was cloned into the expression vector to  
25 create pSJE85. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

**Example 27 - Design and Construction of LD78 Variant Gln48 > Ser (Mutant 70)  
and Construction of an LD78 Gln48 > Ser Expression Vector**

LD78 Gln48 > Ser was constructed and cloned into the pSW6 yeast expression  
5 vector as described in Example 1. A 21-mer oligonucleotide BB9512 (5'-  
CAGCACAGACAGATCTCGAGC-3' SEQ ID NO 72) was used to mutate the  
LD78 gene and a correct clone identified (pGHC670). The mutant gene was  
cloned into the expression vector to create pRC59/70. Expression of the mutant  
LD78 protein was achieved according to methods described in Preparation 3.

10

**Example 28 - Design and Construction of LD78 Variant Asp26 > Ser (Mutant 39)  
and Construction of an LD78 Asp26 > Ser Expression Vector**

LD78 Asp26 > Ser was constructed and cloned into the pSW6 yeast expression  
15 vector as described in Example 1. An 18-mer oligonucleotide BB9432 (5'-  
CAAAGTAGGAAGCAATGA-3' SEQ ID NO 73) was used to mutate the LD78  
gene and a correct clone identified (pGHC638). The mutant gene was cloned into  
the expression vector to create pSJE88. Expression of the mutant LD78 protein  
was achieved according to methods described in Preparation 3.

20

**Example 29 - Design and Construction of LD78 Variant Phe12 > Ala (Mutant 77)  
and Construction of an LD78 Phe12 > Ala Expression Vector**

LD78 Phe12 > Ala was constructed and cloned into the pSW6 yeast expression  
25 vector as described in Example 1. A 19-mer oligonucleotide BB9519 (5'-  
GTGTAAGAGGCACAACAAG-3' SEQ ID NO 74) was used to mutate the LD78  
gene and a correct clone identified (pGHC676). The mutant gene was cloned into  
the expression vector to create pDB127. Expression of the mutant LD78 protein  
was achieved according to methods described in Preparation 3.

**Example 30 - Design and Construction of LD78 Variant LD78 Phe28 > Ala (Mutant 85) and Construction of an LD78 Phe28 > Ala Expression Vector**

LD78 Phe28 > Ala was constructed and is cloned into the pSW6 yeast expression vector as described in Example 1. A 19-mer oligonucleotide BB9527 (5'-GAAGTTTCAGCGTAGTCAG-3' SEQ ID NO 75) was used to mutate the LD78 gene and a correct clone identified (pGHC684). The mutant gene was cloned into the expression vector to create pDB130. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

10

**Example 31 - Design and Construction of LD78 Variant Ile24 > Ala (Mutant 38) and Construction of an LD78 Ile24 > Ala Expression Vector**

LD78 Ile24 > Ala was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 21-mer oligonucleotide BB9431 (5'-GTAGTCAGCAGCGAAATTTG-3' SEQ ID NO 76) was used to mutate the LD78 gene and a correct clone identified (pGHC637). The mutant gene was cloned into the expression vector to create pSJE87. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

20

**Example 32 - Design and Construction of LD78 Variant Ile40 > Ala (Mutant 92) and Construction of an LD78 Ile40 > Ala Expression Vector**

LD78 Ile40 > Ala was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 19-mer oligonucleotide BB9534 (5'-GTCAAGAAGGCGACACCTG-3' SEQ ID NO 77) was used to mutate the LD78 gene and a correct clone identified (M13DB104). The mutant gene was cloned into the expression vector to create pDB114. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

Example 33 - Design and Construction of LD78 Variant LD78 Arg47>Ser (Mutant 44) and Construction of an LD78 Arg47>Ser Expression Vector

LD78 Arg47>Ser was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 21-mer oligonucleotide BB9437 (5'-CACAGACTTGAGACGAGCGCT-3' SEQ ID NO 78) was used to mutate the LD78 gene and a correct clone identified (pGHC643). The mutant gene was cloned into the expression vector to create pDB144. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

10

Example 34 - Design and Construction of LD78 Variant Glu29>Ser (Mutant 40) and Construction of an LD78 Glu29>Ser Expression Vector

LD78 Glu29>Ser was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 22-mer oligonucleotide BB9433 (5'-GAGAAGAAGTAGAAAAGTAGTC-3' SEQ ID NO 79) was used to mutate the LD78 gene and a correct clone identified (pGHC639). The mutant gene was cloned into the expression vector to create pDB135. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

20

Example 35 - Design and Construction of LD78 Variant Gln18>Ser (Mutant 64) and Construction of an LD78 Gln18>Ser Expression Vector

LD78 Gln18>Ser was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 21-mer oligonucleotide BB9506 (5'-TTTGTGGAATAGATCTAGAGG-3' SEQ ID NO 80) was used to mutate the LD78 gene and a correct clone identified (pGHC663). The mutant gene was cloned into the expression vector to create pRC59/64. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

**Example 36 - Design and Construction of LD78 Variant Asp5 > Arg (Mutant 104)**  
**and Construction of an LD78 Asp5 > Arg Expression Vector**

LD78 Asp5 > Arg was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 23-mer oligonucleotide BB10194 (5'-GGTTGGAGTGCGAGCAGCCAAGG-3' SEQ ID NO 81) was used to mutate the LD78 gene and a correct clone identified (pGHC566). The mutant gene is cloned into the expression vector according to the method of Example 1 and expression of the mutant LD78 protein is achieved according to methods described in Preparation 3.

**Example 37 - Construction of LD78 Variant Arg17 > Glu, (Gln, Ile, Pro) Insertion between residues 20 and 21 (Mutant 105) and Construction of an LD78 Arg17 > Glu (Gln, Ile, Pro) Insertion between residues 20 and 21 Expression Vector**

LD78 Arg17 > Glu (Gln, Ile, Pro) Insertion between residues 20 and 21 is constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 22-mer oligonucleotide BB10195 (5'-GGAATTGTTCAGAGGTGTAAG-3' SEQ ID NO 82) was used to mutate the LD78 gene and a clone containing the desired site-directed sequence mutation and an additional unintentional three amino-acid insertion identified (M13DB120). The mutant gene was cloned into the expression vector to create pDB138. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

**Example 38 - Design and Construction of LD78 Variant Ser46 > Glu (Mutant 106) and Construction of an LD78 Ser46 > Glu Expression Vector**

LD78 Ser46>Glu is constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 27-mer oligonucleotide BB10196 (5'-GCACAGACTTGTCTTCGCGCTTAGTC-3' SEQ ID NO 83) was used to mutate the LD78 gene and a correct clone was identified (M13DB121). The mutant gene was cloned into the expression vector to create pDB146. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

**Example 39 - Design and Construction of LD78 Variant Leu2 > Glu (Mutant 107) and Construction of an LD78 Leu2 > Glu Expression Vector**

LD78 Leu2>Glu is constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 29-mer oligonucleotide BB10197 (5'-GGAGTGTCAAGCAGCTTCGGATCTTTATC-3' SEQ ID NO 84) was used to mutate the LD78 gene and a correct clone identified (M13DB122). The mutant gene was cloned into the expression vector to create pDB139. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

**Example 40 - Design and Construction of LD78 Variant Ala3 > Glu (Mutant 108) and Construction of an LD78 Ala3 > Glu Expression Vector**

LD78 Ala3>Glu is constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 22-mer oligonucleotide BB10198 (5'-GGAGTGTCAAGCTTCCAAGGATC-3' SEQ ID NO 85) was used to mutate the LD78 gene and a correct clone identified (M13DB123). The mutant gene is cloned

into the expression vector according to the method of Example 1 and expression of the mutant LD78 protein is achieved according to methods described in Preparation 3.

5      Example 41 - Design and Construction of LD78 Variant Ala4 > Glu (Mutant 109) and Construction of an LD78 Ala4 > Glu Expression Vector

LD78 Ala4 > Glu is constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 23-mer oligonucleotide BB10199 (5'-GGTTGGAGTGTCTTCAGCCAAGG-3' SEQ ID NO 86) was used to mutate the 10 LD78 gene and a correct clone identified (M13DB126). The mutant gene was cloned into the expression vector to create pDB147. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

15     Example 42 - Design and Construction of LD78 Variant Arg17 > Glu Gln18 > Glu (Mutant 110) and Construction of an LD78 Arg17 > Glu Gln18 > Glu Expression Vector

LD78 Arg17 > Glu Gln18 > Glu is constructed and cloned into the pSW6 yeast 20 expression vector as described in Example 1. A 22-mer oligonucleotide BB10200 (5'-GGAATTCTTCAGAGGTGTAAG-3' SEQ ID NO 87) was used to mutate the LD78 gene and a correct clone identified (M13DB124). The mutant gene was cloned into the expression vector to create pDB140. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

25     Example 43 - Design and Construction of LD78 Variant Leu67 > Glu (Mutant 111) and Construction of an LD78 Leu67 > Glu Expression Vector

LD78 Leu67 > Glu is constructed and cloned into the pSW6 yeast expression vector

as described in Example 1. A 28-mer oligonucleotide BB10201 (5'-CCTTATTAGGCAGATTCTCCAAGTCAG-3' SEQ ID NO 88) was used to mutate the LD78 gene and a correct clone identified (M13DB125). The mutant gene was cloned into the expression vector to create pDB141. Expression of the 5 mutant LD78 protein was achieved according to methods described in Preparation 3.

**Example 44 - Design and Construction of LD78 Variant Ser46>Ala (Mutant 95) and Construction of an LD78 Ser46>Ala Expression Vector**

10

LD78 Ser46>Ala was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 20-mer oligonucleotide BB9537 (5'-GACTTGTCTAGCGCGCTTAG-3' SEQ ID NO 89) was used to mutate the LD78 gene and a correct clone identified (M13DB107). The mutant gene was 15 cloned into the expression vector to create pDB117. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

**Example 45 - Design and Construction of LD78 Variant Leu2>Ala (Mutant 55) and Construction of an LD78 Leu2>Ala Expression Vector**

20

LD78 Leu2>Ala was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 19-mer oligonucleotide BB9497 (5'-GTCAGCAGCAGCGGATCTT-3' SEQ ID NO 90) was used to mutate the LD78 gene and a correct clone identified (pGHC654). The mutant gene was cloned into 25 the expression vector to create pDB102. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

**Example 46 - Design and Construction of LD78 Variant Ala3 > Ser (Mutant 56) and Construction of an LD78 Ala3 > Ser Expression Vector**

LD78 Ala3 > Ser was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 17-mer oligonucleotide BB9498 (5'-GTCAGCAGACAAGGATC-3' SEQ ID NO 91) was used to mutate the LD78 gene and a correct clone identified (pGHC655). The mutant gene was cloned into the expression vector to create pDB123. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

10

**Example 47 - Design and Construction of LD78 Variant Ala4 > Ser (Mutant 57) and Construction of an LD78 Ala4 > Ser Expression Vector**

LD78 Ala4 > Ser was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. An 18-mer oligonucleotide BB9499 (5'-GAGTGTAGAAGCCAAGG-3' SEQ ID NO 92) was used to mutate the LD78 gene and a correct clone identified (pGHC656). The mutant gene was cloned into the expression vector to create pDB124. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

20

**Example 48 - Design and Construction of LD78 Variant Leu67 > Ala (Mutant 75) and Construction of an LD78 Leu67 > Ala Expression Vector**

LD78 Leu67 > Ala was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 22-mer oligonucleotide BB9517 (5'-ATTAGGCAGAGGCTTCCAAGTC-3' SEQ ID NO 93) was used to mutate the LD78 gene and a correct clone identified (pRC58/75). The mutant gene was cloned into the expression vector to create pRC59/75. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

**Example 49 - Design and Construction of LD78 Variant with the First Six Amino Acids Deleted (N1-6) and Pro7>Ser (Mutant 103) and Construction of an N1-6 Pro7>Ser Expression Vector**

5 N1-6 Pro7>Ser LD78 was constructed and cloned into the pSW6 yeast expression vector as described in Example 1.. A 34-mer oligonucleotide BB9781 (5'-GAGAAACAACAAGCGGTAGATCTTTATCCAAGC-3' SEQ ID NO 94) was used to mutate the LD78 gene and a correct clone identified (pRC58/103). The mutant gene was cloned in to the expression vector to create pRC59/103.

10 Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

**Example 50 - Design and Construction of LD78 Variant Phe28>Tyr (Mutant 12) and Construction of an LD78 Phe28>Tyr Expression Vector**

15 LD78 Phe28>Tyr was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 25-mer oligonucleotide BB6381 (5'-GAAGAAGTTCA(G/C/T)AGTAGTCAGCAA-3' SEQ ID NO 51) was used to mutate the LD78 gene and a correct clone identified (pGHC611). The mutant gene was cloned into the expression vector to create pRC59/12. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

**Example 51 - Design and Construction of LD78 Variant Asp5>Ser (Mutant 37) and Construction of an LD78 Asp5>Ser Expression Vector**

LD78 Asp5>Ser was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 20-mer oligonucleotide BB9430 (5'-GTTGGAGTGGAAAGCAGCCAA-3' SEQ ID NO 95) was used to mutate the

LD78 gene and a correct clone identified (pGHC636). The mutant gene was cloned into the expression vector to create pDB134. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

5       **Example 52 - Design and Construction of LD78 Variant Phe23 > Ala (Mutant 83)**  
**and Construction of an LD78 Phe23 > Ala Expression Vector**

LD78 Phe23 > Ala was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. An 18-mer oligonucleotide BB9525 (5'-10 CAGCAATGGCATTGTG-3' SEQ ID NO 96) was used to mutate the LD78 gene and a correct clone identified (M13DB119). The mutant gene was cloned into the expression vector to create pDB137. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

15       **Example 53 - Design and Construction of LD78 Variant Lys44 > Ser (Mutant 42)**  
**and Construction of an LD78 Lys44 > Ser Expression Vector**

LD78 Lys44 > Ser was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 21-mer oligonucleotide BB9435 (5'-20 GTCTCGAGCGAGAAGTCAAGA-3' SEQ ID NO 97) was used to mutate the LD78 gene and a correct clone identified (pGHC641). The mutant gene was cloned into the expression vector to create pSJE91. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

25       **Example 54 - Design and Construction of LD78 Variant Arg45 > Ser (Mutant 43)**  
**and Construction of an LD78 Arg45 > Ser Expression Vector**

LD78 Arg45 > Ser was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. An 18-mer oligonucleotide BB9436 (5'-

GTCTCGAGGACTTAGTCA-3' SEQ ID NO 98) was used to mutate the LD78 gene and a correct clone identified (pGHC642). The mutant gene was cloned into the expression vector to create pRC59/43. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

5

Example 55 - Design and Construction of LD78 Variant Glu55 > Ser (Mutant 46) and Construction of an LD78 Glu55 > Ser Expression Vector

LD78 Glu55 > Ser was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 22-mer oligonucleotide BB9423 (5'-GAACCCATTCAAGATGGGTC-3' SEQ ID NO 99) was used to mutate the LD78 gene and a correct clone identified (pGHC645). The mutant gene was cloned into the expression vector to create pSJE95. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

10  
15

Example 56 - Design and Construction of LD78 Variant Glu56 > Ser (Mutant 47) and Construction of an LD78 Glu56 > Ser Expression Vector

LD78 Glu56 > Ser is constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 21-mer oligonucleotide BB9424 (5'-TTTGAACCCAAGATTCAAGATG-3' SEQ ID NO 100) is used to mutate the LD78 gene. The mutant gene was cloned into the expression vector according to the method of Example 1 and expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

20  
25

Example 57 - Design and Construction of LD78 Variant Lys60 > Ser (Mutant 48) and Construction of an LD78 Lys60 > Ser Expression Vector

LD78 Lys60 > Ser was constructed and cloned into the pSW6 yeast expression

vector as described in Example 1. A 21-mer oligonucleotide BB9425 (5'-CAGAAACATAAGATTGAACCC-3' SEQ ID NO 101) was used to mutate the LD78 gene and a correct clone identified (pGHC647). The mutant gene was cloned into the expression vector to create pSJE97. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

**5**

**Example 58 - Design and Construction of LD78 Variant Asp64 > Ser (Mutant 50) and Construction of an LD78 Asp64 > Ser Expression Vector**

10 LD78 Asp64 > Ser was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 20-mer oligonucleotide BB9427 (5'-CAATTCCAAGGAAGAACAT-3' SEQ ID NO 102) was used to mutate the LD78 gene and a correct clone identified (pGHC649). The mutant gene was cloned into the expression vector to create pSJE99. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

15

**Example 59 - Design and Construction of an LD78 Variant With the Five C-terminal Amino Acids Deleted (C65-69) (Mutant 61) and Construction of an C65-69 LD78 Expression Vector**

20 C65-59 LD78 was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 17-mer oligonucleotide BB9503 (5'-CCTTATTAGTCAGAAC-3' SEQ ID NO 103) was used to mutate the LD78 gene and a correct clone identified (M13DB113). The mutant gene was cloned into the expression vector to create pDB103. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

Example 60 - Design and Construction of LD78 Variant Asp26> Ala Glu29> Arg (Mutant 101) and Construction of an LD78 Asp26> Ala Glu29> Arg Expression Vector

5 LD78 Asp26> Ala Glu29> Arg was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 33-mer oligonucleotide BB9443 (5'-TTGAGAAGAAGTTCTAAAGTAGGCAGCAATGAA-3' SEQ ID NO 104) was used to mutate the LD78 gene. The mutant gene was cloned into the expression vector to create pDB133. Expression of the mutant LD78 protein was  
10 achieved according to methods described in Preparation 3.

Example 61 - Design and Construction of LD78 Variant Asp26> Ala Glu29> Arg Arg47> Glu (Mutant 102) and Construction of an LD78 Asp26> Ala Glu29> Arg Arg47> Glu Expression Vector

15 LD78 Asp26> Ala Glu29> Arg Arg47> Glu is constructed and cloned into the pSW6 yeast expression vector essentially as described in Example 1. A 33-mer oligonucleotide BB9443 (5'-TTGAGAAGAAGTTCTAAAGTAGGCAGCAATGAA-3' SEQ ID NO 104) was used to mutate the LD78 Arg47> Glu gene (pGHC614 of Example 11) and a correct clone identified (pRC58/102). The mutant gene was cloned into the expression vector to create pRC59/102. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

25 Example 62 - Design and Construction of LD78 Variant Lys36> Ser (Mutant 41) and Construction of an LD78 Lys36> Ser Expression Vector

LD78 Lys36> Ser was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 20-mer oligonucleotide BB9434 (5'-

GACACCTGGAGAGGAACATT-3' SEQ ID NO 105) was used to mutate the LD78 gene and a correct clone identified (pGHC640). The mutant gene was cloned into the expression vector to create pRC59/41. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

5

Example 63 - Design and Construction of LD78 Variant Leu65 > Ala (Mutant 51)  
and Construction of an LD78 Leu65 > Ala Expression Vector

LD78 Leu65 > Ala was constructed and cloned into the pSW6 yeast expression 10 vector as described in Example 1. A 22-mer oligonucleotide BB9428 (5'-CAGACAATTCAAGCGTCAGAAC-3' SEQ ID NO 106) was used to mutate the LD78 gene and a correct clone identified (pGHC650). The mutant gene was cloned into the expression vector to create pSJE100. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

15

Example 64 - Design and Construction of LD78 Variant Glu66 > Ser (Mutant 52)  
and Construction of an LD78 Glu66 > Ser Expression Vector

LD78 Glu66 > Ser was constructed and cloned into the pSW6 yeast expression 20 vector as described in Example 1. A 20-mer oligonucleotide BB9429 (5'-GGCAGACAAAGACAAGTCAG-3' SEQ ID NO 107) was used to mutate the LD78 gene and a correct clone identified (pGHC651). The mutant gene was cloned into the expression vector to create pSJE101. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

25

Example 65 - Design and Construction of LD78 Variant Ala69 > Ser (Mutant 53)  
and Construction of an LD78 Ala69 > Ser Expression Vector

LD78 Ala69 > Ser is constructed and cloned into the pSW6 yeast expression vector

as described in Example 1. A 19-mer oligonucleotide BB9495 (5'-CTTATTAGGAAGACAATT-3' SEQ ID NO 108) was used to mutate the LD78 gene and a correct clone identified (pRC58/53). The mutant gene was cloned into the expression vector to create pRC59/53. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

5

Example 66 - Design and Construction of LD78 Variant Ser1 > Ala (Mutant 54) and Construction of an LD78 Ser1 > Ala Expression Vector

10

LD78 Ser1 > Ala was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 19-mer oligonucleotide BB9496 (5'-CAGCCAAGGCTTTTATC-3' SEQ ID NO 109) was used to mutate the LD78 gene and a correct clone identified (pGHC653). The mutant gene was cloned into the expression vector to create pDB101. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

15

Example 67 - Design and Construction of LD78 Variant Gln33 > Ser (Mutant 67) and Construction of an LD78 Gln33 > Ser Expression Vector

20

LD78 Gln33 > Ser was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 20-mer oligonucleotide BB9509 (5'-CTTGGAACAAAGAAGAAGAAG-3' SEQ ID NO 110) was used to mutate the LD78 gene and a correct clone identified (M13DB127). The mutant gene was cloned into the expression vector to create pDB143. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

25

**Example 68 - Design and Construction of LD78 Variant Tyr61 > Ala (Mutant 73)  
and Construction of an LD78 Tyr61 > Ala Expression Vector**

LD78 Tyr61 > Ala was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 19-mer oligonucleotide BB9515 (5'-GTCAGAACAGCTTTGA-3' SEQ ID NO 111) was used to mutate the LD78 gene and a correct clone identified (M13DB115). The mutant gene was cloned into the expression vector to create pDB106. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

10

**Example 69 - Design and Construction of LD78 Variant Ser31 > Ala (Mutant 87)  
and Construction of an LD78 Ser31 > Ala Expression Vector**

LD78 Ser31 > Ala was constructed and is cloned into the pSW6 yeast expression vector as described in Example 1. A 19-mer oligonucleotide BB9529 (5'-CATTGAGAACAGCTTCAA-3' SEQ ID NO 112) was used to mutate the LD78 gene and a correct clone identified (pGHC686). The mutant gene was cloned into the expression vector to create pDB132. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

15

**Example 70 - Design and Construction of LD78 Variant Ser32 > Ala (Mutant 88)  
and Construction of an LD78 Ser32 > Ala Expression Vector**

LD78 Ser32 > Ala was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 19-mer oligonucleotide BB9530 (5'-GAACATTGAGCAGAACGTT-3' SEQ ID NO 113) was used to mutate the LD78 gene and a correct clone identified (M13DB101). The mutant gene was cloned into the expression vector to create pDB110. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

Example 71 - Design and Construction of LD78 Variant Leu42 > Ala (Mutant 94) and Construction of an LD78 Leu42 > Ala Expression Vector

LD78 Leu42 > Ala was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 21-mer oligonucleotide BB9536 (5'-GCGCTTAGTAGCGAAGATGAC-3' SEQ ID NO 114) was used to mutate the LD78 gene and a correct clone identified (M13DB106). The mutant gene was cloned into the expression vector to create pDB116. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

10

Example 72 - Design and Construction of LD78 Variant Asp52 > Ser (Mutant 45) and Construction of an LD78 Asp52 > Ser Expression Vector

LD78 Asp52 > Ser was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 22-mer oligonucleotide BB9422 (5'-CTTCAGATGGAGAAGCACAGAC-3' SEQ ID NO 115) was used to mutate the LD78 gene and a correct clone identified (pGHC644). The mutant gene was cloned into the expression vector to create pSJE94. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

15

Example 73 - Design and Construction of LD78 Variant Val62 > Ala (Mutant 49) and Construction of an LD78 Val62 > Ala Expression Vector

LD78 Val62 > Ala was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 21-mer oligonucleotide BB9426 (5'-CAAGTCAGAAGCATATTTTG-3' SEQ ID NO 116) was used to mutate the LD78 gene and a correct clone identified (pGHC648). The mutant gene was cloned into the expression vector to create pDB100. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

20

25

**Example 74 - Design and Construction of LD78 Variant Ser13> Ala (Mutant 62)**  
**and Construction of an LD78 Ser13> Ala Expression Vector**

LD78 Ser13> Ala was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 17-mer oligonucleotide BB9504 (5'-GGTGTAAGCGAAACAAAC-3' SEQ ID NO 117) was used to mutate the LD78 gene and a correct clone identified (pGHC661). The mutant gene was cloned into the expression vector to create pSJE111. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

10

**Example 75 - Design and Construction of LD78 Variant Ser16> Ala (Mutant 63)**  
**and Construction of an LD78 Ser16> Ala Expression Vector**

LD78 Ser16> Ala was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 19-mer oligonucleotide BB9505 (5'-ATTTGTCTAGCGGTGTAAG-3' SEQ ID NO 118) was used to mutate the LD78 gene and a correct clone identified (pGHC662). The mutant gene was cloned into the expression vector to create pSJE112. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

15

**Example 76 - Design and Construction of LD78 Variant Pro20> Ala (Mutant 65)**  
**and Construction of an LD78 Pro20> Ala Expression Vector**

LD78 Pro20> Ala was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 20-mer oligonucleotide BB9507 (5'-GAAATTGAGCAATTGTC-3' SEQ ID NO 119) was used to mutate the LD78 gene and a correct clone identified (pGHC664). The mutant gene was cloned into the expression vector to create pDB104. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

20

25

**Example 77 - Design and Construction of LD78 Variant Ser35 > Ala (Mutant 68)**  
**and Construction of an LD78 Ser35 > Ala Expression Vector**

LD78 Ser35 > Ala was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. An 18-mer oligonucleotide BB9510 (5'-CTGGCTTGGCACATTGAG-3' SEQ ID NO 120) was used to mutate the LD78 gene and a correct clone identified (pGHC668). The mutant gene was cloned into the expression vector to create pSJE117. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

10

**Example 78 - Design and Construction of LD78 Variant Gln59 > Ser (Mutant 72)**  
**and Construction of an LD78 Gln59 > Ser Expression Vector**

LD78 Gln59 > Ser was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 23-mer oligonucleotide BB9514 (5'-GAAACATATTAGAAACCCATT-3' SEQ ID NO 121) was used to mutate the LD78 gene and a correct clone identified (M13DB114). The mutant gene was cloned into the expression vector to create pDB105. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

15

**Example 79 - Design and Construction of LD78 Variant Ser68 > Ala (Mutant 76)**  
**and Construction of an LD78 Ser68 > Ala Expression Vector**

LD78 Ser68 > Ala was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 19-mer oligonucleotide BB9518 (5'-ATTAGGCAGCCAATTCAA-3' SEQ ID NO 122) was used to mutate the LD78 gene and a correct clone identified (M13DB100). The mutant gene was cloned into the expression vector to create pDB107. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

20

25

**Example 80 - Design and Construction of LD78 Variant Tyr14 > Ala (Mutant 78)**  
**and Construction of an LD78 Tyr14 > Ala Expression Vector**

LD78 Tyr14 > Ala was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 19-mer oligonucleotide BB9520 (5'-CTAGAGGTGGCAGAGAAC-3' SEQ ID NO 123) was used to mutate the LD78 gene and a correct clone identified (M13DB116). The mutant gene was cloned into the expression vector to create pDB108. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

10

**Example 81 - Design and Construction of LD78 Variant Ile19 > Ala (Mutant 80)**  
**and Construction of an LD78 Ile19 > Ala Expression Vector**

LD78 Ile19 > Ala was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 19-mer oligonucleotide BB9522 (5'-TTTTGTGGAGCTTGTCTAG-3' SEQ ID NO 124) was used to mutate the LD78 gene and a correct clone identified (M13DB117). The mutant gene was cloned into the expression vector to create pDB109. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

15

**Example 82 - Design and Construction of LD78 Variant Pro37 > Ala (Mutant 89)**  
**and Construction of an LD78 Pro37 > Ala Expression Vector**

LD78 Pro37 > Ala was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 20-mer oligonucleotide BB9531 (5'-GATGACACCAGCCTTGGAAC-3' SEQ ID NO 125) was used to mutate the LD78 gene and a correct clone identified (M13DB102). The mutant gene was cloned into the expression vector to create pDB111. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

20

25

Example 83 - Design and Construction of LD78 Variant Gly38> Ala (Mutant 90)  
and Construction of an LD78 Gly38> Ala Expression Vector

LD78 Gly38> Ala was constructed and cloned into the pSW6 yeast expression 5 vector as described in Example 1. A 20-mer oligonucleotide BB9532 (5'-GAAGATGACAGCTGGCTTGG-3' SEQ ID NO 126) was used to mutate the LD78 gene and a correct clone identified (M13DB103). The mutant gene was cloned into the expression vector to create pDB112. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

10

Example 84 - Design and Construction of LD78 Variant Val39> Ala (Mutant 91)  
and Construction of an LD78 Val39> Ala Expression Vector

LD78 Val39> Ala was constructed and cloned into the pSW6 yeast expression 15 vector as described in Example 1. An 18-mer oligonucleotide BB9533 (5'-AGAAGATGGCACCTGGCT-3' SEQ ID NO 127) was used to mutate the LD78 gene and a correct clone identified (M13DB118). The mutant gene was cloned into the expression vector to create pDB113. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

20

Example 85 - Design and Construction of LD78 Variant Thr6> Ala (Mutant 58)  
and Construction of an LD78 Thr6> Ala Expression Vector

LD78 Thr6> Ala was constructed and cloned into the pSW6 yeast expression 25 vector as described in Example 1. A 17-mer oligonucleotide BB9500 (5'-GGTTGGAGCGTCAGCAG-3' SEQ ID NO 128) was used to mutate the LD78 gene and a correct clone identified (pRC58/58). The mutant gene was cloned into the expression vector to create pRC59/58. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

**Example 86 - Design and Construction of LD78 Variant Gln21 > Ser (Mutant 81)  
and Construction of an LD78 Gln21 > Ser Expression Vector**

LD78 Gln21 > Ser was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 22-mer oligonucleotide BB9523 (5'-CAATGAAATTAGATGGAATTG-3' SEQ ID NO 129) was used to mutate the LD78 gene and a correct clone identified (M13DB118). The mutant gene was cloned into the expression vector to create pDB136. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

10

**Example 87 - Design and Construction of LD78 Variant Thr43 > Ala (Mutant 69)  
and Construction of an LD78 Thr43 > Ala Expression Vector**

LD78 Thr43 > Ala was constructed and is cloned into the pSW6 yeast expression vector as described in Example 1. A 17-mer oligonucleotide BB9511 (5'-GCGCTTAGCCAAGAAGA-3' SEQ ID NO 130) was used to mutate the LD78 gene and a correct clone identified (pGHC669). The mutant gene was cloned into the expression vector to create pRC59/69. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

15

**Example 88 - Design and Construction of LD78 Variant Pro7 > Ala (Mutant 59)  
and Construction of an LD78 Pro7 > Ala Expression Vector**

LD78 Pro7 > Ala was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 19-mer oligonucleotide BB9501 (5'-CAAGCGGTAGCAGTGTCA-3' SEQ ID NO 131) was used to mutate the LD78 gene and a correct clone identified (pGHC658). The mutant gene was cloned into the expression vector to create pDB125. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

20

25

**Example 89 - Design and Construction of LD78 Variant Thr8> Ala (Mutant 60)**  
**and Construction of an LD78 Thr8> Ala Expression Vector**

LD78 Thr8> Ala was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. An 18-mer oligonucleotide BB9502 (5'-ACAAGCGGCTGGAGTGTC-3' SEQ ID NO 132) was used to mutate the LD78 gene and a correct clone identified (pRC58/60). The mutant gene was cloned into the expression vector to create pRC59/60. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

10

**Example 90 - Design and Construction of LD78 Variant Tyr27> Ala (Mutant 66)**  
**and Construction of an LD78 Tyr27> Ala Expression Vector**

LD78 Tyr27> Ala was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. An 18-mer oligonucleotide BB9508 (5'-GTTTCAAAGGCGTCAGCA-3' SEQ ID NO 133) was used to mutate the LD78 gene and a correct clone identified (pGHC665). The mutant gene was cloned into the expression vector to create pDB126. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

15

**Example 91 - Design and Construction of LD78 Variant Pro53> Ala (Mutant 71)**  
**and Construction of an LD78 Pro53> Ala Expression Vector**

LD78 Pro53> Ala was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 20-mer oligonucleotide BB9513 (5'-TTCTTCAGATGCGTCAGCAC-3' SEQ ID NO 134) was used to mutate the LD78 gene and a correct clone identified (pRC58/71). The mutant gene was cloned into the expression vector to create pRC59/71. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

20

25

**Example 92 - Design and Construction of LD78 Variant Ser63 > Ala (Mutant 74) and Construction of an LD78 Ser63 > Ala Expression Vector**

LD78 Ser63 > Ala was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. An 18-mer oligonucleotide BB9516 (5'-CAAGTCAGCAACATATTT-3' SEQ ID NO 135) was used to mutate the LD78 gene and a correct clone identified (pGHC674). The mutant gene was cloned into the expression vector to create pDB145. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

10

**Example 93 - Design and Construction of LD78 Variant Thr15 > Ala (Mutant 79) and Construction of an LD78 Thr15 > Ala Expression Vector**

LD78 Thr15 > Ala was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 17-mer oligonucleotide BB9521 (5'-GTCTAGAGGCGTAAGAG-3' SEQ ID NO 136) was used to mutate the LD78 gene and a correct clone identified (pGHC678). The mutant gene was cloned into the expression vector to create pDB128. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

15

**Example 94 - Design and Construction of LD78 Variant Asn22 > Ser (Mutant 82) and Construction of an LD78 Asn22 > Ser Expression Vector**

LD78 Asn22 > Ser was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. An 18-mer oligonucleotide BB9524 (5'-CAATGAAAGATTGTGGAA-3' SEQ ID NO 137) was used to mutate the LD78 gene and a correct clone identified (pGHC681). The mutant gene was cloned into the expression vector to create pDB129. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

20

25

**Example 95 - Design and Construction of LD78 Variant Ala25 > Ser (Mutant 84)  
and Construction of an LD78 Ala25 > Ser Expression Vector**

LD78 Ala25>Ser was constructed and cloned into the pSW6 yeast expression  
5 vector as described in Example 1. A 17-mer oligonucleotide BB9526  
(5'-GTAGTCAGAAATGAAAT-3' SEQ ID NO 138) was used to mutate the  
LD78 gene and a correct clone identified (pRC58/84). The mutant gene was  
cloned into the expression vector to create pRC59/84. Expression of the mutant  
LD78 protein was achieved according to methods described in Preparation 3.

10

**Example 96 - Design and Construction of LD78 Variant Thr30 > Ala (Mutant 86)  
and Construction of an LD78 Thr30 > Ala Expression Vector**

LD78 Thr30>Ala was constructed and cloned into the pSW6 yeast expression  
15 vector as described in Example 1. An 18-mer oligonucleotide BB9528  
(5'-GAGAAGAAGCTTCAAAGT-3' SEQ ID NO 139) was used to mutate the  
LD78 gene and a correct clone identified (pGHC685). The mutant gene was  
cloned into the expression vector to create pDB131. Expression of the mutant  
LD78 protein was achieved according to methods described in Preparation 3.

20

**Example 97 - Design and Construction of LD78 Variant Phe41 > Ala (Mutant 93)  
and Construction of an LD78 Phe41 > Ala Expression Vector**

LD78 Phe41>Ala was constructed and cloned into the pSW6 yeast expression  
25 vector as described in Example 1. A 20-mer oligonucleotide BB9535  
(5'CTTAGTCAAGGCGATGACAC-3' SEQ ID NO 140) was used to mutate the  
LD78 gene and a correct clone identified (M13DB105). The mutant gene was  
cloned into the expression vector to create pDB115. Expression of the mutant  
LD78 protein was achieved according to methods described in Preparation 3.

**Example 98 - Design and Construction of LD78 Variant Val49 > Ala (Mutant 96)**  
**and Construction of an LD78 Val49 > Ala Expression Vector**

LD78 Val49 > Ala was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 20-mer oligonucleotide BB9538 (5'-GTCAGCACAGGCTTGTCTCG-3' SEQ ID NO 141) was used to mutate the LD78 gene and a correct clone identified (M13DB108). The mutant gene was cloned into the expression vector to create pDB118. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

10

**Example 99 - Design and Construction of LD78 Variant Ala51 > Ser (Mutant 97)**  
**and Construction of an LD78 Ala51 > Ser Expression Vector**

LD78 Ala51 > Ser was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 17-mer oligonucleotide BB9539 (5'-TGGGTCAGAACAGACTT-3' SEQ ID NO 142) was used to mutate the LD78 gene and a correct clone identified (M13DB109). The mutant gene was cloned into the expression vector to create pDB119. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

15

**Example 100 - Design and Construction of LD78 Variant Ser54 > Ala (Mutant 98)**  
**and Construction of an LD78 Ser54 > Ala Expression Vector**

LD78 Ser54 > Ala was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 19-mer oligonucleotide BB9540 (5'-CATTCTTCAGCTGGGTCAG-3' SEQ ID NO 143) was used to mutate the LD78 gene and a correct clone identified (M13DB110). The mutant gene was cloned into the expression vector to create pDB120. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

20

25

Example 101 - Design and Construction of LD78 Variant Trp57> Ala (Mutant 99) and Construction of an LD78 Trp57> Ala Expression Vector

LD78 Trp57> Ala was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 20-mer oligonucleotide BB9541 (5'-ATTTTGAAACAGCTTCTTCA-3' SEQ ID NO 144) was used to mutate the LD78 gene and a correct clone identified (M13DB111). The mutant gene was cloned into the expression vector to create pDB121. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

10

Example 102 - Design and Construction of LD78 Variant Val58> Ala (Mutant 100) and Construction of an LD78 Val58> Ala Expression Vector

LD78 Val58> Ala was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 22-mer oligonucleotide BB9542 (5'-CATATTTGAGGCCATTCTTC-3' SEQ ID NO 145) was used to mutate the LD78 gene and a correct clone identified (M13DB132). The mutant gene was cloned into the expression vector to create pDB122. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

15

Example 103 - Design and Construction of LD78 Variant Trp57> Leu (Mutant 112) and Construction of an LD78 Trp57> Leu Expression Vector

LD78 Trp57> Leu was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 21-mer oligonucleotide BB10374 (5'-TTTTGAACCAATTCTTCAGA-3' SEQ ID NO 146) was used to mutate the LD78 gene and a correct clone identified (pRC58/112). The mutant gene was cloned into the expression vector to create pRC59/112. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

20

25

Example 104 - Design and Construction of LD78 Variant Lys60>Asp (Mutant 113) and Construction of an LD78 Lys60>Asp Expression Vector

LD78 Lys60>Asp was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 21-mer oligonucleotide BB10375 (5'-CAGAACATAATCTTGAACCC-3' SEQ ID NO 147) was used to mutate the LD78 gene and a correct clone identified (pRC58/113). The mutant gene was cloned into the expression vector to create pDB142. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

10

Example 105 - Design and Construction of LD78 Variant Tyr61>Asp (Mutant 114) and Construction of an LD78 Tyr61>Asp Expression Vector

LD78 Tyr61>Asp was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 19-mer oligonucleotide BB10376 (5'-GTCAGAACATCTTTTGA-3' SEQ ID NO 148) was used to mutate the LD78 gene and a correct clone identified (pRC58/114). The mutant gene was cloned into the expression vector to create pRC59/114. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

15

Example 106 - Design and Construction of LD78 Variant Phe12>Asp (Mutant 115) and Construction of an LD78 Phe12>Asp Expression Vector

LD78Phe12>Asp was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 19-mer oligonucleotide BB10377 (5'-GTGTAAGAACATCACAAACAAG-3' SEQ ID NO 149) was used to mutate the LD78 gene and a correct clone identified (pRC58/115). The mutant gene was cloned into the expression vector to create pRC59/115. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

Example 107 - Design and Construction of LD78 Variant Thr8 > Glu (Mutant 116) and Construction of an LD78 Thr8 > Glu Expression Vector

LD78 Thr8 > Glu is constructed and is cloned into the pSW6 yeast expression vector as described in Example 1. A 23-mer oligonucleotide BB11235 (5'-GAAACAACAAGCTTCTGGAGTGT-3' SEQ ID NO 150) is used to mutate the LD78 gene. The mutant gene is cloned into the expression vector according to the methods of Example 1 and expression of the mutant LD78 protein is achieved according to methods described in Preparation 3.

10

Example 108 - Design and Construction of LD78 Variant Ser68 > Glu (Mutant 117) and Construction of an LD78 Ser68 > Glu Expression Vector

LD78 Ser68 > Glu was constructed and is cloned into the pSW6 yeast expression vector as described in Example 1. A 19-mer oligonucleotide BB10379 (5'-ATTAGGCTTCCAATTCCAA-3' SEQ ID NO 151) was used to mutate the LD78 gene and a correct clone identified (pRC58/117). The mutant gene is cloned into the expression vector according to the methods of Example 1 and expression of the mutant LD78 protein is achieved according to methods described in Preparation 3.

Example 109 - Design and Construction of LD78 Variant Leu67 > Asp (Mutant 118) and Construction of an LD78 Leu67 > Asp Expression Vector

LD78 Leu67 > Asp was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 22-mer oligonucleotide BB10380 (5'-ATTAGGCAGAATCTTCCAAGTC-3' SEQ ID NO 152) was used to mutate the LD78 gene and a correct clone identified (M13DB130). The mutant gene was cloned into the expression vector to create pDB148. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

**Example 110 - Design and Construction of LD78 Variant Asp64>Arg (Mutant 119) and Construction of an LD78 Asp64>Arg Expression Vector**

LD78 Asp64>Arg was constructed and was cloned into the pSW6 yeast expression vector as described in Example 1. A 20-mer oligonucleotide BB10381 (5'-CAATTCCAATCTAGAAACAT-3' SEQ ID NO 153) is used to mutate the LD78 gene and a correct clone identified (pGHC569). The mutant gene is cloned into the expression vector according to the methods of Example 1 and expression of the mutant LD78 protein is achieved according to methods described in Preparation 3.

**Example 111 - Design and Construction of LD78 Variant Ser31>Glu (Mutant 120) and Construction of an LD78 Ser31>Glu Expression Vector**

LD78 Ser31>Glu is constructed and is cloned into the pSW6 yeast expression vector as described in Example 1. A 19-mer oligonucleotide BB10382 (5'-CATTGAGATTCAAGTTCAA-3' SEQ ID NO 154) is used to mutate the LD78 gene. The mutant gene is cloned into the expression vector according to the methods of Example 1 and expression of the mutant LD78 protein is achieved according to methods described in Preparation 3.

**Example 112 - Design and Construction of LD78 Variant Ile40>Asn (Mutant 121) and Construction of an LD78 Ile40>Asn Expression Vector**

LD78 Ile40>Asn was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 19-mer oligonucleotide BB10383 (5'-GTCAAGAAGTTGACACCTG-3' SEQ ID NO 155) was used to mutate the LD78 gene and a correct clone identified (pRC58/121). The mutant gene was cloned into the expression vector to create pRC59/121. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

Example 113 - Design and Construction of LD78 Variant Leu42 > Asn (Mutant 122) and Construction of an LD78 Leu42 > Asn Expression Vector

LD78 Leu42 > Asn was constructed and was cloned into the pSW6 yeast expression vector as described in Example 1. A 21-mer oligonucleotide BB10964 (5'-GCGCTTAGTGGTGAAGATGAC-3' SEQ ID NO 156) is used to mutate the LD78 gene and a correct clone identified (pGHC568). The mutant gene is cloned into the expression vector according to the methods of Example 1 and expression of the mutant LD78 protein is achieved according to methods described in Preparation 3.

Example 114 - Design and Construction of LD78 Variant Cys10, Cys11 > Cys-Gln-Cys (Mutant 123) and Construction of an LD78 Cys10, Cys11 > Cys-Gln-Cys Expression Vector

LD78 Cys10, Cys11 > Cys-Gln-Cys was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 27-mer oligonucleotide BB10385 (5'-GTAAGAGAACATTGACAAGCGGTTGG-3' SEQ ID NO 157) was used to mutate the LD78 gene and a correct clone identified (pRC58/123). The mutant gene was cloned into the expression vector to create pRC59/123. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

Example 115 - Design and Construction of LD78 Variant Glu55 > Gln, Glu56 > Gln (Mutant 124) and Construction of an LD78 Glu55 > Gln, Glu56 > Gln Expression Vector

LD78 Glu55 > Gln, Glu56 > Gln is constructed and is cloned into the pSW6 yeast expression vector as described in Example 1. A 24-mer oligonucleotide BB10386

(5'-TTGAACCCATTGTTGAGATGGGTC-3' SEQ ID NO 158) is used to mutate the LD78 gene. The mutant gene is cloned into the expression vector according to the methods of Example 1 and expression of the mutant LD78 protein is achieved according to methods described in Preparation 3.

5

**Example 116 - Design and Construction of LD78 Variant Asp26>Gln (Mutant 125) and Construction of an LD78 Asp26>Gln Expression Vector**

LD78 Asp26>Gln was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 21-mer oligonucleotide BB10529 (5'-GTTTCAAAGTATTGAGCAATG-3' SEQ ID NO 159) was used to mutate the LD78 gene and a correct clone identified (pRC58/125). The mutant gene was cloned into the expression vector to create pRC59/125. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

10  
15

**Example 117 - Design and Construction of LD78 Variant Lys36>Glu (Mutant 126) and Construction of an LD78 Lys36>Glu Expression Vector**

LD78 Lys36>Glu was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 26-mer oligonucleotide BB10530 (5'-GATGACACCTGGTTCGGAACATTGAG-3' SEQ ID NO 160) was used to mutate the LD78 gene and a correct clone identified (pRC58/126). The mutant gene was cloned into the expression vector to create pRC59/126. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

20  
25

Example 118 - Design and Construction of LD78 Variant Lys44 > Glu (Mutant 127) and Construction of an LD78 Lys44 > Glu Expression Vector

LD78 Lys44 > Glu was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 26-mer oligonucleotide BB10531 (5'-CTTGTCTCGAGCGTTCAGTCAAGAAG-3' SEQ ID NO 161) was used to mutate the LD78 gene and a correct clone identified (pRC58/127). The mutant gene was cloned into the expression vector to create pRC59/127. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

Example 119 - Design and Construction of LD78 Variant Arg45 > Glu (Mutant 128) and Construction of an LD78 Arg45 > Glu Expression Vector

LD78 Arg45 > Glu was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 25-mer oligonucleotide BB10532 (5'-GACTTGTCTCGATTCCCTAGTCAAG-3' SEQ ID NO 162) was used to mutate the LD78 gene and a correct clone identified (pRC58/128). The mutant gene was cloned into the expression vector to create pRC59/128. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

Example 120 - Design and Construction of LD78 Variant Asp52 > Gln (Mutant 129) and Construction of an LD78 Asp52 > Gln Expression Vector

LD78 Asp52 > Gln was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 27-mer oligonucleotide BB10533 (5'-CCATTCTTCAGATGGTGGAGCACAGAC-3' SEQ ID NO 163) was used to mutate the LD78 gene and a correct clone identified (M13DB131). The mutant

gene was cloned into the expression vector to create pDB149. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

5      **Example 121 - Design and Construction of LD78 Variant Glu66>Gln (Mutant 130) and Construction of an LD78 Glu66>Gln Expression Vector**

LD78 Glu66>Gln was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 19-mer oligonucleotide BB10534 (5'-GCAGACAATTGCAAGTCAG-3' SEQ ID NO 164) was used to mutate the LD78 gene and a correct clone identified (pRC58/130). The mutant gene was cloned into the expression vector to create pRC59/130. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

15     **Example 122 - Design and Construction of LD78 Variant Ile24>Leu (Mutant 131) and Construction of an LD78 Ile24>Leu Expression Vector**

LD78 Ile24>Leu was constructed and is cloned into the pSW6 yeast expression vector as described in Example 1. A 21-mer oligonucleotide BB10535 (5'-GTAGTCAGCCAAGAAAATTTG-3' SEQ ID NO 165) was used to mutate the LD78 gene and a correct clone identified (M13DB128). The mutant gene is cloned into the expression vector according to the methods of Example 1 and expression of the mutant LD78 protein is achieved according to methods described in Preparation 3.

25     **Example 123 - Design and Construction of LD78 Variant Ile24>Val (Mutant 132) and Construction of an LD78 Ile24>Val Expression Vector**

LD78 Ile24>Val was constructed and cloned into the pSW6 yeast expression

vector as described in Example 1. A 21-mer oligonucleotide BB10536 (5'-GTAGTCAGCGACGAAATTTG-3' SEQ ID NO 166) was used to mutate the LD78 gene and a correct clone identified (M13DB129). The mutant gene was cloned into the expression vector to create pDB150. Expression of the mutant LD78 protein was achieved according to methods described in Preparation 3.

5

Example 124 - Design and Construction of LD78 Variant Arg17>Glu (Mutant 133) and Construction of an LD78 Arg17>Glu Expression Vector

10

LD78 Arg17>Glu was constructed and cloned into the pSW6 yeast expression vector as described in Example 1. A 22-mer oligonucleotide BB10195 (5'GGAATTGTTCAGAGGTGTAAG-3' SEQ ID NO 167) was used to mutate the LD78 gene and a correct clone identified (pGHC567). The mutant gene is cloned into the expression vector according to the methods of Example 1 and expression of the mutant LD78 protein is achieved according to methods described in Preparation 3.

15

Example 125 - Primary screening of LD78 mutants to identify non-multimerising variant molecules

20

In order to screen mutant LD78 molecules for non-multimerising properties, supernatants of the expressed constructs were initially analysed by native PAGE and the molecular weight of the LD78 variant protein identified by immunoblot with a rabbit anti-MIP-1 $\alpha$  polyclonal antiserum.

25

Mutant constructs (described in Examples 1-124) were expressed and grown in shake-flasks according to the methods described in Preparation 3. 100 $\mu$ l aliquots of the culture supernatant were dried using a SPEEDIVAC<sup>™</sup> concentrator and reconstituted in 7 $\mu$ l of native PAGE sample buffer (25mM Tris, 10% glycerol, 30 0.02% bromophenol blue).

5  $5\mu\text{l}$  of sample was loaded onto a 5-50% GRADIPORE HYLIX<sup>TM</sup> native acrylamide gel (Flowgen) together with high molecular weight range RAINBOW<sup>TM</sup> markers (Amersham International plc, Amersham Place, Little Chalfont, Amersham, Bucks HP7 9NA) and standard LD78 (purified as described in Preparation 4). The gel was electrophoresed at 100 volts for 15 minutes according to the manufacturers' instructions as detailed in Comparative Example 3. The gel was then sandwiched between sheets of nitrocellulose and electroblotted at 100mV for 30 minutes in 125mM Tris, 20mM glycine, 10% methanol, pH8.8 buffer.

10 After the protein was blotted onto the nitrocellulose membrane, the membrane was placed in 20ml of blocking buffer (0.5% casein, 154mM NaCl, 20mM Tris pH7.4, 0.05% Triton) for 30 minutes at room temperature. The membrane was then incubated for 30 minutes at room temperature with a 1:2,000 (v/v) dilution (in blocking buffer) of the primary antibody (polyclonal rabbit anti-MIP-1 $\alpha$  produced using standard techniques) with gentle rotation. The membrane was then given 3x5 minute washes in blocking buffer. Following the last wash, the membrane was incubated with a 1:10,000 (v/v) dilution (in blocking buffer) of the secondary antibody goat anti-rabbit peroxidase (Sigma) for 30 minutes with gentle rotation at room temperature. Following this incubation, the membrane was given 3 successive 5 minute washes with 150mM phosphate buffered saline, pH7.4, and developed as described in Comparative Example 2.

15 20 25 Whilst this system proved a useful screen, estimates of molecular weight could not be made due to the sharp (5-50%) acrylamide gradient required to effect separation of a broad mass range.

In order to focus more directly on the mass range expected for non-multimerising variants (8,000 - 100,000 daltons), 12% acrylamide BIORAD<sup>TM</sup> native gels (pre-cast in 0.375M Tris-HCl pH8.8, electrophoresis as per manufacturers' instructions with

25mM Tris, 192mM glycine, pH8.3, running buffer) have been used to screen both expressed supernatants and Q-SEPHAROSE™ purified (method described in Preparation 4) LD78 variants prepared for electrophoresis as described above. The gels were electrophoresed at 150V for 60 minutes and then electroblotted or stained as described above. A coomassie stained example of the results obtained in this native PAGE system as shown in Figures 12 and 13. The results clearly demonstrate (from the mobility of protein bands during electrophoresis) that LD78(Glu44;Gln45, (mutant 2 of Example 2)), LD78(Glu47, (mutant 15 of Example 11)) and LD78(Glu28;Glu47, (mutant 26 of Example 16)), LD78(Ser17;Glu18 (mutant 30 of Example 20)) and LD78(Gln12 (mutant 11 of Example 8)) do not form large multimeric complexes. The results in Figures 12 and 13 also show that LD78(Ala26 (mutant 10 of Example 7)), LD78(Glu48 (mutant 1 of Example 1)), LD78(Glu18 (mutant 29 of Example 19)) and LD78(Ser66 (mutant 52 of Example 64)) have increased mobility of electrophoresis, suggesting non-wild-type multimerisation. Known LD78 variants such as LD78 (Leu, Ser, Ala, Pro1, Ser38 ,Gly46, (mutant 35 of Example 25)) and LD78(Ala, Pro1 (mutant 34 of Example 24)) were observed to have the same low mobility, high molecular weight bands as the wild type control.

Table 1 details the results of the native PAGE primary analysis of LD78 variants where those identified to have non-wild type multimerisation properties are classed as "small", "mix" or "large" according to the classification in Table 1. Some variants were expressed very poorly and could not be definitively examined. Variants in Examples 1 to 124 not listed in Table 1 showed wild type electrophoretic mobility. It is probable in these cases that the mutated sites are key structural residues leading to destabilization of the protein. Selected variants identified in this screen were purified to >95% homogeneity (as described in preparation 4) for analysis by SEC and analytical ultracentrifugation as described in Comparative Example 3. The results of these analyses are detailed in subsequent examples.

It should be noted that the gel screen does not always tally with the analytical centrifuge data (see for example LD78 (Glu 48) mutant 1 in Example 135), and that selection of optimum embodiments of the invention should preferably not be undertaken on the basis of gel screen data alone. Possible scientific rationales for this are: (i) in the gel screen TRIS glycine buffers may chelate metal ions, thus destabilising aggregation and (ii) changing the number and/or type of charged side chains can affect the mass/charge ratio on electrophoresis. Also, the concentration used in the analytical ultracentrifuge assays is 0.5 mg/ml, which is not the case in the gel screen assays shown.

TABLE 1

# Mutation	Size by Native PAGE	SEC kDa	$M_w^o$ kDa	$M_w\zeta=0$	$M_w\zeta=1$
5 Wt LD78	Large Wt	Excl	160	10	>250
1 Glu-48 (E135)	Large	131(excl)	400	100	600
2 Glu-44; Glu-45 (E128)	Small	21	16-5	-	-
5 Ser-17 (E129)	Small	29	57.5	30	100*
10 Ala-26 (E133)	Large	24.5	30	-	-*
11 Glu-12 (E132)	Small	12.8	98	45	140
15 Glu-47 (E127)	Small	21	17.5	-	-
17 Glu-28 (E153)	Small	n.d.	n.d.	n.d.	n.d.
24 Asn-24 (E153)	Small	n.d.	n.d.	n.d.	n.d.
25 Glu-28, Glu-48 (E136)	Small	60	n.d.	n.d.	n.d.
15 26 Glu-28, Glu-47 (E126)	Small	21	15	-	-
28 Arg-29 (E134)	Small	24	n.d.	n.d.	n.d.
29 Glu-18 (E130)	Large	48.5	130	75	170
30 Ser-17; Glu-18 (E131)	Mix*	25	41	37	50
34 (E24)(154)	Small	Excl	350	260	480
20 35 (E25)(154)	Small	Excl	155	90	200
42 Ser-44 (E138)	Small	-	45	35	48
43 Ser-45 (E137)	Small	-	25	-	-
51 Ala-65 (E139)	Large	-	120	-	-
52 Ser-66 (E140)	Large	-	27	-	-
25 59 Ala-7 (E141)	Small	-	1000	400	1200
64 Ser-18 (E142)	Large	-	200	-	-
73 Ala-61 (E143)	Mix*	-	400	-	-
77 Ala-12 (E147)	Small	-	150	110	170
79 Ala-15 (E150)	Small	-	180	110	250
30 80 Ala-19 (E144)	Mix*	-	6	-	-
81 Ser-21 (E152)	Large	-	112	-	-
91 Ala-39 (E145)	Mix*	-	8.2	-	-
109 Glu-5 (E149)	Small	-	72	-	-
115 Asp-12 (E148)	Small	-	30	-	-
35 126 Glu-36 (E151)	Small	-	200	100	250
MIP-1 $\alpha$	Large Wt	Excl	310	230	350
110 Glu17;Glu18 (E146)	Small	-	30	-	-

40  $M_w^o$  = Whole cell weight average molecular weight

$M_w\zeta=0$  Point average molecular weight at the meniscus

$M_w\zeta=1$  Point average molecular weight at the cell base

[where no values for  $M_w\zeta=0$  and  $M_w\zeta=1$  are given with  $M_w^o$ ,  
the sample is monodisperse]

45 E = Example No. of size analysis

\* = large and small species present

Large Wt = Electrophoretic mobility on Native PAGE  
equivalent to Wt LD78

Large = Minor increase in electrophoretic mobility compared to Wt LD78 on Native PAGE

Small = Major increase in electrophoretic mobility compared to Wt LD78 on Native PAGE

5      Excl = Excluded from the SEC gel matrix

**Example 126 - Mutation of residues Phe28 to Glu and Arg47 to Glu prevents the association of LD78 dimers to form tetramers**

10     As detailed in Table 1, pure LD78(Glu28;Glu47, (mutant 26 of Example 16)) protein has been studied in 150mM PBS pH7.4 buffer using Size Exclusion Chromatography on SUPERDEX 75™ resin and by Sedimentation Equilibrium with wild type LD78 for comparison. The SEC profile (Figure 14) of this LD78 mutant is a single, symmetrical peak demonstrating a defined, homogenous population of 21kDa mass. Analysis of the sedimentation equilibrium data shows that 15     LD78(Glu28;Glu47) exists as a monodisperse population of protein species with a mass ( $M_w^0$ ) of 15.2kDa corresponding to dimers.

20     The 21kDa mass measured by SEC in 150mM PBS pH7.4 is close to that expected for an LD78 trimer. The model of association for this molecule does not predict formation of this mass species. The absolute mass determination by sedimentation equilibrium in this buffer gives very precise data proving the molecule is a single molecular species of 15.2kDa. The anomalously high mass by SEC arises due to 25     the asymmetrical shape of the LD78 dimer causing non-ideal (non-globular) hydrodynamic behaviour on chromatography.

30     These results demonstrate that in physiological ionic strength and pH, i.e. 150mM PBS pH7.4, at a concentration of 0.5mg/ml, LD78(Glu28;Glu47) exists as a single, defined, dimeric species with no large multimers apparently present, under the methods of analysis used.

**Example 127 - Mutation of residue Arg47 to Glu prevents the formation of high molecular weight LD78 multimeric complexes**

As detailed in Table 1, pure LD78(Glu47 (mutant 15 of Example 11)) protein has  
 5 been studied in 150mM PBS pH7.4 buffer using Size Exclusion Chromatography on SUPERDEX 75™ resin and by Sedimentation Equilibrium with wild type LD78 for comparison. The SEC profile of this LD78 mutant is a single, symmetrical peak demonstrating a defined, homogenous population of 21kDa mass. Analysis of the sedimentation equilibrium data shows that LD78(Glu47) exists as a  
 10 monodisperse population of protein species with a mass ( $M_w^0$ ) of 17kDa corresponding to dimers.

The 21kDa mass measured by SEC in 150mM PBS pH7.4 is close to that expected for an LD78 trimer. Our model of association for this molecule does not predict  
 15 formation of this mass species. The absolute mass determination by sedimentation equilibrium in this buffer gives very precise data proving the molecule is a single molecular species of 15.2kDa. The anomalously high mass by SEC arises due to the asymmetrical shape of the LD78 dimer causing non-ideal (non-globular) hydrodynamic behaviour on chromatography.

20 These results demonstrate that in physiological ionic strength and pH, i.e. 150mM PBS pH7.4, at a concentration of 0.5mg/ml, LD78(Glu47) exists as a single, defined, dimeric species with no large multimers apparently present under conditions of analysis used.

25 **Example 128 - Mutation of residues Lys44 to Glu and Arg 45 to Gln prevents the formation of high molecular weight LD78 multimeric complexes**

As detailed in Table 1, pure LD78(Glu44; Gln45, (mutant 2 of Example 2))

protein has been studied in 150mM PBS pH7.4 buffer using Size Exclusion Chromatography on SUPERDEX 75™ resin and by Sedimentation Equilibrium with wild type LD78 for comparison. The SEC profile of this LD78 variant is a single peak, Figure 14, demonstrating a defined population of mass 21kDa. Analysis of the sedimentation equilibrium data shows that LD78(Glu44; Gln45) exists as a monodisperse population of protein species with a mass ( $M_w^0$ ) of 16.5kDa corresponding to dimers.

The 21kDa mass measured by SEC in 150mM PBS pH7.4 is close to that expected for an LD78 trimer. The model of association for this molecule does not predict formation of this mass species. The absolute mass determination by sedimentation equilibrium in this buffer gives very precise data proving the molecule is a single molecular species of 16.5kDa. The anomalously high mass by SEC arises due to the asymmetrical shape of the LD78 dimer causing non-ideal (non-globular) hydrodynamic behaviour on chromatography.

These results demonstrate that in physiological ionic strength and pH, i.e. 150mM PBS pH7.4, at a concentration of 0.5mg/ml, LD78(Glu44; Gln45) exists as a single, defined, dimeric species with no large multimers apparently present under the conditions of analysis used.

Example 129 - Mutation of residue Arg17 to Ser disrupts formation of high molecular weight LD78 multimeric complexes

As detailed in Table 1, pure LD78(Ser17, (mutant 5 of Example 5)) protein has been studied at 0.5 mg/ml in 150mM PBS pH 7.4 buffer, using Size Exclusion Chromatography on SUPERDEX 75™ resin and by Sedimentation Equilibrium with wild type LD78 for comparison. The size exclusion profile is a single peak of mass 29kDa. The tetrameric LD78 molecule is expected to be symmetrical and globular,

and, therefore, should chromatograph correctly. The observed elution of this LD78 mutant correlates with the tetramer species. Analysis of the sedimentation equilibrium data reveals the presence of mixed molecular weight species ranging from 30kDa (tetramer) to 100kDa (dodecamer). No masses higher than a dodecamer are observed.

These results demonstrate that mutation of Arg17> Ser in LD78 gives a molecule that is incapable of associating to heterogenous high molecular weight complexes. The mutation does not completely block association of tetramers to dodecamers, however, it would appear to energetically favour the equilibrium shifting to the tetramer.

**15 Example 130 - Mutation of residue Gln18 to Glu disrupts association of high molecular weight LD78 multimeric complexes**

As detailed in Table 1, pure LD78(Glu18, (mutant 29 of Example 19)) protein has been studied in 150mM PBS pH 7.4 buffer, using Size Exclusion Chromatography on SUPERDEX 75™ resin and by Sedimentation Equilibrium with wild type LD78 for comparison. The size exclusion profile is a large broad peak, of mass centred at 48.5kDa with a smaller component at 160kDa. The tetrameric LD78 molecule is expected to be symmetrical and globular, and, therefore, should chromatograph correctly. The observed elution of this LD78 mutant is anomalously high to correlate with the tetramer species. Analysis of the sedimentation equilibrium data reveals the presence of mixed molecular weight species ranging from 75kDa to 170kDa.

These results demonstrate that mutation of Gln-18> Glu in LD78 gives a molecule that still has some ability to form heterogenous high molecular weight complexes at physiological ionic strength. It is clear from the results, however, that the

mutation does have some disruptive effect on the association equilibrium. The mass range observed for this mutant is smaller than that seen for wild type LD78 (Table 1), and the SEC profile demonstrates that the molecule has significantly smaller solution mass. Whilst the mutation of Gln18> Glu does not completely stop the formation of high molecular weight LD78 multimers, it is obvious from the behaviour of the mutant molecule that this residue plays some role in stabilising the multimeric complexes. At protein concentrations <0.5mg/ml in physiological ionic strength, this mutant may well exist as a smaller defined mass species.

10      **Example 131 - Mutation of residues Arg17 to Ser and Gln 18 to Glu disrupts**  
**formation of high molecular weight LD78 complexes**

15      As detailed in Table 1, pure LD78(Ser17; Glu18, (mutant 30 of Example 20)) protein has been studied in 150mM PBS pH 7.4 buffer, using Size Exclusion Chromatography on SUPERDEX 75™ resin and by Sedimentation Equilibrium with wild type LD78 for comparison. The size exclusion profile is a single peak of mass 25kDa. The tetrameric LD78 molecule is expected to be symmetrical and globular, and, therefore, should chromatograph correctly. The observed elution of this LD78 mutant is slightly lower than expected for the tetramer species, however, the shift in molecular mass compared to wild type is marked. Analysis of the sedimentation equilibrium data reveals the presence of mixed molecular weight species ranging from 37kDa to 50kDa. No masses higher than 50kDa are observed.

20      These results demonstrate that the combined mutation of Arg17> Ser and Gln18> Glu in LD78 gives a molecule that is incapable of associating (at 0.5mg/ml in physiological ionic strength) to high molecular weight complexes. In fact the LD78 mutant does not appear to form any molecular weight species higher than 50kDa.

It is suggested that the results reflect the LD78 mutant exists as a tetramer, though some unstable, limited associations can occur.

5      **Example 132 - Mutation of residue Phe12 to Gln disrupts formation of high molecular weight LD78 multimeric complexes**

As detailed in Table 1, pure LD78(Gln12, (mutant 11 of Example 8)) protein has been studied at 0.5mg/ml in 150mM PBS pH7.4 buffer using Size Exclusion Chromatography on SUPERDEX™ 75 and by sedimentation equilibrium with wild type LD78 for comparison. The observed SEC elution for this molecule is a single peak of 12.8kDa, the smallest mass yet seen for an LD78 mutant. Given the non-ideal behaviour of dimeric LD78 on SEC (e.g. Example 126), this profile suggests that the mutant exists as a monomer. The sedimentation equilibrium, however, indicates that the LD78(Gln12) is a dodecamer in solution. The original native gel screen (Example 125) showed the presence of a small species. The data in Table 1 may reflect an equilibrium between a dodecamer and a smaller species and the presence of the sephadex resin may have some physical effect on the actual equilibrium. Alternatively, the protein may adhere to the resin during chromatography and elute much later with an apparent smaller mass.

20      Despite the anomaly in mass determination for this mutant, it is obvious that mutation of Phe12> Gln gives a LD78 variant that does not multimerise to the same extent as wild type. The N-terminal region of this molecule may play a role in stabilizing more than one state on the equilibrium association pathway.

25      **Example 133 - Mutation of Asp26 to Ala disrupts formation of high molecular weight LD78 multimeric complexes**

As detailed in Table 1 pure LD78 (Ala26, (mutant 10 of Example 7)) has been

studied at 0.5mg/ml in 150mM PBS pH7.4 using Size Exclusion Chromatography on SUPERDEX™ 75 resin and sedimentation equilibrium with wild type LD78 for comparison. The elution profile gives a single peak of mass 24.5kDa. Analysis of the sedimentation equilibrium data demonstrates that the protein exists as a monodisperse mass population with  $M_w^o = 30$  kDa.

5 This result demonstrates that mutation of Asp26 to Ala gives an LD78 molecule which exists at physiological ionic strength as a homogeneous tetramer.

10 **Example 134 - Mutation of Glu29 to Arg disrupts association of LD78 dimers to form tetramers**

15 As detailed in Table 1, pure LD78 (Arg29, (mutant 28 of Example 18)) has been studied at 0.5mg/ml in 150mM PBS pH7.4 using Size Exclusion Chromatography on SUPERDEX™ 75 resin. The elution profile gives a single peak of mass 24kDa. As discussed in Example 86, this observed mass most probably relates to a homogeneous dimeric species.

20 This result demonstrates that mutation of Glu29 to Arg gives an LD78 molecule which exists at physiological ionic strength as a single dimeric species.

**Example 135 - Mutation of Gln 48 to Glu does not affect the multimerisation properties of LD78**

25 As detailed in Table 1, pure LD78 (Glu48, (mutant 1 of Example 1)) protein has been studied at 0.5mg/ml in 150mM PBS pH7.4 buffer using Size Exclusion Chromatography on SUPERDEX™ 75 and by sedimentation equilibrium with wild type LD78 for comparison. The observed SEC elution for this molecule is a single, broad, excluded peak of estimated mass 131kDa. The sedimentation equilibrium

shows that LD78(Glu48) exists as a heterogenous range of species from 100kDa to 600kDa. Even though this mutant was observed to have increased mobility on native PAGE, the two independent size analyses confirm that at this concentration in physiological buffer, the protein has wild type multimerisation.

5

In actual fact the observed mass ranges at equilibrium in the ultracentrifuge appear to show this mutant forms larger more stable multimers than wild type. In this case, therefore, introduction of a negative charge at this site may have a stabilizing effect.

10

Example 136 - Mutation of Phe28 to Glu and Gln48 to Glu disrupts formation of high molecular weight LD78 multimers

15

As detailed in Table 1, pure LD78 (Glu28; Glu48, (mutant 25 of Example 15)) has been studied at 0.5mg/ml in 150mM PBS pH7.4 using Size Exclusion Chromatography on SUPERDEX™ 75 resin. The elution profile shows a single, broad asymmetric peak at a molecular mass of approximately 60kDa. The broad asymmetry suggests a heterogeneous mix of mass species. The combined mutations produce a variant that has markedly different multimerisation properties to wild type.

20

Example 137 - Mutation of Arg45 to Ser disrupts formation of high molecular weight LD78 multimeric complexes

25

As detailed in Table 1, pure LD78 (Ser45, (Mutant 43 of Example 54)) protein has been studied at 0.5mg/ml in 150mM PBS pH7.4 buffer by sedimentation equilibrium with wild type LD78 for comparison. Analysis of the sedimentation equilibrium data demonstrates that the protein exists as a monodisperse mass population with  $M_w^o = 25$ kDa. This mass is anomalously high for a dimer and low

for a tetramer. Given that stable trimers are unlikely to form, this mass most probably represents a homogeneous tetramer species.

5 **Example 138 - Mutation of Lys44 to Ser disrupts formation of high molecular weight LD78 multimeric complexes**

10 As detailed in Table 1, pure LD78 (Ser44,(Mutant 42 of Example 53)) protein has been studied at 0.5mg/ml in 150mM PBS pH7.4 buffer by sedimentation equilibrium with wild type LD78 for comparison. Analysis of the sedimentation equilibrium data demonstrates that the protein exists as a polydisperse population of species ranging in mass from 35 - 48kDa.

15 This result demonstrates that the mutation of Lys44 to Ser in LD78 gives a molecule that is incapable of associating (at 0.5mg/ml in physiological ionic strength) to high molecular weight complexes. The fact that no molecular weight species higher than 48kDa is observed suggests that the mutation destabilizes the association of tetramers to form dodecamers.

20 This result is very similar to that obtained for LD78(Ser17;Glu18,(mutant 30 of example 20)) described in Example 131. It is suggested, therefore, that the results reflect the LD78 mutant exists as a tetramer, though some unstable, limited associations between a tetramer and dimer (or monomers) can occur.

25 **Example 139 - Mutation of Leu65 to Ala stabilizes a homogeneous high molecular weight LD78 multimeric complex**

As detailed in Table 1, pure LD78 (Ala65,(Mutant 51 of Example 63)) protein has been studied at 0.5mg/ml in 150mM PBS pH7.4 buffer by sedimentation equilibrium with wild type LD78 for comparison. Analysis of the sedimentation

equilibrium data demonstrates that the protein exists as a monodisperse mass population with  $M^{\circ}_w = 120\text{kDa}$ .

5 The mutation of Leu65 to Ala gives an LD78 molecule that can associate to a stable, homogeneous complex at 0.5mg/ml in physiological ionic strength. No other molecular weight species are observed under these conditions, therefore, the wild-type self-association properties of LD78 have been modified.

10 **Example 140 - Mutation of Glu66 to Ser disrupts formation of high molecular weight LD78 multimeric complexes**

15 As detailed in Table 1, pure LD78 (Ser66,(Mutant 52 of Example 64)) protein has been studied at 0.5mg/ml in 150mM PBS pH7.4 buffer by sedimentation equilibrium with wild type LD78 for comparison. Analysis of the sedimentation equilibrium data demonstrates that the protein exists as a monodisperse mass population with  $M^{\circ}_w = 27\text{kDa}$ .

20 The results demonstrate that in physiological ionic strength and pH, i.e. 150mM PBS pH7.4, at a concentration of 0.5mg/ml, LD78(Ser66) exists as a single, defined, tetrameric species with no large multimers present.

25 **Example 141 - Mutation of Pro7 to Ala promotes formation of heterogeneous high molecular weight LD78 multimeric complexes**

As detailed in Table 1, pure LD78 (Ala7,(Mutant 59 of Example 88)) protein has been studied at 0.5mg/ml in 150mM PBS pH7.4 buffer by sedimentation equilibrium with wild type for comparison. Analysis of the sedimentation equilibrium data demonstrates that the protein exists as a polydisperse population of mass species ranging from 400 - 1000kDa.

The results demonstrate that in physiological ionic strength and pH, i.e. 150mM PBS pH7.4 at a concentration of 0.5mg/ml, LD78(Ala7) exists as a heterogeneous range of large multimeric complexes. The mass range observed for these complexes is much greater than normally observed for wild type LD78 under the same conditions (Comparative Example 3).

The mutation of Pro7 to Ala, therefore, promotes the self-association properties of LD78 and the results suggest that the N-terminal arm of the protein plays a major role in the multimerisation of this molecule.

10

**Example 142 - Mutation of Gln18 to Ser stabilizes a homogeneous high molecular weight LD78 multimeric complex**

As detailed in Table 1, pure LD78 (Ser18,(Mutant 64 of Example 35)) protein has 15 been studied at 0.5mg/ml in 150mM PBS pH7.4 buffer by sedimentation equilibrium with wild type for comparison. Analysis of the sedimentation equilibrium data demonstrates that the protein exists as a monodisperse mass population with  $M^{\circ}_w = 200\text{kDa}$ .

20 The mutation of Gln18 to Ser gives an LD78 molecule that can associate to a stable, homogeneous complex of 26 monomers at 0.5mg/ml in physiological ionic strength. No other molecular weight species are observed under these conditions, therefore, the wild-type self-association properties of LD78 have been significantly modified.

25

**Example 143 - Mutation of Tyr61 to Ala stabilizes a homogeneous high molecular weight LD78 multimeric complex**

As detailed in Table 1, pure LD78 (Ala 61,(Mutant 73 of Example 68)) protein has

been studied at 0.5mg/ml in 150mM PBS pH7.4 buffer by sedimentation equilibrium with wild type for comparison. Analysis of the sedimentation equilibrium data demonstrates that the protein exists essentially as a monodisperse mass population with  $M^{\circ}_w = 400$ kDa though a slight upward curvature of  $\ln A$  vs

5  $\zeta$  was evident.

The mutation of Tyr61 to Ala gives an LD78 molecule that can associate to a stable, homogeneous complex at 0.5mg/ml in physiological ionic strength. No other molecular weight species are observed under these conditions, therefore, the

10 wild-type self-association properties of LD78 have been significantly modified.

**Example 144 - Mutation of Ile19 to Ala gives a homogeneous LD78 monomer**

As detailed in Table 1, pure LD78 (Ala 19,(Mutant 80 of Example 81)) protein has

15 been studied at 0.5mg/ml in 150mM PBS pH7.4 buffer by sedimentation equilibrium with wild type for comparison. Analysis of the sedimentation equilibrium data demonstrates that the protein exists as a monodisperse mass population with  $M^{\circ}_w = 6$ kDa.

20 The mutation of Ile19 to Ala gives an LD78 molecule that exists as a homogeneous monomer at 0.5mg/ml in physiological ionic strength. No other molecular weight species are observed under these conditions, therefore, the wild-type self-association properties of LD78 have been completely inhibited.

**25 Example 145 - Mutation of Val39 to Ala gives a homogeneous LD78 monomer**

As detailed in Table 1, pure LD78 (Ala 39,(Mutant 91 of Example 84)) protein has been studied at 0.5mg/ml in 150mM PBS pH7.4 buffer by sedimentation equilibrium with wild type for comparison. Analysis of the sedimentation

equilibrium data demonstrates that the protein exists as a monodisperse mass population with  $M^{\circ}_w=8\text{kDa}$ .

5 The mutation of Val39 to Ala gives an LD78 molecule that exists as a homogeneous monomer at 0.5mg/ml in physiological ionic strength. No other molecular weight species are observed under these conditions, therefore, the wild-type self-association properties of LD78 have been completely inhibited.

10 **Example 146 - Mutation of Arg17 to Glu and Gln18 to Glu disrupts formation of high molecular weight LD78 multimeric complexes**

15 As detailed in Table 1, pure LD78 (Glu17;Glu18,(Mutant 110 of Example 42)) protein has been studied at 0.5mg/ml in 150mM PBS pH7.4 buffer by sedimentation equilibrium with wild type for comparison. Analysis of the sedimentation equilibrium data demonstrates that the protein exists as a monodisperse mass population with  $M^{\circ}_w=30\text{kDa}$ .

20 This result demonstrates that the combined mutation of Arg17 to Glu and Gln18 to Glu in LD78 gives a molecule that is incapable of associating (at 0.5mg/ml in physiological ionic strength) to multimeric complexes greater than a tetramer. Comparison with the results obtained for mutant 30 described in Example 131 shows that the more radical substitution of Arg17 to Glu combined with Gln18 to Glu completely disrupts the further association of tetrameric units.

25 **Example 147 - Mutation of Phe12 to Ala partially disrupts the multimerisation properties of LD78**

As detailed in Table 1, pure LD78 (Ala12(mutant 77 of Example 29)) protein has been studied at 0.5mg/ml in 150mM PBS pH7.4 buffer by sedimentation

equilibrium with wild type LD78 for comparison. Analysis of the sedimentation equilibrium data demonstrates that the protein exists as a polydisperse population of species ranging in mass from 110 - 170kDa.

5 This result demonstrates that despite an apparent high mobility in Native PAGE, this variant displays only slight differences in self-association compared to wild type LD78 at 0.5mg/ml in physiological ionic strength (Table 1 and Comparative Example 3). This may reflect a protein concentration dependence of association such that at the low protein concentrations in Native PAGE the variant exists as 10 a significantly smaller mass. It is clear from the results obtained for LD78 variants containing substitutions of Phe12 to Gln or Asp (mutants 11 and 115 described in Examples 132 and 148 respectively) that radical mutation is required at this site to prevent formation of high molecular weight multimers at higher protein concentrations.

15 **Example 148 - Mutation of Phe12 to Asp prevents formation of high molecular weight LD78 multimeric complexes**

20 As detailed in Table 1, pure LD78 (Asp12(mutant 115 of Example 106)) protein has been studied at 0.5mg/ml in 150mM PBS pH7.4 buffer by sedimentation equilibrium with wild-type LD78 for comparison. Analysis of the sedimentation equilibrium data demonstrates that the protein exists as a monodisperse mass population with  $M^{\circ}_w = 30$ kDa.

25 The mutation of Phe12 to Asp gives an LD78 molecule that exists as a homogeneous tetramer at 0.5mg/ml in physiological ionic strength. No other molecular weight species are observed under these conditions, therefore, this mutation inhibits the association of tetramers to higher order structures.

**Example 149 - Mutation of Ala4 to Glu disrupts formation of high molecular weight LD78 multimeric complexes**

As detailed in Table 1, pure LD78 (Glu4(mutant 109 of Example 41)) protein has  
5 been studied at 0.5mg/ml in 150mM PBS pH7.4 buffer by sedimentation equilibrium with wild-type LD78 for comparison. Analysis of the sedimentation equilibrium data demonstrates that the protein exists as a monodisperse mass population with  $M^{\circ}_w = 71\text{kDa}$ .

10 The mutation of Ala4 to Glu gives an LD78 molecule that associates to a stable homogeneous complex of mass 71kDa at 0.5mg/ml in physiological ionic strength. The self-association of LD78 has, therefore, been dramatically reduced by this mutation demonstrating that the N-terminal arm of the protein is directly involved in the multimerisation process.

15 **Example 150 - Mutation of Thr15 to Ala does not significantly affect the multimerisation properties of LD78**

As detailed in Table 1, pure LD78 (Ala15(mutant 79 of Example 93)) protein has  
20 been studied at 0.5mg/ml in 150mM PBS pH7.4 buffer by sedimentation equilibrium with wild-type LD78 for comparison. Analysis of the sedimentation equilibrium data demonstrates that the protein exists as a polydisperse population of species ranging in mass from approximately 100 - 250kDa with  $M^{\circ}_w = 200\text{kDa}$ .

25 This result demonstrates that the mutation of Thr15 to Ala gives a molecule that has wild-type association properties at 0.5mg/ml in physiological ionic strength. The increased mobility observed on Native PAGE may reflect a concentration dependence of self-association with smaller mass species predominating at the low concentrations loaded onto gels. A more radical substitution to a polar or charged  
30 amino acid would elucidate this possibility further.

**Example 151 - Mutation of Lys36 to Glu does not significantly affect the multimerisation properties of LD78**

As detailed in Table 1, pure LD78 (Glu36(mutant 126 of Example 117)) protein has been studied at 0.5mg/ml in 150mM PBS pH7.4 buffer by sedimentation equilibrium with wild-type LD78 for comparison. Analysis of the sedimentation equilibrium data demonstrates that the protein exists as a polydisperse population of species ranging in mass from approximately 100 - 250kDa with  $M^{\circ}_w = 200$ kDa.

This result demonstrates that the mutation of Lys36 to Glu gives a molecule that has wild-type association properties at 0.5mg/ml in physiological ionic strength. The increased mobility observed on Native PAGE may reflect a concentration dependence of self-association with smaller mass species predominating at the low concentrations loaded onto gels.

**15      Example 152 - Mutation of Gln21 to Ser partially disrupts formation of high molecular weight LD78 multimeric complexes**

As detailed in Table 1, pure LD78 (Ser21(mutant 81 of Example 86)) protein has been studied at 0.5mg/ml in 150mM PBS pH7.4 buffer by sedimentation equilibrium with wild-type LD78 for comparison. Analysis of the sedimentation equilibrium data demonstrates that the protein exists as a monodisperse mass population with  $M^{\circ}_w = 112$ kDa.

The mutation of Gln21 to Ser gives an LD78 molecule that can associate to a stable homogeneous complex of mass 112kDa at 0.5mg/ml in physiological ionic strength. No other molecular weight species are observed under these conditions, therefore, the wild -type self association properties of LD78 have been modified.

**Example 153 - Further LD78 molecules containing amino-acid substitutions which show higher mobility than wild-type in Native PAGE**

5 In the Native PAGE screening assay described in Example 125, a number of other LD78 variants have been identified as a single species with greatly increased mobility than wild type. These variants are: LD78 (Glu28,(mutant 17 of Example 13)), LD78 (Asn24,(mutant 24 of Example 14)), LD78 (Gln26,(mutant 125 of Example 116)), LD78 (Glu44,(mutant 127 of Example 118)), LD78 (Glu45,(mutant 128 of Example 119)) and LD78 (Gln66,(mutant 130 of Example 10 121)).

15 In addition four variants have been identified which exhibit a mixture of high and low molecular weight species on Native PAGE. These variants are: LD78 (Ala43(mutant 69 of Example 87)), LD78 (Ser48(mutant 70 of Example 27)), LD78 (Ser51(mutant 97 of Example 99)) and LD78 (Ala58(mutant 100 of Example 102)).

20 A further 5 variants have been observed to run with a slight increase in mobility compared to wild-type on Native PAGE which suggests that though large, they also reflect in a modification of the LD78 self-association properties. This conclusion is supported by the analysis of mutants 10, 51, 52 and 64 (of Examples 133, 139, 140 & 142 respectively) which showed only slight increases in gel mobility and very striking difference to wild type when examined by sedimentation equilibrium. These variants are: LD78 (Ser26(mutant 39 of Example 28)), LD78 (Ala13(mutant 62 of Example 74)), LD78 (Ala23(mutant 83 of Example 52)), LD78 (Ala32(mutant 88 of Example 70)) and (Ala49(mutant 96 of Example 98)).

25 Some of the variants identified above contain substitutions at sites known to be involved in multimerisation described in the previous Examples and it is not

unexpected, therefore, to observe changes in gel mobility. The remaining sites, however, are, subject to the limitations of the gel screen, likely to be involved either directly or indirectly with the LD78 self-association process.

5      **Example 154 - Known natural variants of LD78 exhibit the same multimerisation properties as the recombinant wild type molecule**

As detailed in Table 1, the natural variants LD78 (Leu-Ser-Ala; Pro1; Ser38; Gly46, (mutant 35 of Example 25)) and LD78 (Ala; Pro1, (mutant 34 of Example 10 24)) have been studied by Size Exclusion Chromatography using a SUPERDEX™ 75 resin and by sedimentation equilibrium with wild type as a control. Both variants are excluded from the SEC resin and the sedimentation equilibrium data shows that they exist as polydisperse masses of 90 - 200kDa and 230 - 350kDa respectively. The N-terminal extensions and amino acid substitutions in these variants do not, 15 therefore, disrupt the multimerisation properties of the LD78 protein.

**Example 155 - Definition of the molecular faces involved in LD78 association**

**Residues important for Monomer -> Dimer association**

20      From the examples above, it can be seen that at least residues 19 and 39 are important for monomer association to dimers.

**Residues important for the Dimer -> Tetramer association**

25      From the examples outlined above, two distinct regions of sequence are identified as important for the stable association of dimers to form tetramers.

30      (i) Individual mutation of residues Phe28> Glu and Glu29> Arg gives rise to a homogeneous population of dimeric LD78. It is clear, therefore, that residues projecting away from the face of the dimer on strand 1 & 1' of the beta sheet form key non-covalent, inter-molecular bonds in the tetramer interface.

5 (ii) Mutation individually of Arg47> Glu or a combination of Lys44> Glu & Arg45> Gln produces stable LD78 dimers in the absence of higher molecular weight forms. The sequence of residues 43-47 in the turn region linking strands 2 (2') and 3 (3') of the beta sheet is, therefore, key for the association of LD78 dimers to form tetramers.

Residues important for tetramer -> dodecamer and dodecamer -> higher order multimer

10 Mutations of Arg17>Glu, Gln18>Glu, Phe12>Asp, Asp26>Ala, Glu66>Ser and Ala4>Glu appear to disrupt the tetramer to dodecamer association. Mutations of Gln21>Ser, Leu65>Ala and Phe12>Gln appear to disrupt the dodecamer to multimer association.

15 Current evidence suggests that these interfaces may overlap or be one and the same. Mutation of Arg17> Ser and Gln18> Glu individually or in combination appear to disrupt both of the associations outlined above. In this case it is predicted that the sequence region involving residues 16-21 on the N-terminal side of strand 1 (1') of the beta sheet are key for the associations.

20 The data so far generated for mutation at residue 48 is ambiguous; however, it may be that this residue also plays a role in the higher order association of the LD78 molecule.

25 Example 156 - *S. cerevisiae* Batch fermentation of wild-type LD78, LD78 (Glu44, Gln45) and LD78 (Glu47).

A convenient way of assessing the potential of a transformed *Saccharomyces cerevisiae* strain to produce recombinant protein is to use a batch fermentation process. This process relies upon providing a controlled environment in which all

of the essential growth nutrients are present in the medium prior to inoculation. Once inoculation has occurred the culture is maintained in an environment appropriate for recombinant protein expression. Scale-up of recombinant protein expression from shake-flask cultures is achieved using fermenter cultures. The 5 *Saccharomyces cerevisiae* strain used for recombinant gene expression in fermenters is MC2 (see Preparation 3). This strain was isolated from a chemostat culture of *S. cerevisiae* strain BJ2168 (see Preparation 3) where galactose was used as a sole and limiting carbon source. Unlike BJ2168, MC2 exhibits a wild-type phenotype when growing on galactose as a sole carbon source. The batch and fed- 10 batch fermentation strategies developed are designed to complement this phenotypic characteristic.

The transformed strains used for this example were prepared as previously described in Preparation 2. The plasmids used to express different forms of the 15 molecule are described in Preparation 3 (wild-type LD78), Example 2 (Lys44>Glu; Arg45>Gln) and Example 11 (Arg47>Glu).

#### Method

A 1ml glycerol stock culture (stored at -70°C in 20% glycerol) was thawed and 20 used to inoculate 50ml of sc/glc medium (6.7g/L yeast nitrogen base w/o amino acids, 10g/L glucose and 20ml/L amino acid solution containing 1g adenine, 1g arginine, 5g aspartic acid, 5g glutamic acid, 1g histidine, 15g iso-leucine, 1.5g lysine, 1g methionine, 2.5g phenylalanine, 17.5g serine, 10g threonine, 2g tryptophan, 1.5g tyrosine, 1g uracil, 6.7g valine). The culture was incubated at 25 30°C for 24hrs on a shaking platform after which time 5ml was aseptically removed and used to seed 500ml of the same sc/glc medium. This culture was incubated at 30°C on a shaking platform for 24hr at which point it was used to seed a fermenter (prepared as below).

A 5L fermenter (LSL Biolafitte) was filled with 3.5L of the defined medium NAMC#4 containing 41g ammonium sulphate ( $(\text{NH}_4)_2\text{SO}_4$ ), 5.25g potassium dihydrogen orthophosphate ( $\text{KH}_2\text{PO}_4$ ), 2.85g magnesium sulphate ( $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ ), 55mg calcium chloride ( $\text{CaCl}_2$ ), 16mg manganous sulphate ( $\text{MnSO}_4 \cdot 4\text{H}_2\text{O}$ ), 5 18.5mg copper sulphate ( $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ ), 5mg zinc sulphate ( $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ ), 1mg potassium iodide (KI), 9mg sodium molybdate ( $\text{Na}_2\text{MoO}_4 \cdot 2\text{H}_2\text{O}$ ), 4mg ferric chloride ( $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ ) and 2ml PPG<sub>2000</sub> (antifoam agent). Once sterilised the fermenter was allowed to cool and the medium within the fermenter was completed with the aseptic addition of 400ml of a filter sterilised sugar/vitamin concentrate containing 15g glucose, 100g galactose, 10mg biotin, 63mg calcium pantothenate, 63mg pyridoxine hydrochloride, 50mg thiamine, 50mg nicotinic acid, 4mg p-amino benzoic acid, 100mg myo-inositol together with 100ml of a filter sterilised amino acid stock (as for seed culture).

10

15 Once the medium was complete the fermenter was set up to maintain the following environment; temperature - 30°C, pH - 5.0 (using 3M sodium hydroxide and 3M phosphoric acid as titrants), impeller - 750rpm, air flow rate - 2.5 L/min and dissolved oxygen tension above 40% saturation (using increasing impeller rates). After obtaining the running conditions the fermenter was inoculated with the seed

20 culture (described previously) and the running conditions were maintained for 65hrs. At this point the cell density of the culture was quantified using a spectrophotometer ( $A_{600}$ ) and LD78 levels assessed (in the culture supernatant) using reverse phase HPLC (Comparative Example 3) using a standard curve of LD78 concentration to give peak height/area.

25

Using the batch protocol the following data have been collected -

	LD78 Species	Final Biomass Level (OD <sub>600</sub> )	Final LD78 Level (mg/L)	Specific Productivity (wild-type=1)
5	Wild-type	26.6	7	1
	LD78 (Lys44>Glu; Arg45>Gln)	24.3	41	6.4
10	LD78 (Arg47>Glu)	26.0	27	3.9

Higher productivities from strains expressing disaggregated variants of LD78 is clearly demonstrated in this experiment.

15 **Example 157 - *S. cerevisiae* Fed-batch fermentation of wild-type LD78 and LD78 variants**

20 The fed-batch strategy is an adaptation of the batch process which promotes higher cell densities within the fermentation culture and thus increases the volumetric level of the recombinant protein. The strains used for the expression of wild-type and mutant LD78 species were as in Example 156. Transformants were produced as described in Preparation 2 and the plasmids used are described in Preparation 2 (wild-type), Example 2 (Lys44 > Glu; Arg45 > Gln), Example 16 (Phe28 > Glu; Arg47 > Glu), Example 53 (Lys44 > Ser), Example 64 (Glu66 > Ser), Example 42 (Arg17 > Glu; Gln18 > Glu) and Example 19 (Gln18 > Glu).

25 **Method**

30 A fermenter was set up as in Example 156. At 18hr post inoculation a feed was applied to the culture. The feed was 1L in volume and consisted of 300g galactose, 8.3g ammonium sulphate ((NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>), 1.05g potassium dihydrogen orthophosphate (KH<sub>2</sub>PO<sub>4</sub>), 0.57g magnesium sulphate (MgSO<sub>4</sub>.7H<sub>2</sub>O), 11mg calcium chloride (CaCl<sub>2</sub>), 3mg manganous sulphate (MnSO<sub>4</sub>.4H<sub>2</sub>O), 4mg copper sulphate (CuSO<sub>4</sub>.5H<sub>2</sub>O), 1mg zinc sulphate (ZnSO<sub>4</sub>.7H<sub>2</sub>O), 0.2mg potassium

iodide (KI), 2mg sodium molybdate ( $\text{Na}_2\text{MoO}_4 \cdot 2\text{H}_2\text{O}$ ), 1mg ferric chloride ( $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ ), 4mg boric acid ( $\text{H}_3\text{BO}_3$ ), 2mg biotin, 12mg calcium pantothenate, 12mg pyridoxine hydrochloride, 10mg thiamine, 10mg nicotinic acid, 1mg p-amino benzoic acid, 20mg myo-inositol in addition to 100ml of the amino acid stock used in the seed stage. The feed was pumped into the vessel at a rate of 0.22ml/min. After 48hrs the feed was stopped and a 250ml pulse of constituents (same as the feed without galactose) was batched into the vessel. This batch phase was then allowed to continue for a further 36hr after which time the cell density and culture supernatant were assayed as before (Example 156).

10

Using transformed MC2 cells and the fed-batch protocol described above the following data have been collected -

	LD78 Species	Mutant No	Final Biomass Level ( $\text{OD}_{600}$ )	Final LD78 Level (mg/L)	Specific Productivity (wild-type = 1)	Multimerisation Status
15	Wild-type LD78	0	45.3	20	1	Wt
20	LD78 (Lys44>Glu; Arg45>Gln)	2	45.8	108	5.3	Dimer
25	LD78 (Phe28>Glu; Arg47>Glu)	26	50.4	120	5.4	Dimer
30	LD78 (Lys44>Ser)	42	43.5	50	2.5	Tetramer Dodecamer
35	LD78 (Glu66>Ser)	52	39.7	50	2.5	Tetramer
40	LD78 (Arg17>Glu; Glu18>Glu)	110	35.3	100	5.0	Tetramer
	LD78 (Gln18>Glu)	29	39.3	40	2.0	Dodecamer

Higher productivities from strains expressing demultimerised variants of LD78 is clearly demonstrated in this experiment.

Example 158 - Construction of a *Pichia Pastoris* expression vector for Human LD78

The methylotrophic yeast *Pichia pastoris* has been used for the production of several proteins. High level expression has been obtained for a number of proteins in this host but some proteins prove difficult to produce. There is no obvious correlation between the properties of a particular polypeptide and its ability to be highly expressed in the *Pichia* system. The *Pichia pastoris* expression system has particular advantages in its ease of scalability for large scale production. Expression of LD78 was investigated in the *Pichia* host strain GS115 (obtainable from the Phillips Petroleum Company, Bartlesville, Oklahoma, USA).

The pSW6-LD78 plasmid was used as a source of the  $\alpha$ -factor LD78 fusion for cloning into the *P. pastoris* expression vector pHILD4. The expression vector pHILD4 is a shuttle vector capable of propagation in *E. coli* and the methylotrophic yeast *P. pastoris*. The vector comprises sequences derived from the *E. coli* vector pBR322 and sequences derived from the genome of *P. pastoris*. The essential features of the vector are the 5' region of the *Pichia AOX1* gene including the regulatable *AOX1* promoter for high level transcription, the 3' region from the *AOX1* gene containing the transcriptional terminator, a further region from the 3' *AOX1* gene which is included together with the 5' *AOX1* region to enable site directed integration of the expression cassette into the host genome. The *P. pastoris* histidinol dehydrogenase gene *HIS4* is carried and used to complement the defective *his4* gene in *Pichia* host strains. The ampicillin resistance gene is carried to allow selection in *E. coli* hosts during genetic manipulation. This vector is similar to the pHILD1 vector described in Example 159 except that it also contains a kanamycin resistance cassette which enables selection for multicopy integrants when the vector is introduced into *Pichia* host strains. The pHILD4 vector is illustrated in Figure 15a. Genes for expression

may be cloned into the *EcoR1* expression cloning site of the pHILD4 vector. pHILD4 can be obtained under licence from Phillips Petroleum Company, Bartlesville, Oklahoma, USA.

5 The pSW6-LD78 vector of preparation 2 was used as a source of the wild-type LD78 gene fused to the *Saccharomyces* mating type  $\alpha$  factor pre-pro leader sequence. Sequences encoding this fusion may be isolated from pSW6-LD78 as a linear DNA fragment following digestion with *BglII* & *BamHI* restriction endonucleases. To render the ends of this linear fragment compatible with cloning  
10 into the *EcoR1* expression cloning site of the pHILD4 vector it was first necessary to fill in the single stranded overhangs which result from the *BglII/BamHI* digestions. This was achieved using the Klenow fragment of *E. coli* DNA polymerase I together with the required deoxynucleoside triphosphates according to standard methodology. The resultant flush ended fragment was then cloned into  
15 the pHILD4 vector that had been treated with *EcoR1* and then blunt ended as above. The integrity of the resultant plasmid pLH12 was checked by a combination of restriction digestion and sequence analysis.

20 Expression host strains containing pLH12 were constructed using the method described in Example 159 below.

**Example 159 - Construction of an improved *Pichia Pastoris* expression vector for variants of Human LD78**

25 Whilst pLH12 of Example 158 was used for the early expression analysis, this vector was improved upon as shown in this example and the resultant improved vector pLH23 was used for the construction of *Pichia* expression vectors for LD78 variants.

*Pichia* expression vector pHILD1 (Figure 16) is a shuttle vector capable of propagation in both *E. coli* (for ease of genetic manipulation) and in the methylotrophic yeast *Pichia pastoris*. The *S. cerevisiae* mating type factor alpha secretion signals were incorporated into the pHILD1 vector to enable export of the LD78 protein to the medium. pHILD1 can be obtained under licence from the Phillips Petroleum Company, Bartlesville Oklahoma, USA. The vector comprises sequences derived from the *E. coli* vector pBR322 and sequences derived from the genome of *Pichia pastoris*. The essential features are the 5' region of the *Pichia* alcohol oxidase (*AOX1*) gene including the regulatable *AOX1* promoter for high level transcription, the 3' region from the *AOX1* gene containing the alcohol oxidase transcriptional terminator sequence, a further region from the 3' part of the *AOX1* gene is included which together with the 5' *AOX1* region is required for site-directed integration of the expression cassette into the host genome. The *P. pastoris* histidinol dehydrogenase gene *HIS4* is carried and used to complement the defective *his4* gene in *Pichia* host strains. The ampicillin resistance gene is carried to enable selection in the *E. coli* hosts used during genetic manipulation. The pHILD1 vector was manipulated to allow expression of the synthetic LD78 gene (obtained from pUC18-LD78) of Preparation 1 under the control of the alpha factor secretion signal. pHILD1 does not carry any sequences encoding secretion signals to allow export of heterologous proteins. To include such a signal, the vector was manipulated by the addition of sequences from the *S. cerevisiae* alpha-factor leader. The vector was further engineered to provide a more optimal promoter context and to remove undesirable *Hind*III restriction sites which may interfere with the cloning of the LD78 gene from pSW6-LD78 of Preparation 2, a *Bam*HI site was then introduced 3' to the remaining *Hind*III to allow cloning of the LD78 gene (pUC18-LD78 of Preparation 1) on a *Hind*III - *Bam*HI restriction site and to include a kanamycin resistance cassette enabling the selection of multicopy integrants in transformed *Pichia* host strains. The stages of the manipulations are below. An outline of the strategy used is shown in Figure 18.

Inclusion of alpha-factor secretion signals

The alpha-factor sequences were cloned into the pHILD1 vector from the *S. cerevisiae* expression vector pSW6 (Figure 2) (see Preparation 2 for details). The alpha-factor sequences were isolated from pSW6 on a ca 430 bp *Bg*III-*Bam*HI DNA fragment, this fragment contains the alpha-factor sequences fused to a human epidermal growth factor synthetic gene (EGF). The overhanging ends of this DNA fragment were first filled in using klenow fragment of *E. coli* DNA polymerase I together with the required deoxynucleoside triphosphates according to standard methodology. The flush-ended fragment was then cloned into the pHILD1 vector that had been treated with *Eco*RI and then blunt-ended as above. The integrity of the resultant plasmid pLH001 was checked by a combination of restriction digestion and DNA sequence analysis. The primer use for sequence analysis was BB5769 (5'- GCATTCTGACATCCTCT-3' SEQ ID NO 168). The sequence of the  $\alpha$  factor coding sequence was confirmed.

15

Mutagenesis to optimise vector for variant LD78 expression

The pLH001 vector was further modified to remove unwanted *Hind*III restriction sites, to optimise the promoter region and to introduce a *Bam*HI site. Relevant fragments were cloned into a bacteriophage M13 vector for site-directed mutagenesis. The fragments cloned, the primers used for mutagenesis, and the primers used for sequencing are detailed below. Furthermore, a kanamycin resistance cassette was modified for introduction into the final expression vector to allow selection for multicopy integrants when the vector is introduced into *Pichia* host strains.

20

A ca 1220 bp *Sac*I-*Sac*I fragment was isolated from pLH001 and cloned into M13 mp19. This M13 construct was then used for mutagenesis in which a *Hind*II site was removed using oligonucleotide primer BB6040 (5'- CGTTAAAATCAACAACTTGTCAATTGGAACC-3' SEQ ID NO 169), the

mutants were identified by sequence analysis with sequencing primer BB6296 (5'-GGAAATCTCACAGATCT-3' SEQ ID NO 170). This fragment was further modified by deletion mutagenesis to optimise the 5' untranslated leader region preceding the AOX1 promoter, which is now identical to that found in the natural 5 5' untranslated leader of the AOX1 gene on the *Pichia* genome. Having the correct context around the 5' untranslated leader is preferred for maximal expression. The mutagenesis primer used for this step was BB8461 (5'GAAGGAAATCTCATCGTTGAATA-3' SEQ ID NO 171). The mutant was identified by sequence analysis with sequencing primer BB8740 (5'-GCTAATGCGGAGGGATGC-3' SEQ ID NO 172).

10 Two further *Hind*III sites were removed from the ca 770bp *Sac*I-*Xba*I fragment of pLH001 by mutagenesis. The *Sac*I-*Xba*I fragment of pLH001 was first cloned into M13 mp18 and one of the *Hind*III sites was removed using the primer BB6394 (5'-CCGGCATTACAACCTATCGATAAGCTTGCAC-3' SEQ ID NO 173). The 15 identity of this mutant was confirmed by sequence analysis using the sequencing primer BB6037 (5'- GCGCATTGTTAGATTTC-3' SEQ ID NO 174). A second *Hind*III site was removed from this newly mutagenised fragment using mutagenesis primer BB6841 (5'-CTTATCGATCAACITGCACAAACG-3' SEQ ID NO 175). 20 The correct mutant was identified by sequence analysis using sequence primer BB6037 (see above).

25 Before reassembly, a *Bam*HI site was introduced into the *Hind*III deleted *Sac*I-*Xba*I fragment to allow subsequent cloning of the LD78 gene of Preparation 2 on a *Hind*III-*Bam*HI fragment. The mutagenesis primer used to introduce the *Bam*HI site was BB6189 (5' GTCATGTCTAAGGC GGATCCTTATTAAC-3' SEQ ID NO 176). The identity of the mutant was identified using sequencing primer BB5769 (5'-GCATTCTGACATCCTCT-3' SEQ ID NO 168).

Modification of the Kanamycin resistance cassette

5 A kanamycin resistance cassette was purchased from Pharmacia Biosystems Limited, Davy Avenue. Knowlhill, Milton Keynes, MK5 8PH. Great Britain. This cassette is supplied as an *Eco*RI fragment by Pharmacia and this was cloned into M13mp19 as an *Eco*RI fragment. The internal *Hind*III restriction site was deleted using mutagenesis primer BB8661 (5'-GAGAATGGCAACAACTTATGCATT-3' SEQ ID NO 177). The mutation was confirmed using sequencing primer BB6038 (5'- CCAACATCAATACAACC-3' SEQ ID NO 178).

10 Reassembly of expression vector

The vector was reconstructed in a stepwise manner using the Phillips petroleum vector pHILD1 as a backbone for the cloning.

15 To rebuild the expression vector including the mutagenised fragments, the modified ca 770 bp *Sac*I-*Xba*I fragment was first ligated into *Sac*I -*Xba*I treated pHILD1 vector. The integrity of the recombinant construct was then confirmed by restriction analysis and DNA sequence analysis using the oligonucleotide sequencing primer BB6037 (5'-GCGCATTGTTAGATTC-3' SEQ ID NO 174), the construct was called intermediary vector 1. The modified *Sac*I-*Sac*I fragment was next cloned into intermediary vector 1 which had been treated with *Sac*I and calf intestinal phosphatase. The resultant construct, named intermediary vector 2, was again confirmed by restriction analysis and DNA sequence analysis with oligonucleotide primers BB6296 (5'-GGAAATCTCATAGATCT-3' SEQ ID NO 170) to read through the deleted *Hind*III site and BB8740 (5'-GCTAATGCGGAGGGATGC-3' SEQ ID NO 172) to read through the optimised 5' untranslated leader region. Intermediary vector 2 is a homologue of pHILD1 which lacks the unwanted *Hind*III sites, has an optimised 5' untranslated region, contains sequences encoding the *S. cerevisiae* alpha-factor secretion signals followed by the remaining *Hind*III site and which has a *Bam*HI site 3' to the

*Hind*III site to allow cloning of the synthetic LD78 gene described in Preparation 1.

5 A 1,200bp *Hinc*II fragment containing the mutagenised kanamycin cassette was removed from the M13 mp19 mutagenesis vector (used to remove the *Hind*III site from the kanamycin resistance gene) and cloned into the unique *Nae*I site of the intermediary vector 2. The vector was renamed pLHD4. The integrity of pLHD4 was confirmed by restriction analysis. A map of pLHD4 is shown in Figure 15b. pLHD4 contains the human EGF gene fused to the *S. cerevisiae* alpha factor secretion signal.

10

Construction of the improved LD78 Pichia expression vector

15 The improved expression vector for wild-type LD78 expression was constructed by cloning a *Hind*III - *Bam*HI fragment of pSW6-LD78 (Preparation 2) into pLHD4. (This *Hind*III-*Bam*HI fragment contains the synthetic LD78 gene fused to the 3' end of a sequence encoding the 5 amino acids of the yeast alpha factor which precede the KEX2 cleavage site required for liberation of the mature peptide following secretion from the *Pichia* host).

20 The *Hind*III-*Bam*HI fragment was obtained by restriction digestion of the *S. cerevisiae* expression vector pSW6-LD78. This fragment was purified on a 1.5% low melting temperature agarose gel then ligated to *Hind*III-*Bam*HI, calf intestinal phosphatase treated pLHD4. The resultant recombinant was called pLH23. The vector is shown in Figure 17. The integrity of the construct was confirmed by restriction analysis and sequencing analysis using the sequencing primer BB5769 (5'-GCATTCTGACATCCTCT -3' SEQ ID NO 168). Figure 18 shows the strategy for the construction of pLH23.

25

**Example 160 Construction of *P. pastoris* expression vectors for demultimerised LD78 variants.**

The improved vector of Example 159 was used as the basic expression vector for 5 all LD78 variants. The DNA encoding the LD78 variants was obtained from the *S. cerevisiae* vector described in Examples 16, 2, 11, 5, 20, 18, 1, 15 and 8. Briefly, the plasmid DNA from these various examples was digested with *Hind*III and *Bam*HI restriction endonucleases. This releases a fragment containing sequences which encode the LD78 variant fused to a sequence encoding the last 10 5 amino-acids of the *S. cerevisiae* mating factor type alpha. The *Hind*III/*Bam*HI DNA fragments were ligated into *Hind*III/*Bam*HI-treated pLH23. The resultant vectors together with the LD78 variant carried can be seen in the table below

	<u>Mutant No</u>	<u>Mutation</u>	<u>Pichia</u>	<u>Vector</u>
15	26	Arg 47 > Glu; Phe28 > Glu	pLH	25
	2	Lys44 > Glu; Arg45 > Glu		26
	15	Arg47 > Glu		27
	5	Arg17 > Ser		28
	30	Arg17 > Ser; Gln18 > Glu		30
	28	Glu29 > Arg		29
20	1	Gln48 > Glu		31
	25	Phe28 > Glu; Gln48 > Glu		24
	11	Phe12 > Gln		32

25

Expression hosts for these various plasmids were constructed according to the method described in Example 161 below.

**Example 161 - Construction of *Pichia* expression strains.**

30

pLH12 plasmid DNA prepared as in Example 158 was linearised by cutting with the restriction endonuclease *Sac* I. This was to enable the expression cassette to

integrate via homologous recombination of sequences on the expression cassette and the host chromosome. The linearised plasmid was then transformed into *P. pastoris* strain GS115 (NRRL Y-1585) which has the genotype *his4*. The use of strain GS115 is not critical for use either in this preparation or in the invention in general. Any suitable strain can be used, such as, for example, strain KM71 or SMD1163 which have the genotypes *his4*, *AOX1::ARG4* and *his4*, *prB1*, *pep4* respectively. Strains GS115 and KM71 are described in Phillips patent number AU-B-63882/86. These hosts can be obtained under licence from the Phillips Petroleum Company, Bartlesville, Oklahoma, USA.

10

Using the method described below the plasmid DNA was transformed into the host strain.

15

Briefly, yeast strain GS115 was grown overnight in 200mL of YEPD medium at 30°C on an orbital shaker. Cultures at an  $A_{600}$  of between 0.1 and 0.3 were harvested by centrifugation at 3000rpm for 5mins, washed in sterile water, recentrifuged, washed in SED buffer (Appendix A at the end of the Examples), recentrifuged, washed in 1M sorbitol, recentrifuged and resuspended in 20mL SCE buffer (Appendix A). Cells were then incubated at 30°C with the enzyme zymolyase to remove the cell wall. Spheroplasting was allowed to continue until approximately 70% of the cells had been turned into spheroplasts. These were then collected by gentle centrifugation (750xg 10mins). Spheroplasts were then washed in 1M sorbitol and resuspended in 600 $\mu$ L CAS buffer (Appendix A). 100 $\mu$ L aliquots of spheroplasts were then incubated for 10mins with 10 $\mu$ g of the linearised DNA. 1mL of PEG buffer was then added and incubated for a further 10mins. After collecting the spheroplasts by gentle centrifugation and aspirating the PEG solution the cells were resuspended in 150 $\mu$ L of SOS medium (Appendix A) and incubated for 20mins. After the addition of 850 $\mu$ L of 1M sorbitol the cells were ready for plating on regeneration agarose.

20  
25

100 $\mu$ L of transformed spheroplasts were then added to 10mL of molten (42°C) agarose-sorbitol regeneration medium and poured onto agarose-sorbitol base plates and allowed to grow for 5-7 days at 30°C.

5 All yeast media and transformation buffers were as described in the appendix.

After 5-7 days transformants were collected along with the agarose overlay they had been growing in, transferred to a 50mL centrifuge tube and resuspended in 50mM sodium phosphate buffer pH6 and after suitable mixing and agitation to remove the cells from the agarose they were diluted and plated onto YEPD agar plates containing the antibiotic G418 at concentrations between 0 and 2,000  $\mu$ g/mL. Only cells in which several copies of the expression cassette had integrated into the host chromosome would be able to grow on high levels of antibiotic by virtue of their enhanced kanamycin resistance. Such cells are deemed desirable since they will also be carrying several copies of the LD78 gene. Previous work has shown such multicopy integrants to be high producers under conditions where the foreign gene is expressed (Clare *et al* (1991)). Plates were incubated at 30°C for 5-7 days. Colonies occurring on plates containing high concentrations of the antibiotic were then picked and streaked onto fresh MD agar plates. Single colonies were obtained after 3-4 days growth at 30°C.

In order to determine the number of copies of the expression cassette that had integrated onto the host chromosome a Southern blotting technique based on that described by Clare *et al.* (1991) was employed.

25 Briefly, chromosomal DNA was prepared from transformed cells and digested with the restriction endonuclease *Bgl*II. The resulting DNA fragments were separated by gel electrophoresis and transferred to nitrocellulose by electroblotting. The resulting Southern blot was then incubated with a labelled probe that recognises

one of the DNA sequences on the expression cassette (for example HIS4). The probe will also recognise the single copy of the *his4* gene present on the host chromosome. By comparing the intensity of the signal from the known single copy with the unknown multicopy signal (by scanning densitometry) it is possible to 5 quantify the number of copies present.

Exactly the same method was employed for transformation and construction of expression strains from the LD78 variant expression vectors described in Example 160.

10

**Example 162 - Expression of wt LD78 in *Pichia pastoris***

Wild-type expression hosts contained pLH12 as described in Example 158.

15 Single colonies of transformed strains were used to inoculate 5mL of BMGC medium (Appendix A) and the cultures were grown overnight at 30°C on an orbital shaker. This 5mL overnight culture was then used to inoculate 2L baffled shake flasks containing 50mL of the medium BMGC. After 24h growth at 30°C on an orbital incubator cells were harvested by centrifugation at 3000rpm for 5min and 20 resuspended in 50mL of BMMC (Appendix A). This induces gene expression from the *AOX1* promoter. Induction was carried out by growth in the methanol containing medium at 30°C for 48-72h.

25 After either 48h or 72h the culture supernatant was collected by centrifugation at 3000rpm for 5min to remove cells. This supernatant was used for further analysis and purification of LD78 according to the methods described in Preparations 3 and 4. Levels of wild-type LD78 produced using this method are typically 3-5 mg/L as determined by HPLC.

Such levels can be improved by growing the producing strain in a fermenter. A single colony was inoculated into 5mL of MD medium (Appendix A) and grown overnight at 30°C in an orbital incubator. This culture was then used to inoculate 500mL of YEPGlycerol medium (Appendix A) in a 2L baffled flask. This culture was grown for between 24-48h and used as an inoculum for the fermentor. The 5L fermenter was autoclaved with 3.5L of the High Cell Density (HCD) medium (Appendix A). After adjusting the pH to 5.85 with ammonia solution and the addition of 10 mL of a trace element solution (PTM<sub>1</sub>, (Appendix A)) the fermenter was inoculated with the culture described above. Growth conditions are typically pH5.85 (maintained by the addition of ammonia solution on demand), 29.8°C , 800-1200rpm, 1-2vvm air, 20-100% DOT. After 20-24h the carbon source in the medium was exhausted and a methanol feed (containing 5mL/L of trace element solution PTM<sub>1</sub> and 2mL/L biotin stock solution - 0.2g/L) started at 3.4g/h. After 24-30 hours the feed rate was increased to 6g/h for approximately 20h. After this the feed rate was increased or decreased to keep the residual methanol concentration in the broth between 1 and 10g/L (as determined by gas chromatography). The fermentation was run for between 70-180h and wild-type LD78 levels in the broth were determined to be 60-100mg/L by HPLC.

The material produced using the *Pichia* expression system was purified and characterised using the techniques applied to the material produced by *Saccharomyces* (see Preparation 3, 4 and 13).

**Example 163 - Enhanced expression of demultimerised mutants**

The expression constructs for the demultimerised variants as described in Example 160 were introduced into *Pichia* host strain GS115 according to the method of Example 161.

It was generally noted that mutations of the LD78 gene that resulted in a demultimerised form of the molecule gave higher levels of expression into culture supernatants than did the wild-type LD78 molecule.

5 As mentioned in Example 162, the expression level in shake flask inductions was determined to be 3-5 mg/L for the wild-type LD78 molecule. When production strains containing integrated expression cassettes of demultimerised mutants were grown as detailed in Example 157 expression levels were seen to be elevated to the order of 50-200mg/L (specifically mutant 26 (LD78 Glu28, Glu47) - 158mg/L, 10 mutant 2 (LD78 Glu44, Gln45) - 76mg/L, mutant 15 (LD78 Glu47) - 63mg/L, mutant 5 (LD78 Ser17) - 79mg/L, mutant 30 (LD78 Ser17, Glu18) - 138mg/L, mutant 28 (LD78 Arg29) - 169mg/L). This phenomenon was not restricted to the *Pichia* system but was also noted with the *Saccharomyces* system (see Examples 156 and 157).

15 When production strains containing the demultimerised mutant expression cassettes were grown in fermenters expression levels were again enhanced. Glycerol stock cultures were used to inoculate 500mL of YEPGlycerol medium in a 2L baffled shake flask. This was grown for 18-24h at 30°C in an orbital shaker. This culture was used as an inoculum for the fermenter. The 5L fermenter was prepared as detailed in Example 162. After the batch phase carbon was exhausted a limiting glycerol feed (500g/L glycerol, 5mL/L trace elements PTM<sub>1</sub>, 2mL/L biotin stock solution 0.2g/L) was started and run for 3-6h at 14g/h. Then the glycerol feed rate was reduced to 10g/h and a methanol feed (methanol plus 5mL/L trace elements PTM<sub>1</sub> and 2mL/L biotin stock solution 0.2g/L) started at 5g/h. The methanol feed was increased exponentially with time to arrive at a final feed rate of 30g/h after a total elapsed fermentation time of 75h. During this period growth conditions were as detailed in Example 162. This process resulted in the production of 1.5g/L of demultimerised mutant 26 (LD78 Glu28, Glu47) into the fermentation broth, compared with 60-100mg/L of the wild-type LD78 molecule.

Clearly, expression levels may be dependent on the number of expression cassettes integrated into the host chromosome. In order to compare expression levels of demultimerised mutants with those of the wild-type, differences in copy number must be taken into account. The strain producing wild-type LD78 has 4 copies of the expression cassette compared to 42 for the mutant 26 producing strain. Even allowing for this difference, however, mutant 26 is produced at higher than expected levels (3.1mg/L/copy as opposed to 0.75-1.25mg/L/copy for wild-type).

5 This phenomenon of enhanced expression of demultimerised mutants in a fermenter  
10 was also observed with the *Saccharomyces* system (see Example 157).

**Example 164 - Demultimerised mutants are active in an in vitro receptor binding assay**

15 The effect of the mutations on LD78 biological activity was assessed initially by measuring their ability to displace radio-labelled LD78 from the murine stem cell line FDCP cell mix (A4 cells) (Dexter *et al.*, *J. Exp. Med.* 152 1036 (1980)). The A4 FDCP cell mix cell line is available on request from the Paterson Cancer Research Institute, Department of Haematology, Wilmslow Road, Manchester, 20 M20 9BX, United Kingdom).

25 The assay procedure is as follows: FDCP-mix A4 cells are diluted with fresh growth medium on the day before use to give  $1-2 \times 10^5$ /ml (usually 2 - 4 fold). On the day of the assay, cells are counted and then harvested by centrifugation. After washing once in serum free medium and once in binding medium, the cells are resuspended at  $5 \times 10^6$ /ml in binding medium (RPMI 1640 + 20mM HEPES + 1mg/ml BSA). 200 $\mu$ l of the cell suspension is pipetted into Eppendorf tubes, followed by 25 $\mu$ l of unlabelled competitor, made up at 10x the required final concentration, and 25 $\mu$ l label prepared in the same way. The final concentration

of labelled ligand used is 0.5nM, i.e. 3.85ng/ml. The tubes are incubated on a suspension mixer for 2 hours at room temperature. 1ml of cold PBS is then added and the tubes centrifuged at 2000rpm. After washing in 2 further volumes of PBS the cells are finally transferred to vials and the radioactivity measured by counting using a Packard Cobra Auto-Gamma counter. The assay was performed in triplicate, and the binding of  $^{125}\text{I}$ -LD78 in the presence of excess cold LD78 or LD78 mutant was compared to binding in the absence of cold material.

LD78 or LD78 mutant was diluted in binding medium to provide a range of concentrations. Routinely, concentrations of 3.85  $\mu\text{g}/\text{ml}$  and 0.385  $\mu\text{g}/\text{ml}$  were prepared, which following a ten-fold dilution into the assay, yielded concentrations of cold material that were 100- and 10-fold the concentration of  $^{125}\text{I}$ -LD78 respectively.  $^{125}\text{I}$ -LD78 was prepared by Amersham plc.

For more detailed characterisation of selected variants, a range of sample concentrations from .01 - 100 ng/ml was employed to construct a detailed dose response curve. To ensure comparability between assays, the activity of LD78 variants was expressed as percentage of the wild-type activity based on IC50 values. Wild-type LD78 was always included as a control. Thus wild-type activity is represented as 100%; a variant that with an IC50 ten times that of wild-type as 10% (i.e. binds the receptor 1/10 as well) and a variant with an IC50 1/2 that of wild-type as 200% (i.e. binds the receptor twice as well).

The receptor binding data for 53 LD78 variants are shown in Table 2, along with a summary of the relevant physicochemical data relating to their multimerisation state.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**